CN117820248A - Triazine derivative with virus proliferation inhibition effect and pharmaceutical composition containing triazine derivative - Google Patents
Triazine derivative with virus proliferation inhibition effect and pharmaceutical composition containing triazine derivative Download PDFInfo
- Publication number
- CN117820248A CN117820248A CN202311797713.0A CN202311797713A CN117820248A CN 117820248 A CN117820248 A CN 117820248A CN 202311797713 A CN202311797713 A CN 202311797713A CN 117820248 A CN117820248 A CN 117820248A
- Authority
- CN
- China
- Prior art keywords
- substituted
- group
- unsubstituted
- substituent
- aromatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 33
- 230000005764 inhibitory process Effects 0.000 title description 16
- 230000000694 effects Effects 0.000 title description 10
- 150000003918 triazines Chemical class 0.000 title description 8
- 230000005727 virus proliferation Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 470
- 150000003839 salts Chemical class 0.000 claims abstract description 138
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 103
- 241000711573 Coronaviridae Species 0.000 claims abstract description 101
- 108091005804 Peptidases Proteins 0.000 claims abstract description 38
- 239000004365 Protease Substances 0.000 claims abstract description 38
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 35
- 125000001424 substituent group Chemical group 0.000 claims description 518
- 125000000217 alkyl group Chemical group 0.000 claims description 181
- 229910052736 halogen Inorganic materials 0.000 claims description 154
- 150000002367 halogens Chemical group 0.000 claims description 143
- 238000000034 method Methods 0.000 claims description 81
- 125000003545 alkoxy group Chemical group 0.000 claims description 59
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 55
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 44
- 125000000304 alkynyl group Chemical group 0.000 claims description 25
- 230000008569 process Effects 0.000 claims description 22
- 125000004429 atom Chemical group 0.000 claims description 21
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 12
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract description 316
- 239000013078 crystal Substances 0.000 abstract description 166
- 125000003118 aryl group Chemical group 0.000 abstract description 120
- 125000004452 carbocyclyl group Chemical group 0.000 abstract description 40
- 230000002401 inhibitory effect Effects 0.000 abstract description 21
- 230000001747 exhibiting effect Effects 0.000 abstract description 6
- 239000008186 active pharmaceutical agent Substances 0.000 abstract description 2
- 229940088679 drug related substance Drugs 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 114
- 239000000126 substance Substances 0.000 description 96
- -1 n-octyl Chemical group 0.000 description 93
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 80
- 239000000243 solution Substances 0.000 description 68
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 56
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 48
- 238000000634 powder X-ray diffraction Methods 0.000 description 48
- 125000002837 carbocyclic group Chemical group 0.000 description 46
- 238000006243 chemical reaction Methods 0.000 description 43
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 41
- 239000001530 fumaric acid Substances 0.000 description 40
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 38
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- 238000001069 Raman spectroscopy Methods 0.000 description 35
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 34
- 238000005259 measurement Methods 0.000 description 33
- 238000003556 assay Methods 0.000 description 32
- 230000015572 biosynthetic process Effects 0.000 description 32
- 239000002904 solvent Substances 0.000 description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 29
- 238000003786 synthesis reaction Methods 0.000 description 29
- 101000912561 Bos taurus Fibrinogen gamma-B chain Proteins 0.000 description 28
- 208000001528 Coronaviridae Infections Diseases 0.000 description 26
- 238000001237 Raman spectrum Methods 0.000 description 26
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 25
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 23
- 230000003595 spectral effect Effects 0.000 description 23
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 125000003277 amino group Chemical group 0.000 description 21
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 20
- 125000000547 substituted alkyl group Chemical group 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 19
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 19
- 239000012044 organic layer Substances 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 230000035755 proliferation Effects 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 16
- 125000001841 imino group Chemical group [H]N=* 0.000 description 16
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 14
- 241000008904 Betacoronavirus Species 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 125000005843 halogen group Chemical group 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 13
- 235000019253 formic acid Nutrition 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 125000004414 alkyl thio group Chemical group 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 159000000000 sodium salts Chemical class 0.000 description 11
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 11
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241001428935 Human coronavirus OC43 Species 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 241000315672 SARS coronavirus Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 9
- 125000005139 alkynylsulfonyl group Chemical group 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- LIENCHBZNNMNKG-OJFNHCPVSA-N nirmatrelvir Chemical compound CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(F)(F)F)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C LIENCHBZNNMNKG-OJFNHCPVSA-N 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 239000001384 succinic acid Substances 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 241000711467 Human coronavirus 229E Species 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 125000005087 alkynylcarbonyl group Chemical group 0.000 description 7
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 125000001425 triazolyl group Chemical group 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 6
- 125000005137 alkenylsulfonyl group Chemical group 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000002447 crystallographic data Methods 0.000 description 6
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000005415 substituted alkoxy group Chemical group 0.000 description 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241001109669 Human coronavirus HKU1 Species 0.000 description 5
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 125000005136 alkenylsulfinyl group Chemical group 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 5
- 150000002513 isocyanates Chemical class 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 229940125674 nirmatrelvir Drugs 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 125000000464 thioxo group Chemical group S=* 0.000 description 5
- 229910052722 tritium Inorganic materials 0.000 description 5
- 238000000825 ultraviolet detection Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 241000482741 Human coronavirus NL63 Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 4
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 150000002431 hydrogen Chemical group 0.000 description 4
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 4
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000004149 thio group Chemical group *S* 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 3
- MPEKZIYOLQCWLL-UHFFFAOYSA-N 5-(bromomethyl)-1,2,3-trifluorobenzene Chemical compound FC1=CC(CBr)=CC(F)=C1F MPEKZIYOLQCWLL-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 3
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- QDIMHKWNHMVDJB-WBAXXEDZSA-N PF-00835231 Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)C=1NC=2C=CC=C(C=2C=1)OC)C(=O)CO)[C@@H]1CCNC1=O QDIMHKWNHMVDJB-WBAXXEDZSA-N 0.000 description 3
- FQKALOFOWPDTED-WBAXXEDZSA-N PF-07304814 Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)COP(=O)(O)O)NC(=O)C2=CC3=C(N2)C=CC=C3OC FQKALOFOWPDTED-WBAXXEDZSA-N 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000005193 alkenylcarbonyloxy group Chemical group 0.000 description 3
- 125000005108 alkenylthio group Chemical group 0.000 description 3
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 3
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229940125251 lufotrelvir Drugs 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- JRHPOFJADXHYBR-HTQZYQBOSA-N (1r,2r)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@@H]1CCCC[C@H]1NC JRHPOFJADXHYBR-HTQZYQBOSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- KISIDCUHOLGEPR-UHFFFAOYSA-N 3-(chloromethyl)-1-methyl-1,2,4-triazole;hydrochloride Chemical compound Cl.CN1C=NC(CCl)=N1 KISIDCUHOLGEPR-UHFFFAOYSA-N 0.000 description 2
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical group C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 102220492046 Phospholipid scramblase 1_H12A_mutation Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 2
- 239000012964 benzotriazole Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 125000005884 carbocyclylalkyl group Chemical group 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000003221 ear drop Substances 0.000 description 2
- 229940047652 ear drops Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 2
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000001979 organolithium group Chemical group 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940125675 paxlovid Drugs 0.000 description 2
- 125000005981 pentynyl group Chemical group 0.000 description 2
- 125000005561 phenanthryl group Chemical group 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 229940090181 propyl acetate Drugs 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000002076 thermal analysis method Methods 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 125000005458 thianyl group Chemical group 0.000 description 2
- 125000004001 thioalkyl group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- KKVZONPEMODBBG-UHFFFAOYSA-N (1-hydroxydodecane-1,1-diyl)bis(phosphonic acid) Chemical compound CCCCCCCCCCCC(O)(P(O)(O)=O)P(O)(O)=O KKVZONPEMODBBG-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- AJGBQAAXUVSBCH-UHFFFAOYSA-N (3,4,5-trifluorophenyl)methanamine Chemical compound NCC1=CC(F)=C(F)C(F)=C1 AJGBQAAXUVSBCH-UHFFFAOYSA-N 0.000 description 1
- HEYONDYPXIUDCK-UHFFFAOYSA-L (5-diphenylphosphanyl-9,9-dimethylxanthen-4-yl)-diphenylphosphane;palladium(2+);dichloride Chemical compound Cl[Pd]Cl.C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 HEYONDYPXIUDCK-UHFFFAOYSA-L 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Substances C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 1
- GAUXEYCSWSMMFZ-UHFFFAOYSA-N 1-(bromomethyl)-2,4,5-trifluorobenzene Chemical compound FC1=CC(F)=C(CBr)C=C1F GAUXEYCSWSMMFZ-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- RBZRMBCLZMEYEH-UHFFFAOYSA-N 1h-pyrazol-1-ium-1-carboximidamide;chloride Chemical compound Cl.NC(=N)N1C=CC=N1 RBZRMBCLZMEYEH-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- XRAKCYJTJGTSMM-UHFFFAOYSA-N 2-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1Cl XRAKCYJTJGTSMM-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 229940093475 2-ethoxyethanol Drugs 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- XUBUISLMIHBGTE-UHFFFAOYSA-N 3-(chloromethyl)-1-methyl-1,2,4-triazole Chemical compound CN1C=NC(CCl)=N1 XUBUISLMIHBGTE-UHFFFAOYSA-N 0.000 description 1
- BWCOLJNFJZDWEF-UHFFFAOYSA-N 3-(chloromethyl)-2-methoxypyridine Chemical compound COC1=NC=CC=C1CCl BWCOLJNFJZDWEF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 229940125673 3C-like protease inhibitor Drugs 0.000 description 1
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- JXUWZXFVCBODAN-UHFFFAOYSA-N 5-methylpyridin-3-amine Chemical compound CC1=CN=CC(N)=C1 JXUWZXFVCBODAN-UHFFFAOYSA-N 0.000 description 1
- PKUFNWPSFCOSLU-UHFFFAOYSA-N 6-chloro-1h-pyrimidine-2,4-dione Chemical compound ClC1=CC(=O)NC(=O)N1 PKUFNWPSFCOSLU-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241000004176 Alphacoronavirus Species 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102220477608 Bis(5'-nucleosyl)-tetraphosphatase [asymmetrical]_H31A_mutation Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101150022946 CYP3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100137368 Dictyostelium discoideum cypD gene Proteins 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102220530780 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 2_H24A_mutation Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 101150009380 PPIF gene Proteins 0.000 description 1
- 102100034943 Peptidyl-prolyl cis-trans isomerase F, mitochondrial Human genes 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000001530 Raman microscopy Methods 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000192617 Sabia mammarenavirus Species 0.000 description 1
- 101100222691 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CPR3 gene Proteins 0.000 description 1
- 101100276454 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYC7 gene Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102220509333 Small integral membrane protein 10_H22A_mutation Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102220504163 Testis-specific XK-related protein, Y-linked 2_H31L_mutation Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102220474838 Ubiquitin-conjugating enzyme E2 D1_H19A_mutation Human genes 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- CPEKAXYCDKETEN-UHFFFAOYSA-N benzoyl isothiocyanate Chemical compound S=C=NC(=O)C1=CC=CC=C1 CPEKAXYCDKETEN-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- GRSTVVGJSKHCCS-UHFFFAOYSA-N bis(1h-imidazol-2-yl)methanone Chemical class N=1C=CNC=1C(=O)C1=NC=CN1 GRSTVVGJSKHCCS-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- GHWVXCQZPNWFRO-UHFFFAOYSA-N butane-2,3-diamine Chemical compound CC(N)C(C)N GHWVXCQZPNWFRO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229940051183 casirivimab Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 125000005066 dodecenyl group Chemical group C(=CCCCCCCCCCC)* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009511 drug repositioning Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 108010083391 glycinin Proteins 0.000 description 1
- 125000005221 halo alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 102000049800 human TMPRSS2 Human genes 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- CLIDMUTWHLMPMN-UHFFFAOYSA-N imidazole-1-carboxamide Chemical compound NC(=O)N1C=CN=C1 CLIDMUTWHLMPMN-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229910052611 pyroxene Inorganic materials 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001028 reflection method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical group C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000005063 tetradecenyl group Chemical group C(=CCCCCCCCCCCCC)* 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005040 tridecenyl group Chemical group C(=CCCCCCCCCCCC)* 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005065 undecenyl group Chemical group C(=CCCCCCCCCC)* 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012982 x-ray structure analysis Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same. Also provided are crystals useful as a drug substance and a pharmaceutical composition containing the same. A compound of formula (I):(wherein Y is N, etc.; R) 1 Substituted or unsubstituted aromatic heterocyclic group, etc.; r is R 2 An aromatic carbocyclyl group which may be substituted or unsubstituted, etc.; r is R 3 Substituted or unsubstituted aromatic heterocyclic group, etc.; -X-is-NH-, etc.; m is 1, etc.; r is R 5a Each independently a hydrogen atom or the like; r is R 5b Each independently a hydrogen atom or the like; n is 1, etc.; r is R 4a Each independently a hydrogen atom or the like; r is R 4b Each independently a hydrogen atom, etc.) or a pharmaceutically acceptable salt thereof.
Description
The present application is a divisional application of the invention application of 2022, 2, 17, 202280000918.9 and entitled "triazine derivative with inhibitory effect on viral proliferation and pharmaceutical composition containing the same".
[ field of technology ]
The present invention relates to a compound exhibiting coronavirus 3CL protease inhibitory activity, and a pharmaceutical composition containing the compound exhibiting coronavirus 3CL protease inhibitory activity. The invention also relates to crystals and co-crystals of a compound exhibiting 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions containing the same.
[ background Art ]
Coronaviruses belong to the order of the nest virus, the family coronaviridae, the subfamily orthocoronaviridae, and have a genome size of about 30kb, and are the largest one strand+strand RNA viruses among known RNA viruses. Coronaviruses are classified into four genera, α, β, γ and δ; as coronaviruses infecting humans, there are known two types of alpha genus coronaviruses (HCoV-229E, HCoV-NL 63) and five types of beta genus coronaviruses (HCoV-HKU 1, HCoV-OC43, SARS-CoV, MERS-CoV, SARS-CoV-2) in total of seven types. Of these, four types (HCoV-229E, HCoV-NL63, HCoV-HKU1, HCoV-OC 43) are causative agents of the common cold, the remaining three types are atypical pneumonia (SARS) coronavirus (SARS-CoV), middle East Respiratory Syndrome (MERS) coronavirus (MERS-CoV) and novel coronavirus (SARS-CoV-2) that cause severe pneumonia.
The new coronavirus infection (covd-19) was 28 days from 2022 to 1 month, and the number of confirmed infections was 3.6 hundred million or more and the number of deaths was 563 ten thousand or more (non-patent document 1). Droplet spreading, contact spreading and aerosol spreading have been reported as the main spreading route of SARS-CoV-2, and it has been confirmed that SARS-CoV-2 floats in the air as an aerosol for about 3 hours and retains its infectivity (non-patent document 2). Typical cold symptoms include fever (87.9%), dry cough (67.7%), hypodynamia (38.1%), and expectoration (33.4%) after a incubation period of about 2 to 14 days (non-patent document 3). Acute respiratory distress syndrome, acute lung injury, interstitial pneumonia, etc. may occur in severe cases. In addition, multiple organ failure such as renal failure and liver failure has been reported.
In japan, antiviral drugs, dexamethasone, and antirheumatic drugs, baratinib, have been batched as therapeutic drugs for covd-19 based on drug repositioning of existing drugs; the anti-IL-6 receptor antibody tolizumab was added to the batch 1 month 2022. Furthermore, at month 7 of 2021, the antibody cocktail therapy ronaprve (casirivimab)/immdevivimab (immdevimab)) was obtained as a specialty batch; the special batch of the Soto-Weizumab is obtained at 9 of 2021; a special lot was obtained from Mo Napi la wei at 12 months 2021. There is insufficient evidence to demonstrate the effectiveness and safety of these agents. Therefore, it is urgent to create a therapeutic agent for covd-19.
When coronaviruses infect cells, two multimeric proteins are synthesized. The two multimeric proteins comprise two proteases: one is the production of structural proteins of new viral particles, and one is the production of replication complexes of viral genomes. Proteases cleave multimeric proteins synthesized by viruses and act to make each protein indispensable for its function. Of these two proteases, 3CL protease (main protease) plays a role in cleavage of many multimeric proteins (non-patent document 4).
A Phase1b clinical trial of the prodrug Lufotrelvir (PF-07304814) of PF-00835231 of the company, completed in month 2021 as a therapeutic agent targeting 3CL protease of COVID-19, was published in ClinicalTrials. Gov (NCT 04535167). Furthermore, 3 months 2021, the company of pyroxene announced the initiation of the Phase1 test of the novel therapeutic drug PF-07321332 for coronavirus infection. The structural formulae of PF-00835231, lufotrelvir and PF-07321332 are shown below, and their chemical structures are different from those of the present compounds (non-patent documents 5, 12, 13 and patent documents 6 and 7).
PF-00835231:
[ chemical formula 1 ]
Lufotrelvir(PF-07304814):
[ chemical formula 2 ]
PF-07321332:
[ chemical 3 ]
Further, a Phase2/3 clinical trial of a combination of PF-07321332 and ritonavir, which was administered to a patient with COVID-19 at 7 beginning at 2021, was published in ClinicalTrials.gov (NCT 04960202). Furthermore, at month 11 of 2021, pamphlet website reported that PAXLOVID (TM) (PF-07321332; ritonavir) reduced the risk of hospitalization or death of high-risk adult patients by 89% compared to placebo (non-patent document 14). Further, at month 12 of 2021, PAXLOVID (TM) was approved for emergency use in the United states, at month 10 of 2022, pack was obtained from a specialty lot in japan.
Although non-patent documents 5 to 8 disclose compounds having 3CL protease inhibitory activity, none of these documents describe or suggest compounds related to the present invention.
Although patent documents 1 to 4 and 8 to 12 disclose having p 2X 3 And/or p 2X 2/3 Triazine derivatives and uracil derivatives which are receptor antagonistic, but none of these documents describe or suggest 3CL protease inhibitory activity and antiviral effects.
Although non-patent documents 9 to 11 disclose triazine derivatives having an antitumor effect, none of these documents describe coronavirus 3CL protease inhibitory activity and antiviral effect, and none of them describe or suggest compounds related to the present invention.
Although patent document 5 discloses triazine derivatives having a glycinin receptor modulating effect, none of these documents describe coronavirus 3CL protease inhibitory activity and antiviral effect, and none of them describe or suggest compounds related to the present invention.
[ Prior Art literature ]
[ patent literature ]
Patent document 1: international publication No. 2012/020749
Patent document 2: international publication No. 2013/089212
Patent document 3: international publication No. 2010/092966
Patent document 4: international publication No. 2014/200078
Patent document 5: international publication No. 2012/009258
Patent document 6: international publication No. 2021/205298
Patent document 7: international publication No. 2021/250648
Patent document 8: chinese patent application publication No. 113620888 specification
Patent document 9: chinese patent application publication No. 113666914 specification
Patent document 10: chinese patent application publication No. 113735838 specification
Patent document 11: chinese patent application publication No. 113773300 specification
Patent document 12: chinese patent application publication No. 113801097 specification
[ non-patent literature ]
Non-patent document 1: "covd-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University", [ online ], johns Hopkins University, [2022, 1, 28 days of checkout ], internet < URL: https:// corenavir. Jhu. Edu/map. Html >
Non-patent document 2: the NEW ENGLAND JOURNAL of MEDICINE (2020) volume 382, pages 1564-1567
Non-patent document 3: "Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (covd-19)", [ online ], 28, 2020, WHO, [2021, 2, 8 retrieval ], internet < URL: https:// www.who.int/docs/defaults-source/corenaviuse/who-china-joint-transmission-on-covid-19-fi-nal-report. Pdf >
Non-patent document 4: science (2003), volume 300, pages 1763-1767
Non-patent document 5: "A comparative analysis of SARS-CoV-2antivirals characterizes 3CLpro inhibitor PF-00835231as a potential new treatment for COVID-19", journal of Virology,2021, 4/26, [2022, 2/15, 6/15 ] Internet < URL: https:// journ als. Asm. Org/doi/10.1128/jvi.01819-20> < doi:10.1128/JVI.01819-20 ]
Non-patent document 6: cell Research (2020), volume 30, pages 678-692
Non-patent document 7: science (2020), volume 368, pages 409-412
Non-patent document 8: ACS Central Science (2021), volume 7, number 3, pages 467-475)
Non-patent document 9: cancer Treatment Reviews (1984), volume 11, support 1, pages 99 to 110
Non-patent document 10: contributions to Oncology (1984), volume 18, pages 221-234
Non-patent document 11: arzneimittel-Forschung (1984), vol.11, no. 6, pages 663-668
Non-patent document 12:261st Am Chem Soc (ACS) Natl Meet 2021-04-05/2021-04-16. Virtual, N/A. Abst 243
Non-patent document 13: science (2021), volume 374, pages 1586-1593
Non-patent document 14: "Pfizer's Novel COVID-19Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase/3 EPIC-HR Study", [ online ], month 11, 5, 2021, pfizer Press Release, [ month 2, 15, 2022, cable ], internet < URL: https:// www.pfizer.com/news/press-release/press-release-tail/pfizer-novel-covid-19-oral-anti-therapeutic-treatment-truck >
[ invention ]
[ problem to be solved by the invention ]
It is an object of the present invention to provide a compound having coronavirus 3CL protease inhibitory activity. Preferably, the present invention provides a compound having an antiviral effect, particularly a coronavirus proliferation inhibitory effect, and a medicament containing the compound. It is another object of the present invention to provide crystals and co-crystals of a compound exhibiting 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof and a medicament containing the same.
[ means for solving the problems ]
The present invention relates to the following.
(1') a compound of formula (I):
[ chemical formula 4 ]
(wherein Y is N or CR 7 ;
R 7 Is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 1 is a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted carbamoyl group or a substituted or unsubstituted amino group;
R 2 is a substituted or unsubstituted aromatic carbocyclic group (except for 1-p-fluorophenyl, 1-p-chlorophenyl and 1-p-methylphenyl), a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group or a substituted or unsubstituted non-aromatic heterocyclic group;
R 3 is a substituted or unsubstituted aromatic carbocyclyl, a substituted or unsubstituted non-aromatic carbocyclyl, a substituted or unsubstituted aromatic heterocyclyl, a substituted or unsubstituted A substituted non-aromatic heterocyclic group or a substituted or unsubstituted alkyl group;
-X-is-NR 6 -、-CR 6 R 6’ -, -O-, -S-or a single bond;
R 6 and R is 6’ Each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
m is 0, 1 or 2;
R 5a each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 5b each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
n is 0, 1 or 2;
R 4a each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 4b each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 4a and R is 4b May together form a substituted or unsubstituted non-aromatic carbocyclic ring or a substituted or unsubstituted non-aromatic heterocyclic ring (but the following compounds:
[ chemical 5 ]
Except for) or a pharmaceutically acceptable salt thereof.
(1') a compound of formula (I):
[ 6 ] A method for producing a polypeptide
(wherein Y is N or CR 7 ;
R 7 Is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 1 is a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted carbamoyl group or a substituted or unsubstituted amino group;
R 2 is a substituted or unsubstituted aromatic carbocyclic group (except for 1-p-fluorophenyl, 1-p-chlorophenyl and 1-p-methylphenyl), a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group or a substituted or unsubstituted non-aromatic heterocyclic group;
R 3 Is a substituted or unsubstituted aromatic carbocyclyl group, a substituted or unsubstituted non-aromatic carbocyclyl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, or a substituted or unsubstituted alkyl group;
-X-is-NR 6 -、-CR 6 R 6’ -, -O-, -S-or a single bond;
R 6 and R is 6’ Each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
m is 0, 1 or 2;
R 5a each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 5b each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
n is 0, 1 or 2;
R 4a each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 4b each independently is a hydrogen atom or a substituted or unsubstituted alkyl group (but the following compounds:
[ chemical 7 ]
Except for) or a pharmaceutically acceptable salt thereof.
(2 ") the compound according to item (1") or (1' ") above, or a pharmaceutically acceptable salt thereof, wherein Y is N.
(3 ") the compound according to any one of items (1"), (2 ") and (1'") above, or a pharmaceutically acceptable salt thereof, wherein, -X "is-NH-.
(4') according to the aboveThe compound of any one of (1 ") to (3") and (1' "), or a pharmaceutically acceptable salt thereof, wherein R 2 Is a substituted or unsubstituted 6-14 membered aromatic carbocyclyl, a substituted or unsubstituted 5-10 membered non-aromatic carbocyclyl, a substituted or unsubstituted 5-10 membered aromatic heterocyclyl or a substituted or unsubstituted 5-10 membered non-aromatic heterocyclyl.
(5 ") the compound according to any one of items (1") to (4 ") and (1'") above, or a pharmaceutically acceptable salt thereof, wherein R 2 A 6-membered aromatic carbocyclic group substituted by 1 halogen or cyano group and further substituted by 1, 2, 3 or 4 substituents selected from substituent group G or a 6-membered aromatic heterocyclic group substituted by 1 halogen or cyano group and further substituted by 1 or 2 substituents selected from substituent group G;
the substituent group G is a group consisting of halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkenyloxy, alkynyloxy, and haloalkoxy.
(6 ") the compound according to any one of items (1") to (5 ") and (1'") above, or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1.
(7 ") the compound according to any one of items (1") to (6 ") and (1'") above, or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.
(8 ") the compound according to any one of items (1") to (7 ") and (1'") above, or a pharmaceutically acceptable salt thereof, wherein R 4a Each independently is a hydrogen atom or an unsubstituted alkyl group, R 4b Each independently is a hydrogen atom.
(9 ") the compound according to any one of items (1") to (8 ") and (1'") above, or a pharmaceutically acceptable salt thereof, wherein R 5a Each independently is a hydrogen atom, R 5b Each independently is a hydrogen atom.
(10 ") the compound according to any one of items (1") to (9 ") and (1'") above, or a pharmaceutically acceptable salt thereof, wherein R 1 Is a substituted or unsubstituted aromatic heterocyclic group.
(11') according to the aboveThe compound of any one of items (1 ") to (9") and (1' "), or a pharmaceutically acceptable salt thereof, wherein R 1 Is a substituted or unsubstituted aromatic heterocyclic group, m is 1, R 5a Is a hydrogen atom, R 5b Is a hydrogen atom.
(12 ") the compound according to any one of items (1") to (9 ") and (1'") above, or a pharmaceutically acceptable salt thereof, wherein R 1 And m is 0, which is a substituted or unsubstituted aromatic heterocyclic group.
(13 ") the compound according to any one of items (1") to (12 ") and (1'") above, or a pharmaceutically acceptable salt thereof, wherein R 3 Is a substituted or unsubstituted 6-membered aromatic carbocyclyl, a substituted or unsubstituted 3-10-membered non-aromatic carbocyclyl, a substituted or unsubstituted 5-6-membered aromatic heterocyclyl, a substituted or unsubstituted 9-10-membered aromatic heterocyclyl, a substituted or unsubstituted 13-15-membered aromatic heterocyclyl, or a substituted or unsubstituted 3-20-membered non-aromatic heterocyclyl.
(14 ") the compound according to any one of items (1") to (12 ") and (1'") above, or a pharmaceutically acceptable salt thereof, wherein R 3 Is a substituted or unsubstituted 6-membered aromatic carbocyclyl, a substituted or unsubstituted 9-10-membered aromatic heterocyclyl, or a substituted or unsubstituted 9-13-membered non-aromatic heterocyclyl.
(15 ") the compound according to item (1") or (1' ") above, or a pharmaceutically acceptable salt thereof, wherein formula (I) is
Formula (I'):
[ chemical formula 8 ]
(wherein R is 1’ Is of the formula:
[ chemical formula 9 ]
A group shown;
R 2’ is of the formula:
[ chemical formula 10 ]
A group shown;
R 3’ is of the formula:
[ chemical formula 11 ]
The radicals shown).
(16 ") the compound according to item (1") or (1' ") above, or a pharmaceutically acceptable salt thereof, wherein formula (I) is
Formula (I'):
[ chemical formula 12 ]
(wherein R is 1’ Is of the formula:
[ chemical formula 13 ]
A group shown;
R 2’ is of the formula:
[ chemical formula 14 ]
A group shown;
R 3’ is of the formula:
[ 15 ] A method of producing a polypeptide
The radicals shown).
(17 ") the compound according to item (1") or (1' ") above, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
[ 16 ] the preparation method
A group of groups.
(18 ") a pharmaceutical composition comprising a compound of any one of items (1") to (17 ") and (1'") above, or a pharmaceutically acceptable salt thereof.
(19 ") a coronavirus 3CL protease inhibitor comprising a compound of any one of items (1") to (17 ") and (1'") above, or a pharmaceutically acceptable salt thereof.
(20 ") a coronavirus proliferation inhibitor comprising the compound of any one of the above items (1") to (17 ") and (1'"), or a pharmaceutically acceptable salt thereof.
(21 ") the coronavirus proliferation inhibitor according to the above item (20"), wherein the coronavirus is an alpha genus coronavirus and/or a beta genus coronavirus.
The coronavirus proliferation inhibitor according to the above item (20'), wherein the coronavirus is SARS-CoV-2.
(23 ") a method for the treatment and/or prophylaxis of a disease associated with coronavirus 3CL protease, characterized by administering a compound of any one of the above items (1") to (17 ") and (1'") or a pharmaceutically acceptable salt thereof.
(24 ") a compound according to any one of items (1") to (17 ") and (1'") above, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of a disease associated with coronavirus 3CL protease.
(1') a compound of the formula (I):
[ chemical formula 17 ]
(wherein Y is N or CR 7 ;
R 7 Is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 1 is a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted carbamoyl group or a substituted or unsubstituted amino group;
R 2 is a substituted or unsubstituted aromatic carbocyclic group (except for 1-p-fluorophenyl, 1-p-chlorophenyl and 1-p-methylphenyl), a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group or a substituted or unsubstituted non-aromatic heterocyclic group;
R 3 is a substituted or unsubstituted aromatic carbocyclyl group, a substituted or unsubstituted non-aromatic carbocyclyl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, or a substituted or unsubstituted alkyl group;
-X-is-NR 6 -、-CR 6 R 6’ -, -O-, -S-or a single bond;
R 6 and R is 6’ Each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
m is 0, 1 or 2;
R 5a each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 5b each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
n is 0, 1 or 2;
R 4a each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 4b each independently is a hydrogen atom or a substituted or unsubstituted alkyl group (but the following compounds:
[ chemical formula 18 ]
Except for) or a pharmaceutically acceptable salt thereof.
(1) A compound of formula (I):
[ chemical formula 19 ]
(in the formula (I),
y is N or CR 7 ;
R 7 Is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 1 is a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted carbamoyl group or a substituted or unsubstituted amino group;
R 2 is a substituted or unsubstituted aromatic carbocyclyl (except p-fluorophenyl, p-chlorophenyl and p-methylphenyl), a substituted or unsubstituted non-aromatic carbocyclyl, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted alkyl group;
R 3 is a substituted or unsubstituted aromatic carbocyclyl, a substituted or unsubstituted non-aromatic carbocyclyl, a substituted or unsubstituted aromatic heterocyclyl, or a substituted or unsubstituted non-aromatic heterocyclyl;
-X-is-NR 6 -、-CR 6 R 6’ -, -O-, -S-or a single bond;
R 6 and R is 6’ Each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
m is 0, 1 or 2;
R 5a each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 5b each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
n is 0, 1 or 2;
R 4a each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 4b Each independently is a hydrogen atom or a substituted or unsubstituted alkyl group (but the following compounds:
[ chemical formula 20 ]
Except for) or a pharmaceutically acceptable salt thereof.
(2) The compound according to item (1) or (1') above, or a pharmaceutically acceptable salt thereof, wherein Y is N.
(3) The compound according to item (1), (2) or (1') above, or a pharmaceutically acceptable salt thereof, wherein-X-is-NH-.
(4 ') the compound according to any one of the above items (1) to (3) and (1'), or a pharmaceutically acceptable salt thereof, wherein R 2 Is a substituted or unsubstituted 6, 10 or 14 membered aromatic carbocyclyl, a substituted or unsubstituted 5, 6, 9 or 10 membered non-aromatic carbocyclyl, a substituted or unsubstituted 5, 6, 9 or 10 membered aromatic heterocyclyl or a substituted or unsubstituted 5, 6, 9 or 10 membered non-aromatic heterocyclyl.
(4) The compound according to any one of the above items (1) to (3) and (1'), or a pharmaceutically acceptable salt thereof, wherein R 2 Is a substituted or unsubstituted 6-membered aromatic carbocyclyl, a substituted or unsubstituted 9-10-membered non-aromatic carbocyclyl, a substituted or unsubstituted 5-6-membered aromatic heterocyclyl, or a substituted or unsubstituted 9-10-membered non-aromatic heterocyclyl.
(5 ') the compound according to any one of the above items (1) to (4), (1 ') and (4 '), or a pharmaceutically acceptable salt thereof, wherein R 2 A 6-membered aromatic carbocyclic group substituted by 1 halogen or cyano group and further substituted by 1, 2, 3 or 4 substituents selected from substituent group G or a 6-membered aromatic heterocyclic group substituted by 1 halogen or cyano group and further substituted by 1 or 2 substituents selected from substituent group G;
the substituent group G is a group consisting of halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkenyloxy, alkynyloxy, and haloalkoxy.
Here, 1, 2, 3 or 4 substituents selected from the substituent group G may be the same or different, respectively.
(5) The compound according to any one of the above items (1) to (4), (1 ') and (4'), or a pharmaceutically acceptable salt thereof, wherein R 2 A 6-membered aromatic carbocyclic group substituted by 1 halogen and further substituted by 1, 2, 3 or 4 substituents selected from substituent group G or a 6-membered aromatic heterocyclic group substituted by 1 halogen and further substituted by 1 or 2 substituents selected from substituent group G;
the substituent group G is a group consisting of halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkenyloxy, alkynyloxy, and haloalkoxy.
(6) The compound according to any one of the above items (1) to (5), (1 '), (4 ') and (5 '), or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1.
(7) The compound according to any one of the above items (1) to (6), (1 '), (4 ') and (5 '), or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.
(8) The compound according to any one of the above items (1) to (7), (1 '), (4 ') and (5 '), or a pharmaceutically acceptable salt thereof, wherein R 4a Each independently is a hydrogen atom or an unsubstituted alkyl group, R 4b Each independently is a hydrogen atom.
(9) The compound according to any one of the above items (1) to (8), (1 '), (4 ') and (5 '), or a pharmaceutically acceptable salt thereof, wherein R 5a Each independently is a hydrogen atom, R 5b Each independently is a hydrogen atom.
(10) The compound according to any one of the above items (1) to (9), (1 '), (4 ') and (5 '), or a pharmaceutically acceptable salt thereof, wherein R 1 Is a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aromatic heterocyclic group.
(10 ') the compound according to any one of the above items (1) to (9), (1'), (4 ') and (5'), or a pharmaceutically acceptable salt thereof, wherein R 1 Is a substituted or unsubstituted aromatic heterocyclic group.
(11) The compound according to any one of the above items (1) to (9), (1 '), (4 ') and (5 '), or a pharmaceutically acceptable salt thereof, wherein R 1 Is a substituted or unsubstituted non-aromatic heterocyclic group or a substituted or unsubstituted aromatic heterocyclic group, m is 1, R 5a Is a hydrogen atom, R 5b Is a hydrogen atom.
(11 ') the compound according to any one of the above items (1) to (9), (1'), (4 ') and (5'), or a pharmaceutically acceptable salt thereof, wherein R 1 Is a substituted or unsubstituted aromatic heterocyclic group, m is 1, R 5a Is a hydrogen atom, R 5b Is a hydrogen atom.
(12) The compound according to any one of the above items (1) to (9), (1 '), (4 ') and (5 '), or a pharmaceutically acceptable salt thereof, wherein R 1 And m is 0, which is a substituted or unsubstituted aromatic heterocyclic group.
(13) The compound according to any one of the above items (1) to (12), (1 '), (4 '), (5 '), (10 ') and (11 '), or a pharmaceutically acceptable salt thereof, wherein R 3 Is a substituted or unsubstituted 6-membered aromatic carbocyclyl, a substituted or unsubstituted 3-10-membered non-aromatic carbocyclyl, a substituted or unsubstituted 5-6-membered aromatic heterocyclyl, a substituted or unsubstituted 9-10-membered aromatic heterocyclyl, a substituted or unsubstituted 13-15-membered aromatic heterocyclyl, or a substituted or unsubstituted 3-20-membered non-aromatic heterocyclyl.
(14) The compound according to any one of the above items (1) to (13), (1 '), (4 '), (5 '), (10 ') and (11 '), or a pharmaceutically acceptable salt thereof, wherein R 3 Is a substituted or unsubstituted 6-membered aromatic carbocyclyl, a substituted or unsubstituted 9-10-membered aromatic heterocyclyl, or a substituted or unsubstituted 9-13-membered non-aromatic heterocyclyl.
(15-1) the compound according to item (1) or (1 ') above, or a pharmaceutically acceptable salt thereof, wherein formula (I) is formula (I'):
[ chemical formula 21 ]
(wherein R is 1’ Is of the formula:
[ chemical formula 22 ]
A group shown;
R 2’ is of the formula:
[ chemical formula 23 ]
A group shown;
R 3’ is of the formula:
[ chemical 24 ]
/>
The radicals shown).
(16-1) the compound according to item (1) or (1 ') above, or a pharmaceutically acceptable salt thereof, wherein formula (I) is formula (I'):
[ chemical 25 ]
(wherein R is 1’ Is of the formula:
[ chemical 26 ]
A group shown; r is R 2’ Is of the formula:
[ chemical formula 27 ]
A group shown; r is R 3’ Is of the formula:
[ chemical 28 ]
The radicals shown).
(15 ') the compound according to the above item (1) or (1 '), or a pharmaceutically acceptable salt thereof, wherein formula (I) is formula (I '):
[ chemical 29 ]
(wherein R is 1’ Is of the formula:
[ chemical formula 30 ]
A group shown;
R 2’ is of the formula:
[ chemical 31 ]
A group shown;
R 3’ is of the formula:
[ chemical formula 32 ]
The radicals shown).
(16 ') the compound according to the above item (1) or (1 '), or a pharmaceutically acceptable salt thereof, wherein formula (I) is formula (I '):
[ chemical formula 33 ]
(wherein R is 1’ Is of the formula:
[ chemical 34 ]
A group shown;
R 2’ is of the formula:
[ 35 ]
A group shown;
R 3’ is of the formula:
[ chemical formula 36 ]
The radicals shown).
(17 ') the compound according to the above item (1) or (1'), or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
[ FORMS 37 ]
A group of groups.
(15) A pharmaceutical composition comprising the compound of any one of items (1) to (14), (1 '), (4 '), (5 '), (10 '), (11 '), (15 ') to (17 '), (15-1) and (16-1) above or a pharmaceutically acceptable salt thereof.
(16) A coronavirus 3CL protease inhibitor comprising the compound of any one of items (1) to (14), (1 '), (4 '), (5 '), (10 '), (11 '), (15 ') to (17 '), (15-1) and (16-1) above or a pharmaceutically acceptable salt thereof.
(17) A coronavirus propagation inhibitor comprising the compound according to any one of the above items (1) to (14), (1 '), (4 '), (5 '), (10 '), (11 '), (15 ') to (17 '), (15-1) and (16-1), or a pharmaceutically acceptable salt thereof.
(18) The coronavirus proliferation inhibitor according to the above item (17), wherein the coronavirus is an alpha genus coronavirus and/or a beta genus coronavirus.
(19) The coronavirus proliferation inhibitor according to the above item (17), wherein the coronavirus is SARS-CoV-2.
(20) A pharmaceutical composition comprising the compound of any one of the above items (1) to (14), (1 '), (4 '), (5 '), (10 '), (11 '), (15 ') to (17 '), (15-1), (16-1), (1 ') and (1 ' ") or a pharmaceutically acceptable salt thereof for use in the prevention and/or treatment of coronavirus infection.
(21) The pharmaceutical composition according to item (20) above, which is used for the prevention and/or treatment of a novel coronavirus infection (COVID-19).
(22) The pharmaceutical composition according to item (20) above, which is used for the prevention and/or treatment of an infection caused by SARS-CoV-2.
(23) A method for inhibiting the proliferation of coronaviruses, which comprises administering the compound of any one of items (1) to (14), (1 '), (4 '), (5 '), (10 '), (11 '), (15 ') to (17 '), (15-1), (16-1), (1 ') and (1 ' ") or a pharmaceutically acceptable salt thereof.
The proliferation inhibition method according to item (23-1) above, wherein the coronavirus is an alpha genus coronavirus and/or a beta genus coronavirus.
(24) The proliferation inhibition method according to item (23) above, wherein the coronavirus is SARS-CoV-2.
(25) A method for the treatment and/or prophylaxis of a disease associated with coronavirus 3CL protease, characterized by administering the compound of any one of items (1) to (14), (1 '), (4 '), (5 '), (10 '), (11 '), (15 ') to (17 '), (15-1), (16-1), (1 ') and (1 ' ") or a pharmaceutically acceptable salt thereof.
(26) A method for the treatment and/or prophylaxis of coronavirus infection, wherein the compound of any one of items (1) to (14), (1 '), (4 '), (5 '), (10 '), (11 '), (15 ') to (17 '), (15-1), (16-1), (1 ') and (1 ' ") or a pharmaceutically acceptable salt thereof is administered.
(27) The method for preventing and/or treating according to item (26) above, wherein the coronavirus infection is a novel coronavirus infection (COVID-19).
(28) The method for preventing and/or treating according to item (26) above, wherein the coronavirus infection is an infection caused by SARS-CoV-2.
(29) Use of the compound according to any one of items (1) to (14), (1 '), (4 '), (5 '), (10 '), (11 '), (15 ') to (17 '), (15-1), (16-1), (1 ') and (1 ' ") or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic and/or prophylactic agent for a disease associated with coronavirus 3CL protease.
(30) Use of the compound of any one of items (1) to (14), (1 '), (4'), (5 '), (10'), (11 '), (15') to (17 '), (15-1), (16-1), (1 ") and (1'") or a pharmaceutically acceptable salt thereof for the manufacture of a proliferation inhibitor for coronaviruses.
(31) The use according to item (30) above, wherein the coronavirus is an alpha genus coronavirus and/or a beta genus coronavirus.
(32) The use according to item (30) above, wherein the coronavirus is SARS-CoV-2.
(33) Use of the compound of any one of items (1) to (14), (1 '), (4'), (5 '), (10'), (11 '), (15') to (17 '), (15-1), (16-1), (1 ") and (1'") or a pharmaceutically acceptable salt thereof for the manufacture of a therapeutic and/or prophylactic agent for coronavirus infection.
(34) The use according to item (33) above, wherein the coronavirus infection is a novel coronavirus infection (COVID-19).
(35) The use according to item (33) above, wherein the coronavirus infection is an infection caused by SARS-CoV-2.
(36) The compound according to any one of the above items (1) to (14), (1 '), (4 '), (5 '), (10 '), (11 '), (15 ') to (17 '), (15-1), (16-1), (1 ') and (1 ' "), or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of a disease associated with coronavirus 3CL protease.
(37) The compound according to any one of the above items (1) to (14), (1 '), (4 '), (5 '), (10 '), (11 '), (15 ') to (17 '), (15-1), (16-1), (1 ') and (1 ' ", or a pharmaceutically acceptable salt thereof, for use in the proliferation inhibition of coronaviruses.
(37-1) the compound according to item (37) above or a pharmaceutically acceptable salt thereof, wherein the coronavirus is an alpha-genus coronavirus and/or a beta-genus coronavirus.
(37-2) the compound according to item (37) above, or a pharmaceutically acceptable salt thereof, wherein the coronavirus is SARS-CoV-2.
(38) The compound according to any one of the above items (1) to (14), (1 '), (4 '), (5 '), (10 '), (11 '), (15 ') to (17 '), (15-1), (16-1), (1 ') and (1 ' ") or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of coronavirus infection.
(39) The compound according to item (38) above, wherein the coronavirus infection is a novel coronavirus infection (covd-19), or a pharmaceutically acceptable salt thereof.
(40) The compound according to item (38) above, or a pharmaceutically acceptable salt thereof, wherein the coronavirus infection is an infection caused by SARS-CoV-2.
(41) A compound of formula (I):
[ chemical 38 ]
(wherein Y is N or CR 7 ;
R 7 Is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 1 is a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted carbamoyl group or a substituted or unsubstituted amino group;
R 2 is a substituted or unsubstituted aromatic carbocyclyl group, a substituted or unsubstituted non-aromatic carbocyclyl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, or a substituted or unsubstituted alkyl group;
R 3 is a substituted or unsubstituted aromatic carbocyclyl, a substituted or unsubstituted non-aromatic carbocyclyl, a substituted or unsubstituted aromatic heterocyclyl, or a substituted or unsubstituted non-aromatic heterocyclyl;
-X-is-NR 6 -、-CR 6 R 6’ -, -O-, -S-or a single bond;
R 6 and R is 6’ Each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
m is 0, 1 or 2;
R 5a each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 5b each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
n is 0, 1 or 2;
R 4a each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 4b each independently of the otherA hydrogen atom or a substituted or unsubstituted alkyl group) or a pharmaceutically acceptable salt thereof.
(42) The compound according to item (41) above, wherein Y is N, or a pharmaceutically acceptable salt thereof.
(43) The compound according to item (41) or (42) above, or a pharmaceutically acceptable salt thereof, wherein R 1 Is a substituted or unsubstituted aromatic heterocyclic group.
(44) The compound according to any one of the above items (41) to (43), or a pharmaceutically acceptable salt thereof, wherein R 2 Is a substituted or unsubstituted 6 membered aromatic carbocyclyl.
(45) The compound according to any one of the above items (41) to (44), or a pharmaceutically acceptable salt thereof, wherein R 3 Is a substituted or unsubstituted aromatic heterocyclic group.
(46) The compound according to any one of the above items (41) to (45), or a pharmaceutically acceptable salt thereof, wherein, -X-is-NH-.
(47) The compound according to any one of the above items (41) to (46), or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1.
(48) The compound according to any one of the above items (41) to (47), or a pharmaceutically acceptable salt thereof, wherein R 5a Is a hydrogen atom.
(49) The compound according to any one of the above items (41) to (48), or a pharmaceutically acceptable salt thereof, wherein R 5b Is a hydrogen atom.
(50) The compound according to any one of the above items (41) to (49), or a pharmaceutically acceptable salt thereof, wherein n is 1.
(51) The compound according to any one of the above items (41) to (50), or a pharmaceutically acceptable salt thereof, wherein R 4a Is a hydrogen atom.
(52) The compound according to any one of the above items (41) to (51), or a pharmaceutically acceptable salt thereof, wherein R 4b Is a hydrogen atom.
(53) The compound according to any one of the above items (41) to (52)Or a pharmaceutically acceptable salt thereof, wherein R 1 Is a substituted or unsubstituted 5-6 membered aromatic heterocyclic group.
(54) The compound according to any one of the above items (41) to (53), or a pharmaceutically acceptable salt thereof, wherein R 2 A 6 membered aromatic carbocyclyl substituted with 1, 2 or 3 substituents selected from substituent group G;
here, the substituent group G is a group consisting of halogen, cyano and alkyl.
(55) The compound according to any one of the above items (41) to (54), or a pharmaceutically acceptable salt thereof, wherein R 3 Is a substituted or unsubstituted 9-10 membered aromatic heterocyclic group.
(AA 1) a formula:
[ chemical formula 39 ]
A compound as shown or a pharmaceutically acceptable salt thereof.
(AA 1') a formula:
[ 40 ]
A compound as shown or a pharmaceutically acceptable salt thereof.
(AA 2) a pharmaceutical composition comprising the compound of item (AA 1) or (AA 1') above or a pharmaceutically acceptable salt thereof.
(AA 3) a coronavirus 3CL protease inhibitor comprising a compound as set forth in item (AA 1) or (AA 1') above, or a pharmaceutically acceptable salt thereof.
(AA 4) a coronavirus proliferation inhibitor comprising the compound described in the above item (AA 1) or (AA 1'), or a pharmaceutically acceptable salt thereof.
(AA 5) the coronavirus proliferation inhibitor according to the above item (AA 4), wherein the coronavirus is an alpha genus coronavirus and/or a beta genus coronavirus.
(AA 6) the coronavirus proliferation inhibitor according to the above item (AA 4), wherein the coronavirus is SARS-CoV-2.
(AA 7) a method for the treatment and/or prophylaxis of diseases associated with coronavirus 3CL protease, characterized in that the compound of item (AA 1) or (AA 1') above or a pharmaceutically acceptable salt thereof is administered.
(AA 8) the compound according to the above item (AA 1) or (AA 1'), or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of a disease associated with coronavirus 3CL protease.
The invention also relates to the following.
(1A) A compound of formula (I-a):
[ chemical formula 41 ]
P-toluenesulfonate salt of the compound shown or a solvate thereof.
(2A) A compound of formula (I-a):
[ chemical 42 ]
Crystals of p-toluenesulfonate salt of the compound shown.
(3A) The p-toluenesulfonate crystal form I according to item (2A) above, said crystal being at a diffraction angle (2. Theta.) in an X-ray powder diffraction pattern: peaks at 9.1.+ -. 0.2 °, 15.2.+ -. 0.2 °, 18.8.+ -. 0.2 °, 23.6.+ -. 0.2 ° and 24.9.+ -. 0.2 °.
(4A) The p-toluenesulfonate crystal form I according to item (2A) above, said crystal being at a diffraction angle (2. Theta.) in an X-ray powder diffraction pattern: peaks at 9.1.+ -. 0.2 °, 11.5.+ -. 0.2 °, 14.6.+ -. 0.2 °, 15.2.+ -. 0.2 °, 18.8.+ -. 0.2 °, 20.2.+ -. 0.2 °, 23.6.+ -. 0.2 °, 24.2.+ -. 0.2 °, 24.9.+ -. 0.2 ° and 26.9.+ -. 0.2 °.
(5A) A pharmaceutical composition comprising the crystal of any one of the above items (2A) to (4A).
(6A) The p-toluenesulfonate crystal form I according to item (2A) above, as determined at 298K, was characterized by the following crystallographic data:
space group: p-1
α=103.7°±0.5°
β=97.4°±0.5°
γ=100.4°±0.5°。
(7A) The crystalline form I of p-toluenesulfonate according to item (2A) above, characterized by crystallographic data substantially equivalent to:
Space group: p-1
/>
α=103.727°
β=97.411°
γ=100.358°。
(8A) The crystalline form I of p-toluenesulfonate according to item (2A) above, characterized by an X-ray powder diffraction pattern substantially in accordance with figure 1.
(9A) A pharmaceutical composition comprising the crystal of any one of the above items (6A) to (8A).
(1B) A composition comprising formula (I-B):
[ chemical formula 43 ]
Complexes of the compounds shown and fumaric acid.
(2B) The complex according to item (1B) above, wherein formula (I-B):
[ 44 ]
The compounds shown and fumaric acid are present in a molar ratio of 1:1.
(3B) A fumaric acid co-crystal according to item (1B) or (2B) above.
(4B) The fumaric acid co-crystal form I according to item (3B) above, wherein in the X-ray powder diffraction pattern, the co-crystal is at a diffraction angle (2. Theta.): peaks at 9.5.+ -. 0.2 °, 10.9.+ -. 0.2 °, 18.6.+ -. 0.2 °, 23.5.+ -. 0.2 ° and 24.6.+ -. 0.2 °.
(5B) The fumaric acid co-crystal form I according to item (3B) above, wherein in the X-ray powder diffraction pattern, the co-crystal is at a diffraction angle (2. Theta.): peaks at 7.8.+ -. 0.2 °, 9.5.+ -. 0.2 °, 10.1.+ -. 0.2 °, 10.9.+ -. 0.2 °, 13.8.+ -. 0.2 °, 14.7.+ -. 0.2 °, 18.6.+ -. 0.2 °, 22.6.+ -. 0.2 °, 23.5.+ -. 0.2 ° and 24.6.+ -. 0.2 °.
(6B') the fumaric acid co-crystal form I according to item (3B) above, wherein the co-crystal is at 676.3cm in Raman spectrum -1 ±2cm -1 、748.0cm -1 ±2cm -1 、1029.3cm -1 ±2cm -1 、1374.4cm -1 ±2cm -1 、1515.5cm -1 ±2cm -1 、1665.7cm -1 ±2cm -1 、1715.7cm -1 ±2cm -1 1739.1cm -1 ±2cm -1 With raman spectral peaks.
(6B) A pharmaceutical composition comprising the co-crystal of any one of items (3B) to (5B) and (6B') above.
(7B) The fumaric acid co-crystal form I according to item (3B) above, which is characterized by the following crystallographic data, in the case of its measurement at 298K:
space group: p-1
α=83.8°±0.5°
β=78.9°±0.5°
γ=77.1°±0.5°。
(8B) The fumaric acid co-crystal form I according to item (3B) above, which is characterized by the following crystallographic data, when measured at 298K:
space group: p-1
α=83.827°
β=78.868°
γ=77.147°。
(9B) The fumaric acid co-crystal form I according to item (3B) above, characterized by one or more spectra and/or curves selected from the following (a) - (c):
(a) An X-ray powder diffraction pattern substantially in accordance with figure 3;
(b) A raman spectrum substantially in accordance with fig. 5; and
(c) A differential scanning calorimetric curve substantially in accordance with that of figure 6.
(10B) A pharmaceutical composition comprising the co-crystal of any one of items (7B) to (9B) above.
[ Effect of the invention ]
The compounds of the present invention have inhibitory activity against coronavirus 3CL protease and are useful as therapeutic and/or prophylactic agents for coronavirus infection.
In addition, among the compounds according to the present invention, the compound (I-0113) or the compound (I-0115) can be used as a drug substance.
Further, pharmaceutical compositions containing the p-toluenesulfonate crystal of the compound (I-0113) or the fumaric acid co-crystal of the compound (I-0115) are very useful as a therapeutic agent for novel coronavirus infection (COVID-19).
[ description of the drawings ]
FIG. 1 shows an X-ray powder diffraction pattern of the p-toluenesulfonate crystal Form I (Form I) of the compound of formula (I-A). The horizontal axis represents 2θ (°), and the vertical axis represents intensity (Count).
FIG. 2 shows a structural diagram in an asymmetric unit of the p-toluenesulfonate crystal form I of the compound of formula (I-A).
FIG. 3 shows an X-ray powder diffraction pattern of fumaric acid co-crystal Form I (Form I) of the compound represented by formula (I-B). The horizontal axis represents 2θ (°), and the vertical axis represents intensity (Count).
FIG. 4 shows a structural diagram in an asymmetric unit of fumaric acid co-crystal Form I (Form I) of the compound of formula (I-B).
FIG. 5 shows a Raman spectrum of fumaric acid co-crystal Form I (Form I) of the compound represented by the formula (I-B). The horizontal axis represents Raman shift (cm) -1 ) The vertical axis represents peak intensity.
FIG. 6 shows DSC analysis results of fumaric co-crystal Form I (Form I) of the compound represented by the formula (I-B). The horizontal axis represents temperature (. Degree. C.) and the vertical axis represents heat flow (W/g).
FIG. 7 shows an X-ray powder diffraction pattern of potassium salt crystal Form I (Form I) of the compound represented by the formula (I-B). The horizontal axis represents 2θ (°), and the vertical axis represents intensity ((Count).
FIG. 8 shows a Raman spectrum of a potassium salt crystal Form I (Form I) of the compound represented by the formula (I-B). The horizontal axis represents Raman shift (cm) -1 ) The vertical axis represents peak intensity.
FIG. 9 shows an X-ray powder diffraction pattern of succinic acid co-crystal Form I (Form I) of the compound represented by formula (I-B). The horizontal axis represents 2θ (°), and the vertical axis represents intensity (Count).
FIG. 10 shows the Raman spectrum of succinic acid co-crystal Form I (Form I) of the compound shown by formula (I-B). The horizontal axis represents Raman shift (cm) -1 ) The vertical axis represents peak intensity.
FIG. 11 shows an X-ray powder diffraction pattern of the anhydrous crystalline Form I (Form I) of the compound of formula (I-B). The horizontal axis represents 2θ (°), and the vertical axis represents intensity (Count).
FIG. 12 shows the Raman spectrum of the anhydrous crystalline Form I (Form I) of the compound of formula (I-B). The horizontal axis represents Raman shift (cm) -1 ) The vertical axis represents peak intensity.
FIG. 13 shows an X-ray powder diffraction pattern of the sodium salt crystal Form I (Form I) of the compound represented by formula (I-B). The horizontal axis represents 2θ (°), and the vertical axis represents intensity (Count).
FIG. 14 shows a Raman spectrum of a sodium salt crystal Form I (Form I) of the compound shown by the formula (I-B). The horizontal axis represents Raman shift (cm) -1 ) The vertical axis represents peak intensity.
FIG. 15 shows the TG/DTA analysis results of the sodium salt crystal Form I (Form I) of the compound represented by the formula (I-B). The vertical axis represents heat (. Mu.V) or weight change (%), and the horizontal axis represents temperature (. Degree. C.). Cel in the figure refers to degrees Celsius (. Degree. C.).
[ detailed description ] of the invention
Hereinafter, the meaning of each term used in the present specification will be described. Unless specifically stated otherwise, each term is used in the same sense when used alone or in combination with other terms.
The term "consisting of … …" means having only constituent elements.
The term "comprising" means not limited to the constituent elements, and does not exclude elements not described.
The present invention will be described below with reference to embodiments. It should be understood that throughout this specification, singular forms refer to concepts that also include plural forms thereof unless otherwise indicated. Accordingly, it should be understood that, unless otherwise indicated, the singular forms of articles (e.g., "a," "an," "the," etc. in english) also include the plural forms of concepts.
Furthermore, it should be understood that the terms used in the specification are used in the meanings commonly used in the art unless otherwise indicated. Accordingly, unless defined otherwise, all terms of art and special purpose and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present specification, including definitions, will control.
"halogen" includes fluorine atoms, chlorine atoms, bromine atoms, and iodine atoms. Fluorine atoms and chlorine atoms are particularly preferred.
"alkyl" includes straight or branched hydrocarbon groups having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, and still more preferably 1 to 4 carbon atoms. Examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, n-decyl and the like.
Preferred embodiments of the "alkyl" group include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and n-pentyl groups. Further preferred embodiments include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.
"alkenyl" includes straight-chain or branched hydrocarbon groups having 2 to 15 carbon atoms, preferably 2 to 10 carbon atoms, more preferably 2 to 6 carbon atoms, still more preferably 2 to 4 carbon atoms, each having one or more double bonds at any position. Examples thereof include vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl, pentadecenyl and the like.
Preferred embodiments of the "alkenyl" group include vinyl, allyl, propenyl, isopropenyl, butenyl. Further preferred embodiments include vinyl, n-propenyl, and the like.
"alkynyl" includes straight-chain or branched hydrocarbon groups having 2 to 10 carbon atoms, preferably 2 to 8 carbon atoms, more preferably 2 to 6 carbon atoms, and even more preferably 2 to 4 carbon atoms, each having one or more triple bonds at any position. Further, it may have a double bond at an arbitrary position. For example, acetylene, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, and the like are included.
Preferred embodiments of "alkynyl" include ethynyl, propynyl, butynyl, pentynyl. Further preferred embodiments include ethynyl, propynyl and the like.
"aromatic carbocyclyl" means a monocyclic or bicyclic and above cyclic aromatic hydrocarbon group. Examples thereof include phenyl, naphthyl, anthryl and phenanthryl. Examples of the 6-membered aromatic carbocyclyl group include phenyl. Examples of the 10-membered aromatic carbocyclyl group include naphthyl. Examples of the 14-membered aromatic carbocyclyl group include anthracyl and phenanthryl.
Preferred embodiments of the "aromatic carbocyclyl" include, for example, phenyl.
"aromatic carbocycle" means a ring derived from the above "aromatic carbocyclyl".
“R 1b And R is 1c Examples of the substituted or unsubstituted aromatic carbocyclic ring "formed together with the bonded carbon atom include the following rings.
[ chemical 45 ]
"non-aromatic carbocyclyl" means a monocyclic or bicyclic or higher cyclic saturated or cyclic non-aromatic unsaturated hydrocarbon group. The "non-aromatic carbocyclyl group" of the double ring and above also includes those in which a ring in the above-described "aromatic carbocyclyl group" is condensed with a single ring or a double ring and above non-aromatic carbocyclyl group.
Further, "non-aromatic carbocyclyl" also includes bridging groups or spiro ring forming groups as follows.
[ chemical 46 ]
The number of carbon atoms of the monocyclic non-aromatic carbocyclic group is preferably 3 to 16, more preferably 3 to 12, still more preferably 4 to 8. Examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclohexanedienyl. Examples of the 5-membered non-aromatic carbocyclyl group include cyclopentyl and cyclopentenyl. Examples of the 6-membered non-aromatic carbocyclyl group include cyclohexyl, cyclohexenyl, and cyclohexadienyl.
The number of carbon atoms of the non-aromatic carbocyclic group having a double ring or more is preferably 4 to 20, more preferably 8 to 16. Examples thereof include indanyl, indenyl, acenaphthylenyl, tetrahydronaphthyl and fluorenyl. Examples of the 4-membered non-aromatic carbocyclyl group include bicyclo [1.1.1] pentyl group. Examples of the 9-membered non-aromatic carbocyclyl group include indanyl and indenyl. Examples of the 10-membered non-aromatic carbocyclic group include a dihydronaphthyl group and a tetrahydronaphthyl group.
"non-aromatic carbocycle" means a ring derived from the above "non-aromatic carbocyclyl".
“R 4a And R is 4b Examples of the substituted or unsubstituted non-aromatic carbon ring "to be formed together include the following rings.
[ chemical formula 47 ]
"aromatic heterocyclic" means a monocyclic or bicyclic ring having one or more heteroatoms, optionally selected from O, S, N, in the ring, and an aromatic ring or groups.
The aromatic heterocyclic group having a double ring or more includes those in which a ring in the above "aromatic carbocyclic group" is condensed with a single ring or an aromatic heterocyclic group having a double ring or more, and the bond may be present in any ring.
The monocyclic aromatic heterocyclic group is preferably 5 to 8 membered, more preferably 5 or 6 membered. Examples of the 5-membered aromatic heterocyclic group include a pyrrolyl group, an imidazolyl group, a pyrazolyl group, a triazolyl group, a tetrazolyl group, a furyl group, a thienyl group, an isoxazolyl group, an oxazolyl group, an oxadiazolyl group, an isothiazolyl group, a thiazolyl group, and a thiadiazolyl group. Examples of the 6-membered aromatic heterocyclic group include pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl.
The bicyclic aromatic heterocyclic group is preferably 8 to 10 membered, more preferably 9 or 10 membered. Examples thereof include indolyl, isoindolyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzimidazolyl, benzisoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuranyl, isobenzofuranyl, benzothienyl, benzotriazole, imidazopyridinyl, triazolopyridinyl, imidazothiazolyl, pyrazinopyridazinyl, oxazolopyridinyl, thiazolopyridinyl, and the like. Examples of the 9-membered aromatic heterocyclic group include indolyl, isoindolyl, indazolyl, indolizinyl, purinyl, benzimidazolyl, benzisoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazole, benzofuranyl, imidazopyridinyl, triazolopyridinyl, oxazolopyridinyl, and thiazolopyridinyl. Examples of the 10-membered aromatic heterocyclic group include a quinolinyl group, an isoquinolinyl group, a cinnolinyl group, a phthalazinyl group, a quinazolinyl group, a naphthyridinyl group, a quinoxalinyl group, a pteridinyl group, and a pyrazinopyridazinyl group.
The aromatic heterocyclic group of tricyclic and higher is preferably 13 to 15 membered. Examples thereof include carbazolyl, acridinyl, xanthenyl, phenothiazinyl, phenoxathiazinyl, phenoxazinyl, dibenzofuranyl and the like.
"aromatic heterocycle" means a ring derived from the above "aromatic heterocyclic group".
“R 1b And R is 1c Examples of the substituted or unsubstituted aromatic heterocyclic ring "formed together with the bonded carbon atom include the following rings.
[ chemical formula 48 ]
"non-aromatic heterocyclic" means a monocyclic or bicyclic ring having one or more heteroatoms, optionally selected from O, S, N, in the ring, and a non-aromatic ring having one or more heteroatoms, optionally selected from O, S, N, in the ring. The non-aromatic heterocyclic group having a double ring or more includes those in which each ring in the above-mentioned "aromatic carbocyclic group", "non-aromatic carbocyclic group" and/or "aromatic heterocyclic group" is condensed with a single ring or a double ring or more of a non-aromatic heterocyclic group, and further includes those in which each ring in the above-mentioned "aromatic heterocyclic group" is condensed with a single ring or a double ring or more of a non-aromatic carbocyclic group, and may have such a bond at any ring.
Further, "non-aromatic heterocyclic group" also includes a bridging group or a spiro ring-forming group as follows.
[ chemical formula 49 ]
The monocyclic non-aromatic heterocyclic group is preferably 3 to 8-membered, more preferably 5-membered or 6-membered.
Examples of the 3-membered non-aromatic heterocyclic group include an ethylene oxide group, and an aziridine group. Examples of the 4-membered non-aromatic heterocyclic group include oxetanyl group and azetidinyl group. Examples of the 5-membered non-aromatic heterocyclic group include oxathiolyl, thiazolidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, tetrahydrofuranyl, dihydrothiazolyl, tetrahydroisothiazolyl, dioxolyl, tetrahydrothienyl (thiolanyl), and the like. Examples of the 6-membered non-aromatic heterocyclic group include a dioxanyl group, a thialkyl group (thianyl group), a piperidyl group, a piperazinyl group, a morpholino group, a thiomorpholino group, a dihydropyridinyl group, a tetrahydropyranyl group, a dihydropyrazinyl group, a tetrahydropyridazinyl group, a hexahydropyrimidinyl group, a dioxazinyl group, a thiaynyl group (thianyl group), a thiazinyl group, and the like. Examples of the 7-membered non-aromatic heterocyclic group include hexahydroazepinyl, tetrahydrodiazepiyl, and oxetanyl.
The non-aromatic heterocyclic group of the bicyclo ring or the above is preferably 8 to 20 membered, more preferably 8 to 13 membered, still more preferably 8 to 10 membered. Examples thereof include indolinyl, isoindolinyl, chromanyl, and isochromanyl. Examples of the 9-membered non-aromatic heterocyclic group include indolinyl and isoindolinyl. Examples of the 10-membered non-aromatic heterocyclic group include a chromanyl group and an isochromanyl group.
"non-aromatic heterocycle" means a ring derived from the aforementioned "non-aromatic heterocyclic group".
“R 4a And R is 4b Examples of the substituted or unsubstituted non-aromatic heterocyclic ring "to be formed together include the following rings.
[ 50 ] of the formula
"trialkylsilyl" means three groups as described above wherein the "alkyl" is bonded to a silicon atom. The three alkyl groups may be the same or different. Examples thereof include trimethylsilyl, triethylsilyl, and t-butyldimethylsilyl.
"Cyclic sulfoximino" means a group in which two carbon atoms bonded to the sulfur atom of the sulfoximino group, together with the bonded sulfur atom, form a non-aromatic heterocyclic ring. For example, the following groups can be mentioned.
[ chemical formula 51 ]
In the present specification, "may be substituted with a substituent group α" means "may be substituted with one or more groups selected from the substituent group α". The same applies to the substituent groups β, γ and γ'.
The substituents for "substituted alkyl", "substituted alkenyl", "substituted alkynyl", "substituted alkoxy", "substituted alkenyloxy", "substituted alkynyloxy", "substituted alkylcarbonyloxy", "substituted alkenylcarbonyloxy", "substituted alkylcarbonyl", "substituted alkenylcarbonyl", "substituted alkynylcarbonyl", "substituted alkoxycarbonyl", "substituted alkenyloxycarbonyl", "substituted alkylthio", "substituted alkenylthio", "substituted alkynylsulfanyl", "substituted alkylsulfinyl", "substituted alkenylsulfinyl", "substituted alkynylsulfonyl", "substituted alkylsulfonyl", "substituted alkenylsulfonyl", "substituted alkynylsulfonyl", "substituted dialkylsulfonylimino" and the like may be exemplified by the following substituent group a. The carbon atom in any position may be bonded to one or more groups selected from the following substituent group a.
Substituent group a: halogen, hydroxy, carboxy, formyl, formyloxy, sulfanyl, sulfinyl, sulfonyl, thiocarbonyl, thiocarboxyl, dithiocarboxyl, thiocarbamoyl, cyano, nitro, nitroso, azido, hydrazino, ureido, amidino, guanidino, pentafluorothio, trialkylsilyl;
an alkoxy group which may be substituted with a substituent group α, an alkenyloxy group which may be substituted with a substituent group α, an alkynyloxy group which may be substituted with a substituent group α, an alkylcarbonyloxy group which may be substituted with a substituent group α, an alkenylcarbonyloxy group which may be substituted with a substituent group α, an alkylcarbonyl group which may be substituted with a substituent group α, an alkenylcarbonyl group which may be substituted with a substituent group α, an alkynylcarbonyl group which may be substituted with a substituent group α, an alkenyloxycarbonyl group which may be substituted with a substituent group α, an alkynyloxycarbonyl group which may be substituted with a substituent group α, an alkylsulfanyl group which may be substituted with a substituent group α, an alkenylsulfanyl group which may be substituted with a substituent group α, an alkylsulfinyl group which may be substituted with a substituent group α, an alkenylsulfinyl group which may be substituted with a substituent group α, an alkylsulfonyl group which may be substituted with a substituent group α, an alkenylsulfonyl group which may be substituted with a substituent group α, an alkynylsulfonyl group which may be substituted with a substituent group α;
Amino group which may be substituted with substituent group β, imino group which may be substituted with substituent group β, carbamoyl group which may be substituted with substituent group β, sulfamoyl group which may be substituted with substituent group β;
an aromatic carbocyclic group which may be substituted with a substituent group gamma, a non-aromatic carbocyclic group which may be substituted with a substituent group gamma ', an aromatic heterocyclic group which may be substituted with a substituent group gamma', a non-aromatic heterocyclic group which may be substituted with a substituent group gamma ', an aromatic carbocyclic oxy group which may be substituted with a substituent group gamma, a non-aromatic carbocyclic oxy group which may be substituted with a substituent group gamma', an aromatic heterocyclyloxy group which may be substituted with a substituent group γ, a non-aromatic heterocyclyloxy group which may be substituted with a substituent group γ ', an aromatic carbocyclic carbooxy group which may be substituted with a substituent group γ', a non-aromatic carbocyclic carbooxy group which may be substituted with a substituent group γ ', an aromatic heterocyclic carbooxy group which may be substituted with a substituent group γ', a non-aromatic heterocyclic carbooxy group which may be substituted with a substituent group γ ', an aromatic carbocyclic carbonyl group which may be substituted with a substituent group γ', a non-aromatic carbocyclic carbonyl group which may be substituted with a substituent group γ ', an aromatic heterocyclic carbonyl group which may be substituted with a substituent group γ', a non-aromatic carbocyclic carbonyl group which may be substituted with a substituent group γ ', an aromatic carbocyclic oxycarbonyl group which may be substituted with a substituent group γ a non-aromatic carbocyclyloxycarbonyl group which may be substituted with a substituent group γ', an aromatic carbocyclyloxycarbonyl group which may be substituted with a substituent group γ ', a non-aromatic carbocyclyloxycarbonyl group which may be substituted with a substituent group γ', an aromatic carbocyclyloxy group which may be substituted with a substituent group γ ', a non-aromatic carbocyclyloxy group which may be substituted with a substituent group γ', an aromatic carbocyclyloxy group which may be substituted with a substituent group γ, A non-aromatic heterocyclic alkoxycarbonyl group which may be substituted with a substituent group γ ', an aromatic heterocyclic thioalkyl group which may be substituted with a substituent group γ', a non-aromatic heterocyclic thioalkyl group which may be substituted with a substituent group γ ', an aromatic carbocyclic sulfinyl group which may be substituted with a substituent group γ', a non-aromatic heterocyclic sulfinyl group which may be substituted with a substituent group γ ', an aromatic carbocyclic sulfonyl group which may be substituted with a substituent group γ', a non-aromatic carbocyclic sulfonyl group which may be substituted with a substituent group γ ', an aromatic heterocyclic sulfonyl group which may be substituted with a substituent group γ', a non-aromatic heterocyclic sulfonyl group which may be substituted with a substituent group γ.
Substituent group α: halogen, hydroxy, carboxy, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, sulfanyl, and cyano.
Substituent group beta: halogen, hydroxy, carboxy, cyano, alkyl which may be substituted by substituent group α, alkenyl which may be substituted by substituent group α, alkynyl which may be substituted by substituent group α, alkylcarbonyl which may be substituted by substituent group α, alkenylcarbonyl which may be substituted by substituent group α, alkynylcarbonyl which may be substituted by substituent group α, alkylsulfanyl which may be substituted by substituent group α, alkenylsulfanyl which may be substituted by substituent group α, alkylsulfinyl which may be substituted by substituent group α, alkenylsulfinyl which may be substituted by substituent group α, alkynylsulfonyl which may be substituted by substituent group α, alkylsulfonyl which may be substituted by substituent group α, alkenylsulfonyl which may be substituted by substituent group α, alkynylsulfonyl which may be substituted by substituent group α;
an aromatic carbocyclic group which may be substituted with a substituent group gamma ', a non-aromatic carbocyclic group which may be substituted with a substituent group gamma ', an aromatic heterocyclic group which may be substituted with a substituent group gamma ', a non-aromatic heterocyclic group which may be substituted with a substituent group gamma ', an aromatic carbocyclic alkyl group which may be substituted with a substituent group gamma ', a non-aromatic carbocyclic alkyl group which may be substituted with a substituent group gamma ', an aromatic heterocyclic alkyl group which may be substituted with a substituent group gamma, a non-aromatic heterocyclic alkyl group which may be substituted with a substituent group gamma ', an aromatic carbocyclic group which may be substituted with a substituent group gamma ', a non-aromatic carbocyclic carbonyl group which may be substituted with a substituent group gamma ', an aromatic heterocyclic carbonyl group which may be substituted with a substituent group gamma ', an aromatic carbocyclic oxycarbonyl group which may be substituted with a substituent group gamma ', a non-aromatic carbocyclic oxycarbonyl group which may be substituted with a substituent group gamma ' an aromatic heterocyclic oxycarbonyl group which may be substituted with a substituent group γ ', a non-aromatic heterocyclic oxycarbonyl group which may be substituted with a substituent group γ ', an aromatic carbocyclic thio group which may be substituted with a substituent group γ ', a non-aromatic carbocyclic thio group which may be substituted with a substituent group γ ', an aromatic heterocyclic thio group which may be substituted with a substituent group γ ', a non-aromatic heterocyclic thio group which may be substituted with a substituent group γ ', an aromatic carbocyclic sulfinyl group which may be substituted with a substituent group γ ', a non-aromatic carbocyclic sulfinyl group which may be substituted with a substituent group γ ', an aromatic heterocyclic sulfinyl group which may be substituted with a substituent group γ ', an aromatic carbocyclic sulfonyl group which may be substituted with a substituent group γ ', a non-aromatic carbocyclic sulfonyl group which may be substituted with a substituent group γ ', an aromatic heterocyclic sulfonyl group which may be substituted with a substituent group γ ', a non-aromatic carbocyclic sulfonyl group which may be substituted with a substituent group γ ', a non-aromatic heterocyclic sulfonyl group which may be substituted with a substituent group γ, A non-aromatic heterocyclic sulfonyl group which may be substituted with a substituent group γ'.
Substituent group γ: substituent groups α, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylcarbonyl, haloalkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl.
Substituent group γ': substituent groups γ and oxo.
The substituents on the rings of the "aromatic carbocycle" and "aromatic heterocycle" such as "substituted aromatic carbocyclyl", "substituted aromatic heterocyclic group", "substituted aromatic carbocyclyloxy", "substituted aromatic heterocyclic carbonyloxy", "substituted aromatic carbocyclylcarbonyl", "substituted aromatic carbocyclyloxycarbonyl", "substituted aromatic carbocyclylthio", "substituted aromatic carbocyclylsulfinyl", "substituted aromatic carbocyclylsulfonyl" and "substituted aromatic heterocyclic sulfonyl" may be exemplified by the following substituent group B. The atoms in any position on the ring may be bonded to one or more groups selected from the following substituent group B.
Substituent group B: halogen, hydroxy, carboxy, formyl, formyloxy, sulfanyl, sulfinyl, sulfo, thiocarbonyl, thiocarboxyl, dithiocarboxyl, thiocarbamoyl, cyano, nitro, nitroso, azido, hydrazino, ureido, amidino, guanidino, pentafluorothio, trialkylsilyl,
an alkyl group which may be substituted with a substituent group α, an alkenyl group which may be substituted with a substituent group α, an alkynyl group which may be substituted with a substituent group α, an alkoxycarbonyl group which may be substituted with a substituent group α, an alkenyloxy group which may be substituted with a substituent group α, an alkylcarbonyloxy group which may be substituted with a substituent group α, an alkenylcarbonyloxy group which may be substituted with a substituent group α, an alkylcarbonyl group which may be substituted with a substituent group α, an alkenylcarbonyl group which may be substituted with a substituent group α, an alkynylcarbonyl group which may be substituted with a substituent group α, an alkoxycarbonyl group which may be substituted with a substituent group α, an alkenyloxycarbonyl group which may be substituted with a substituent group α, an alkylthio group which may be substituted with a substituent group α, an alkenylthio group which may be substituted with a substituent group α, an alkynylsulfanyl group which may be substituted with a substituent group α, an alkylsulfinyl group which may be substituted with a substituent group α, an alkenylsulfinyl group which may be substituted with a substituent group α, an alkynylsulfonyl group which may be substituted with a substituent group α, an alkylsulfonyl group which may be substituted with a substituent group α;
Amino group which may be substituted with substituent group β, imino group which may be substituted with substituent group β, carbamoyl group which may be substituted with substituent group β, sulfamoyl group which may be substituted with substituent group β;
an aromatic carbocyclic group which may be substituted with a substituent group gamma, a non-aromatic carbocyclic group which may be substituted with a substituent group gamma ', an aromatic heterocyclic group which may be substituted with a substituent group gamma', a non-aromatic heterocyclic group which may be substituted with a substituent group gamma ', an aromatic carbocyclic oxy group which may be substituted with a substituent group gamma, a non-aromatic carbocyclic oxy group which may be substituted with a substituent group gamma', an aromatic heterocyclyloxy group which may be substituted with a substituent group γ, a non-aromatic heterocyclyloxy group which may be substituted with a substituent group γ ', an aromatic carbocyclic carbooxy group which may be substituted with a substituent group γ', a non-aromatic carbocyclic carbooxy group which may be substituted with a substituent group γ ', an aromatic heterocyclic carbooxy group which may be substituted with a substituent group γ', a non-aromatic heterocyclic carbooxy group which may be substituted with a substituent group γ ', an aromatic carbocyclic carbonyl group which may be substituted with a substituent group γ', a non-aromatic carbocyclic carbonyl group which may be substituted with a substituent group γ ', an aromatic heterocyclic carbonyl group which may be substituted with a substituent group γ', a non-aromatic carbocyclic carbonyl group which may be substituted with a substituent group γ ', an aromatic carbocyclic oxycarbonyl group which may be substituted with a substituent group γ a non-aromatic carbocyclyloxycarbonyl group which may be substituted with the substituent group γ', an aromatic carbocyclyloxycarbonyl group which may be substituted with the substituent group γ ', a non-aromatic carbocyclyloxycarbonyl group which may be substituted with the substituent group γ', an aromatic carbocyclylalkyl group which may be substituted with the substituent group γ ', a non-aromatic carbocyclylalkyl group which may be substituted with the substituent group γ', an aromatic carbocyclyloxy group which may be substituted with the substituent group γ ', a non-aromatic carbocyclyloxy group which may be substituted with the substituent group γ', an aromatic carbocyclyloxy group which may be substituted with the substituent group γ A non-aromatic heterocyclic alkoxy group which may be substituted with a substituent group γ ', an aromatic carbocyclic alkoxycarbonyl group which may be substituted with a substituent group γ', a non-aromatic carbocyclic alkoxycarbonyl group which may be substituted with a substituent group γ ', an aromatic heterocyclic alkoxycarbonyl group which may be substituted with a substituent group γ', a non-aromatic heterocyclic alkoxycarbonyl group which may be substituted with a substituent group γ ', an aromatic carbocyclic alkoxyalkyl group which may be substituted with a substituent group γ', a non-aromatic carbocyclic alkoxyalkyl group which may be substituted with a substituent group γ ', an aromatic heterocyclic alkoxyalkyl group which may be substituted with a substituent group γ', a non-aromatic heterocyclic alkoxyalkyl group which may be substituted with a substituent group γ ', an aromatic carbocyclic thioalkyl group which may be substituted with a substituent group γ', a non-aromatic carbocyclic thioalkyl group which may be substituted with a substituent group γ 'an aromatic heterocyclic sulfanyl group which may be substituted with a substituent group γ', a non-aromatic heterocyclic sulfanyl group which may be substituted with a substituent group γ ', an aromatic carbocyclic sulfinyl group which may be substituted with a substituent group γ', a non-aromatic carbocyclic sulfinyl group which may be substituted with a substituent group γ ', an aromatic heterocyclic sulfinyl group which may be substituted with a substituent group γ', an aromatic carbocyclic sulfonyl group which may be substituted with a substituent group γ ', a non-aromatic carbocyclic sulfonyl group which may be substituted with a substituent group γ', an aromatic heterocyclic sulfonyl group which may be substituted with a substituent group γ ', a non-aromatic heterocyclic sulfonyl group which may be substituted with a substituent group γ'.
"substituted non-aromatic carbocyclyl", "substituted non-aromatic heterocyclyl", "substituted non-aromatic carbocyclyloxy", "substituted non-aromatic heterocyclyloxy"substituted non-aromatic carbocyclic carbonyloxy", "substituted non-aromatic heterocyclic carbonyloxy", "substituted non-aromatic carbocyclic carbonyl", "substituted non-aromatic heterocyclic carbonyl", "substituted non-aromatic carbocyclic oxycarbonyl", "substituted non-aromatic heterocyclic oxycarbonyl", "substituted non-aromatic carbocyclic sulfanyl", "substituted non-aromatic heterocyclic sulfanyl", "substituted non-aromatic carbocyclic sulfinyl", "substituted non-aromatic heterocyclic sulfinyl", "substituted non-aromatic carbocyclic sulfonyl", "substituted non-aromatic heterocyclic sulfonyl", "R", and combinations thereof 4a And R is 4b Substituted non-aromatic carbocyclic ring ' and ' R ' formed together 4a And R is 4b The substituents on the rings of the "non-aromatic carbocyclic ring" and the "non-aromatic heterocyclic ring" etc. which are formed together are exemplified by the following substituent group C. The atoms in any position on the ring may be bonded to one or more groups selected from the following substituent group C.
Substituent group C: substituent group B and oxo.
When "non-aromatic carbocyclic ring" and "non-aromatic heterocyclic ring" are substituted with "oxo", it is meant a ring in which two hydrogen atoms on carbon atoms are substituted as follows.
[ chemical formula 52 ]
The substituents for "substituted amino", "substituted imino", "substituted carbamoyl", "substituted sulfamoyl" may be exemplified by the following substituent group D. May be substituted with 1 or 2 groups selected from substituent group D.
Substituent group D: halogen, hydroxy, carboxy, cyano, alkyl which may be substituted by substituent group α, alkenyl which may be substituted by substituent group α, alkynyl which may be substituted by substituent group α, alkylcarbonyl which may be substituted by substituent group α, alkenylcarbonyl which may be substituted by substituent group α, alkynylcarbonyl which may be substituted by substituent group α, alkylsulfanyl which may be substituted by substituent group α, alkenylsulfanyl which may be substituted by substituent group α, alkylsulfinyl which may be substituted by substituent group α, alkenylsulfinyl which may be substituted by substituent group α, alkylsulfonyl which may be substituted by substituent group α, alkenylsulfonyl which may be substituted by substituent group α, alkynylsulfonyl which may be substituted by substituent group α;
Amino group which may be substituted with substituent group β, imino group which may be substituted with substituent group β, carbamoyl group which may be substituted with substituent group β, sulfamoyl group which may be substituted with substituent group β;
an aromatic carbocyclic group which may be substituted with a substituent group gamma ', a non-aromatic carbocyclic group which may be substituted with a substituent group gamma ', an aromatic heterocyclic group which may be substituted with a substituent group gamma ', a non-aromatic heterocyclic group which may be substituted with a substituent group gamma ', an aromatic carbocyclic alkyl group which may be substituted with a substituent group gamma ', a non-aromatic carbocyclic alkyl group which may be substituted with a substituent group gamma ', an aromatic heterocyclic alkyl group which may be substituted with a substituent group gamma, a non-aromatic heterocyclic alkyl group which may be substituted with a substituent group gamma ', an aromatic carbocyclic group which may be substituted with a substituent group gamma ', a non-aromatic carbocyclic carbonyl group which may be substituted with a substituent group gamma ', an aromatic heterocyclic carbonyl group which may be substituted with a substituent group gamma ', an aromatic carbocyclic oxycarbonyl group which may be substituted with a substituent group gamma ', a non-aromatic carbocyclic oxycarbonyl group which may be substituted with a substituent group gamma ' an aromatic heterocyclic oxycarbonyl group which may be substituted with a substituent group γ ', a non-aromatic heterocyclic oxycarbonyl group which may be substituted with a substituent group γ ', an aromatic carbocyclic thio group which may be substituted with a substituent group γ ', a non-aromatic carbocyclic thio group which may be substituted with a substituent group γ ', an aromatic heterocyclic thio group which may be substituted with a substituent group γ ', a non-aromatic heterocyclic thio group which may be substituted with a substituent group γ ', an aromatic carbocyclic sulfinyl group which may be substituted with a substituent group γ ', a non-aromatic carbocyclic sulfinyl group which may be substituted with a substituent group γ ', an aromatic heterocyclic sulfinyl group which may be substituted with a substituent group γ ', an aromatic carbocyclic sulfonyl group which may be substituted with a substituent group γ ', a non-aromatic carbocyclic sulfonyl group which may be substituted with a substituent group γ ', an aromatic heterocyclic sulfonyl group which may be substituted with a substituent group γ ', a non-aromatic carbocyclic sulfonyl group which may be substituted with a substituent group γ ', a non-aromatic heterocyclic sulfonyl group which may be substituted with a substituent group γ, A non-aromatic heterocyclic sulfonyl group which may be substituted with a substituent group γ'.
R 1 Examples of the substituent of the "substituted or unsubstituted non-aromatic heterocyclic group" in (a) may include
Oxo; thiooxo; halogen; cyano group; a nitro group; a carboxyl group;
a substituted or unsubstituted carbamoyl group;
substituted or unsubstituted alkyl;
substituted or unsubstituted alkoxy;
substituted or unsubstituted alkylcarbonyl;
a substituted or unsubstituted alkoxycarbonyl group;
substituted or unsubstituted alkylthio;
substituted or unsubstituted amino;
substituted or unsubstituted aromatic carbocyclyl;
a substituted or unsubstituted aromatic heterocyclic group;
a substituted or unsubstituted non-aromatic carbocyclyl;
a substituted or unsubstituted non-aromatic heterocyclic group;
a substituted or unsubstituted non-aromatic heterocyclic carbonyl group.
May be substituted with one or more groups selected from the above.
R 1 Examples of the substituent of the "substituted or unsubstituted non-aromatic heterocyclic group" in (a) may include
Oxo; thiooxo; halogen; cyano group; a nitro group; a carboxyl group;
substituted carbamoyl (alkyl, alkylaminoalkyl, non-aromatic carbocyclyl as substituents); unsubstituted carbamoyl;
substituted alkyl (halogen, hydroxy as substituents); unsubstituted alkyl;
unsubstituted alkoxy;
Unsubstituted alkylcarbonyl;
unsubstituted alkoxycarbonyl;
unsubstituted alkylthio;
substituted amino groups (alkyl, alkylcarbonyl, hydroxyalkyl as substituents);
substituted aromatic carbocyclyl (halogen as a substituent); unsubstituted aromatic carbocyclyl;
substituted aromatic heterocyclic group (alkyl group as substituent); unsubstituted aromatic heterocyclic group;
unsubstituted non-aromatic carbocyclyl;
unsubstituted non-aromatic heterocyclic groups;
unsubstituted, non-aromatic heterocyclic carbonyl groups.
May be substituted with one or more groups selected from the above.
R 1 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) may include
Halogen; cyano group; a hydroxyl group;
substituted or unsubstituted alkyl;
substituted or unsubstituted alkoxy;
a substituted or unsubstituted alkoxycarbonyl group;
substituted or unsubstituted aromatic carbocyclyl.
May be substituted with one or more groups selected from the above.
R 1 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) may include
Halogen; cyano group; a hydroxyl group;
substituted alkyl (halogen, hydroxy, carbamoyl, aromatic carbocyclyl, non-aromatic carbocyclyl as substituents); unsubstituted alkyl;
Unsubstituted alkoxy;
unsubstituted alkoxycarbonyl;
unsubstituted aromatic carbocyclyl.
May be substituted with one or more groups selected from the above.
R 1 Examples of the substituent of the "substituted or unsubstituted carbamoyl" in (a) may include
Substituted or unsubstituted alkyl; substituted or unsubstituted amino.
May be substituted with one or more groups selected from the above.
R 1 Examples of the substituent of the "substituted or unsubstituted carbamoyl" in (a) may include
Substituted alkyl (aromatic carbocyclyl as a substituent); unsubstituted alkyl; unsubstituted amino groups.
May be substituted with one or more groups selected from the above.
R 2 Examples of the substituent of the "substituted or unsubstituted aromatic carbocyclyl" in (a) include halogen; cyano group;
substituted or unsubstituted alkyl; substituted or unsubstituted alkoxy.
May be substituted with one or more groups selected from the above.
R 2 Examples of the substituent of the "substituted or unsubstituted aromatic carbocyclyl" in (a) include halogen; cyano group;
substituted alkyl (halogen as substituent); unsubstituted alkyl;
substituted alkoxy (halogen, aromatic carbocyclyl as substituents); unsubstituted alkoxy groups.
May be substituted with one or more groups selected from the above.
R 2 Examples of the substituent of the "substituted or unsubstituted non-aromatic carbocyclyl" in (a) include halogen.
May be substituted with one or more groups selected from the above.
R 2 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) include halogen; substituted or unsubstituted alkyl.
May be substituted with one or more groups selected from the above.
R 2 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) include halogen; unsubstituted alkyl.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted aromatic carbocyclyl" in (a) include halogen; cyano group; a hydroxyl group; a carboxyl group;
substituted or unsubstituted alkyl;
substituted or unsubstituted alkynyl;
substituted or unsubstituted alkoxy;
substituted or unsubstituted alkylcarbonyl;
a substituted or unsubstituted alkoxycarbonyl group;
substituted or unsubstituted alkylthio;
a substituted or unsubstituted alkylsulfinyl group;
a substituted or unsubstituted alkylsulfonyl group;
substituted or unsubstituted amino;
a substituted or unsubstituted carbamoyl group;
a substituted or unsubstituted non-aromatic carbocyclyl;
A substituted or unsubstituted aromatic heterocyclic group;
a substituted or unsubstituted non-aromatic heterocyclic group;
substituted or unsubstituted non-aromatic carbocyclic oxy.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted aromatic carbocyclyl" in (a) include halogen; cyano group; a hydroxyl group; a carboxyl group;
substituted alkyl (halogen as substituent); unsubstituted alkyl;
unsubstituted alkynyl;
substituted alkoxy (halogen, hydroxy, carboxy, alkoxy, alkoxycarbonyl, carbamoyl, alkylcarbamoyl, alkylamino, aromatic carbocyclyl as substituents); unsubstituted alkoxy;
substituted alkylcarbonyl (amino as substituent);
unsubstituted alkoxycarbonyl;
unsubstituted alkylthio;
unsubstituted alkylsulfinyl;
unsubstituted alkylsulfonyl;
substituted amino groups (alkylcarbonyl, alkylcarbamoyl, alkylsulfonyl as substituents);
substituted carbamoyl (alkyl as a substituent); unsubstituted carbamoyl;
unsubstituted non-aromatic carbocyclyl;
substituted aromatic heterocyclic group (alkyl group as substituent); unsubstituted aromatic heterocyclic group;
Substituted non-aromatic heterocyclic group (oxo as a substituent);
unsubstituted non-aromatic carbocyclic oxy.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted non-aromatic carbocyclic group" in (a) may include
A hydroxyl group; substituted or unsubstituted alkoxy.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted non-aromatic carbocyclic group" in (a) may include
A hydroxyl group; unsubstituted alkoxy groups.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) may include
Halogen; a hydroxyl group;
substituted or unsubstituted alkyl;
substituted or unsubstituted alkoxy;
substituted or unsubstituted amino;
a substituted or unsubstituted non-aromatic carbocyclyl;
a substituted or unsubstituted non-aromatic heterocyclic group.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) may include
Halogen; a hydroxyl group;
substituted alkyl (halo, hydroxy, alkoxy, haloalkoxy, alkylamino, alkylcarbonylamino, alkylcarbamoyl, alkylsulfonyl, non-aromatic carbocyclyl, non-aromatic heterocyclyl as substituents); unsubstituted alkyl;
Unsubstituted alkoxy;
substituted amino (alkyl, alkylcarbonyl, alkoxycarbonyl as substituents); unsubstituted amino;
substituted non-aromatic carbocyclyl (halogen, hydroxy as substituents); unsubstituted non-aromatic carbocyclyl;
substituted non-aromatic heterocyclic group (alkylcarbonyl group as substituent); unsubstituted non-aromatic heterocyclic groups.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted non-aromatic heterocyclic group" in (a) may include
Halogen; oxo;
substituted or unsubstituted alkyl;
substituted or unsubstituted alkoxy;
substituted or unsubstituted amino.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted non-aromatic heterocyclic group" in (a) may include
Halogen; oxo;
substituted alkyl (carbamoyl as a substituent); unsubstituted alkyl;
unsubstituted alkoxy;
substituted amino (alkylcarbonyl as a substituent).
May be substituted with one or more groups selected from the above.
R 1 Examples of the substituents of the "substituted or unsubstituted aromatic heterocyclic group" in (a)As an example, there may be mentioned
Halogen;
cyano group;
a hydroxyl group;
Substituted or unsubstituted alkyl;
substituted or unsubstituted alkynyl;
substituted or unsubstituted alkoxy;
substituted or unsubstituted amino group
A substituted or unsubstituted alkoxycarbonyl group;
substituted or unsubstituted aromatic carbocyclyl;
a substituted or unsubstituted non-aromatic carbocyclyl;
substituted or unsubstituted aromatic heterocyclic group.
May be substituted with one or more groups selected from the above.
R 1 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) may include
Halogen;
cyano group;
a hydroxyl group;
substituted alkyl (halogen, hydroxy, alkoxy, alkoxycarbonyl, carbamoyl as substituents; which may be substituted with one or more groups selected from the above); unsubstituted alkyl;
unsubstituted alkynyl;
unsubstituted alkoxy;
substituted amino (alkyl as substituent); unsubstituted amino;
unsubstituted alkoxycarbonyl;
unsubstituted aromatic carbocyclyl
Unsubstituted non-aromatic carbocyclyl;
substituted aromatic heterocyclic group (alkyl group as substituent).
May be substituted with one or more groups selected from the above.
In one embodiment, R 1 The substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) may be halogen;
Substituted alkyl (halogen, hydroxy, alkoxy, alkoxycarbonyl, carbamoyl as substituents; which may be substituted with one or more groups selected from the above); unsubstituted alkyl.
May be substituted with one or more groups selected from the above.
In one embodiment, R 1 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) include halogen, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted alkynyl, haloalkyl, and unsubstituted alkoxy.
May be substituted with one or more groups selected from the above.
R 1 Examples of the substituent of the "substituted or unsubstituted non-aromatic heterocyclic group" in (a) may include
Oxo;
thiooxo;
halogen;
cyano group;
a carboxyl group;
a substituted or unsubstituted carbamoyl group;
substituted or unsubstituted alkyl;
substituted or unsubstituted alkoxy;
substituted or unsubstituted aromatic carbocyclyl;
a substituted or unsubstituted aromatic heterocyclic group;
a substituted or unsubstituted non-aromatic heterocyclic group.
May be substituted with one or more groups selected from the above.
R 1 Examples of the substituent of the "substituted or unsubstituted non-aromatic heterocyclic group" in (a) may include
Oxo;
thiooxo;
Halogen;
cyano group;
a carboxyl group;
substituted carbamoyl (alkyl, alkylaminoalkyl, non-aromatic carbocyclyl, alkylaromatic heterocyclylalkyl as substituents, which may be substituted with one or more groups selected from the above); unsubstituted carbamoyl;
substituted alkyl (halogen as substituent); unsubstituted alkyl;
unsubstituted alkoxy;
unsubstituted aromatic carbocyclyl;
substituted aromatic heterocyclic group (alkyl group as substituent); unsubstituted aromatic heterocyclic group;
unsubstituted non-aromatic heterocyclic groups.
May be substituted with one or more groups selected from the above.
R 1 Examples of the substituent of the "substituted or unsubstituted carbamoyl" in (a) may include
Substituted or unsubstituted alkyl;
substituted or unsubstituted non-aromatic carbocyclyl.
May be substituted with one or more groups selected from the above.
R 1 Examples of the substituent of the "substituted or unsubstituted carbamoyl" in (a) may include
Unsubstituted alkyl; unsubstituted non-aromatic carbocyclyl.
May be substituted with one or more groups selected from the above.
R 1 Examples of the substituent of the "substituted or unsubstituted amino group" in (a) may include
Unsubstituted alkyl; unsubstituted alkylcarbonyl; unsubstituted alkoxycarbonyl; unsubstituted alkylaminocarbonyl groups; unsubstituted alkylsulfonyl.
May be substituted with one or more groups selected from the above.
In one embodiment, R 1 The substituent of the "substituted or unsubstituted amino group" in (a) may be exemplified by
Unsubstituted alkyl.
May be substituted with one or more groups selected from the above.
R 2 Examples of the substituent of the "substituted or unsubstituted aromatic carbocyclyl" in (a) may include
Halogen;
cyano group;
a nitro group;
a hydroxyl group;
substituted or unsubstituted alkyl;
substituted or unsubstituted alkenyl;
substituted or unsubstituted alkynyl;
substituted or unsubstituted alkoxy;
a substituted or unsubstituted alkoxycarbonyl group;
substituted or unsubstituted amino;
substituted or unsubstituted non-aromatic carbocyclyl.
May be substituted with one or more groups selected from the above.
R 2 Examples of the substituent of the "substituted or unsubstituted aromatic carbocyclyl" in (a) may include
Halogen;
cyano group;
a nitro group;
a hydroxyl group;
substituted alkyl (halogen, hydroxy, aromatic carbocyclyl, halogen aromatic carbocyclyl, hydroxyalkyl aromatic carbocyclyl, alkyl aromatic heterocyclyl as substituents; optionally substituted with one or more groups selected from the group consisting of the above); unsubstituted alkyl;
unsubstituted alkenyl;
unsubstituted alkynyl;
Substituted alkoxy (halogen, hydroxy, halogen aromatic carbocyclyl, non-aromatic carbocyclyl as substituents; optionally substituted with one or more groups selected from the above); unsubstituted alkoxy;
unsubstituted alkoxycarbonyl;
substituted amino (alkylcarbonyl as a substituent); unsubstituted amino;
unsubstituted non-aromatic carbocyclyl.
May be substituted with one or more groups selected from the above.
In one embodiment, R 2 The substituent of the "substituted or unsubstituted aromatic carbocyclyl" in (a) may be halogen;
cyano group;
substituted alkyl (halogen, hydroxy, aromatic carbocyclyl, halogen aromatic carbocyclyl, hydroxyalkyl aromatic carbocyclyl, alkyl aromatic heterocyclyl as substituents; optionally substituted with one or more groups selected from the group consisting of the above); unsubstituted alkyl.
May be substituted with one or more groups selected from the above.
In one embodiment, R 2 The substituent of the "substituted or unsubstituted aromatic carbocyclyl" in (a) may be halogen;
cyano group;
substituted alkyl (halogen as substituent); unsubstituted alkyl.
May be substituted with one or more groups selected from the above.
R 2 Examples of the substituent of the "substituted or unsubstituted non-aromatic carbocyclyl" in (a) include halogen.
May be substituted with one or more groups selected from the above.
R 2 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) may include
Halogen; cyano group; substituted or unsubstituted alkyl.
May be substituted with one or more groups selected from the above.
R 2 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) may include
Halogen; cyano group; unsubstituted alkyl.
May be substituted with one or more groups selected from the above.
R 2 Examples of the substituent of the "substituted or unsubstituted non-aromatic heterocyclic group" in (a) may include
Halogen; substituted or unsubstituted alkylcarbonyl.
May be substituted with one or more groups selected from the above.
R 2 In (a) and (b)Examples of the substituent of the "substituted or unsubstituted non-aromatic heterocyclic group" include
Halogen; substituted alkylcarbonyl (haloalkylcarbonylamino as a substituent).
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted aromatic carbocyclyl" in (a) may include
Halogen;
a hydroxyl group;
a carboxyl group;
substituted or unsubstituted alkyl;
substituted or unsubstituted alkoxy;
a substituted or unsubstituted alkylsulfonyl group;
a substituted or unsubstituted dialkylsulfoximino group;
A substituted or unsubstituted cyclic sulfooxyimino group;
substituted or unsubstituted amino;
a substituted or unsubstituted carbamoyl group;
a substituted or unsubstituted aromatic heterocyclic group;
a substituted or unsubstituted non-aromatic heterocyclic group;
a substituted or unsubstituted non-aromatic carbocyclic oxy group;
substituted or unsubstituted aromatic heterocyclyloxy.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted aromatic carbocyclyl" in (a) may include
Halogen;
a hydroxyl group;
a carboxyl group;
substituted alkyl (halogen as substituent); unsubstituted alkyl;
substituted alkoxy (halogen, hydroxy, carboxy, alkoxy, alkoxycarbonyl, alkylcarbamoyl as substituents; optionally substituted with one or more groups selected from the above); unsubstituted alkoxy;
unsubstituted alkylsulfonyl;
unsubstituted dialkylsulfoximino;
unsubstituted cyclic sulfooxyimino;
substituted amino (alkylsulfonyl) as a substituent;
substituted carbamoyl (alkyl as a substituent);
unsubstituted aromatic heterocyclic group;
unsubstituted non-aromatic heterocyclic groups;
unsubstituted non-aromatic carbocyclic oxy;
Substituted aromatic heterocyclyloxy (alkyl as a substituent).
May be substituted with one or more groups selected from the above.
In one embodiment, R 3 The substituent of the "substituted or unsubstituted aromatic carbocyclyl" in (a) may be halogen;
a hydroxyl group;
unsubstituted alkoxy;
unsubstituted dialkylsulfoximino;
unsubstituted cyclic sulfooxyimino.
May be substituted with one or more groups selected from the above.
In one embodiment, R 3 The substituent of the "substituted or unsubstituted aromatic carbocyclyl" in (a) may be halogen;
unsubstituted alkoxy groups.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted non-aromatic carbocyclic group" in (a) may include
Halogen;
substituted or unsubstituted alkoxy;
substituted or unsubstituted amino;
substituted or unsubstituted aromatic carbocyclyl;
substituted or unsubstituted aromatic heterocyclic group.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted non-aromatic carbocyclic group" in (a) may include
Halogen;
unsubstituted alkoxy;
substituted amino groups (alkoxycarbonyl, aromatic heterocyclic groups, halogenated aromatic heterocyclic groups, dihaloaromatic heterocyclic groups, alkylaromatic heterocyclic groups, dialkylaromatic heterocyclic groups, halogenated alkylaromatic heterocyclic groups, alkoxyaromatic heterocyclic groups, dialkoxyaromatic heterocyclic groups, nonaromatic carbocyclic aromatic heterocyclic groups as substituents; may be substituted with one or more groups selected from the above);
Substituted aromatic carbocyclyl (alkylcarbamoyl as a substituent);
substituted aromatic heterocyclic group (alkyl group as substituent).
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) may include
Halogen;
cyano group;
substituted or unsubstituted alkyl;
substituted or unsubstituted alkoxy;
substituted or unsubstituted amino;
a substituted or unsubstituted non-aromatic carbocyclyl;
substituted or unsubstituted aromatic heterocyclic group
A substituted or unsubstituted non-aromatic heterocyclic group.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) may include
Halogen;
cyano group;
substituted alkyl (halo, hydroxy, cyano, carboxy, alkoxy, haloalkoxy, alkoxycarbonyl, amino, alkylamino, alkylcarbamoyl, substituted carbamoyl (substituents: alkoxyalkyl and alkyl), substituted carbamoyl (substituents: non-aromatic carbocyclyl and alkyl), alkylsulfonyl, non-aromatic carbocyclyl, cyano non-aromatic carbocyclyl, hydroxy non-aromatic carbocyclyl, amino non-aromatic carbocyclyl, alkoxycarbamoyl non-aromatic carbocyclyl, alkylaromatic heterocyclyl, aromatic heterocyclyl, non-aromatic carbocyclyl, non-aromatic heterocyclylcarbonyl, halogenated non-aromatic heterocyclylcarbonyl, may be substituted with one or more groups selected from the above); unsubstituted alkyl;
Substituted alkoxy (halogen as substituent); unsubstituted alkoxy;
substituted amino (alkyl, haloalkyl, non-aromatic carbocyclylalkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, non-aromatic carbocyclyl as substituents, optionally substituted with one or more groups selected from the group consisting of the above); unsubstituted amino;
substituted non-aromatic carbocyclyl (halogen, hydroxy, amino as substituents; optionally substituted with one or more groups selected from the above); unsubstituted non-aromatic carbocyclyl;
unsubstituted aromatic heterocyclic group;
substituted non-aromatic heterocyclic groups (oxo, alkyl, alkylcarbonyl as substituents; optionally substituted with one or more groups selected from the above); unsubstituted non-aromatic heterocyclic groups.
May be substituted with one or more groups selected from the above.
In one embodiment, R 3 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) include halogen;
substituted alkyl (halogen, hydroxy, cyano, carboxy, alkoxy, haloalkoxy, alkoxycarbonyl, amino, alkylamino, alkylcarbamoyl, substituted carbamoyl (substituents: alkoxyalkyl and alkyl), substituted carbamoyl (substituents: non-aromatic carbocyclyl and alkyl), alkylsulfonyl, non-aromatic carbocyclyl, hydroxy non-aromatic carbocyclyl, alkyl non-aromatic heterocyclyl, non-aromatic carbocyclylcarbamoyl as substituents, which may be substituted with one or more groups selected from the above); unsubstituted alkyl;
Substituted amino (alkyl, haloalkyl, non-aromatic carbocyclylalkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, non-aromatic carbocyclyl as substituents, optionally substituted with one or more groups selected from the group consisting of the above); unsubstituted amino;
substituted non-aromatic carbocyclyl (halogen, hydroxy, amino as substituents; optionally substituted with one or more groups selected from the above); unsubstituted non-aromatic carbocyclyl;
unsubstituted aromatic heterocyclic group;
substituted non-aromatic heterocyclic groups (oxo, alkyl, alkylcarbonyl as substituents; optionally substituted with one or more groups selected from the above); unsubstituted non-aromatic heterocyclic groups.
May be substituted with one or more groups selected from the above.
In one embodiment, R 3 Examples of the substituent of the "substituted or unsubstituted aromatic heterocyclic group" in (a) include halogen;
substituted alkyl (halogen, non-aromatic carbocyclyl as substituent; may be substituted with one or more groups selected from the above); unsubstituted alkyl;
substituted amino (alkyl as substituent); unsubstituted amino groups.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted non-aromatic heterocyclic group" in (a) may include
Halogen;
oxo;
substituted or unsubstituted alkyl;
a substituted or unsubstituted alkoxycarbonyl group;
substituted or unsubstituted aromatic carbocyclyl;
substituted or unsubstituted aromatic heterocyclic group.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted non-aromatic heterocyclic group" in (a) may include
Halogen;
oxo;
unsubstituted alkyl;
unsubstituted alkoxycarbonyl;
substituted aromatic carbocyclyl (halogen as a substituent);
unsubstituted aromatic heterocyclic group.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted alkyl" in (a) may include
Halogen;
substituted or unsubstituted aromatic carbocyclyl;
substituted or unsubstituted non-aromatic carbocyclyl.
May be substituted with one or more groups selected from the above.
R 3 Examples of the substituent of the "substituted or unsubstituted alkyl" in (a) may include
Halogen;
substituted aromatic carbocyclyl (halogen, hydroxy as substituent; may be substituted with one or more groups selected from the above); unsubstituted aromatic carbocyclyl;
unsubstituted non-aromatic carbocyclyl.
May be substituted with one or more groups selected from the above.
R 7 Examples of the substituent of the "substituted or unsubstituted alkyl" in (a) may include
Halogen;
a hydroxyl group;
unsubstituted alkoxy groups.
May be substituted with one or more groups selected from the above.
R 6 Examples of the substituent of the "substituted or unsubstituted alkyl" in (a) may include
Halogen;
a hydroxyl group;
unsubstituted alkoxy groups.
May be substituted with one or more groups selected from the above.
R 6’ Examples of the substituent of the "substituted or unsubstituted alkyl" in (a) may include
Halogen;
a hydroxyl group;
unsubstituted alkoxy groups.
May be substituted with one or more groups selected from the above.
R 5a Examples of the substituent of the "substituted or unsubstituted alkyl" in (a) may include
Halogen;
a hydroxyl group.
May be substituted with one or more groups selected from the above.
R 5b Examples of the substituent of the "substituted or unsubstituted alkyl" in (a) may include
Halogen;
a hydroxyl group.
May be substituted with one or more groups selected from the above.
R 4a Examples of the substituent of the "substituted or unsubstituted alkyl" in (a) may include
Halogen;
a hydroxyl group;
unsubstituted alkoxy groups.
May be substituted with one or more groups selected from the above.
R 4b Examples of the substituent of the "substituted or unsubstituted alkyl" in (a) may include
Halogen;
A hydroxyl group;
unsubstituted alkoxy groups.
May be substituted with one or more groups selected from the above.
Formula (I):
[ FORMATION 53 ]
Of the compounds shown, Y, R 7 、R 1 、R 2 、R 3 、-X-、R 6 、R 6’ 、m、R 5a 、R 5b 、n、R 4a 、R 4b 、Z、R 1a 、R 1b R is R 1c The preferred embodiments of (2) are shown below. As the compound represented by the formula (I), embodiments of all combinations of the specific examples shown below are exemplified.
In the present specification, "may be substituted with the substituent group ω" means "may be substituted with one or more groups selected from the substituent group ω". The same holds true for the substituent groups ω1, ω2, ω3, ω4, ω5 and ω'.
Y may be N or CR 7 (hereinafter referred to as AA-1).
Y may be N (hereinafter referred to as AA-2).
Y may be CH (hereinafter referred to as AA-3).
R 7 Examples thereof include a hydrogen atom and a substituted or unsubstituted alkyl group (hereinafter referred to as AA-4).
R 7 The hydrogen atom (hereinafter referred to as AA-5) may be mentioned.
R 1 Examples thereof include a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted carbamoyl group, and a substituted or unsubstituted amino group (hereinafter referred to as A-1).
R 1 Examples thereof include a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted aromatic heterocyclic group, and a substituted or unsubstituted carbamoyl group (hereinafter referred to as A-2).
R 1 Examples thereof include a substituted or unsubstituted non-aromatic heterocyclic group and a substituted or unsubstituted aromatic heterocyclic group (hereinafter referred to as A-3).
R 1 Examples thereof include a substituted or unsubstituted non-aromatic heterocyclic group (hereinafter referred to as A-4).
R 1 Examples thereof include a substituted or unsubstituted aromatic heterocyclic group (hereinafter referred to as A-5).
R 1 Examples thereof include a substituted or unsubstituted 5-membered non-aromatic heterocyclic group, a substituted or unsubstituted 6-membered non-aromatic heterocyclic group, a substituted or unsubstituted 10-membered non-aromatic heterocyclic group, a substituted or unsubstituted 5-membered aromatic heterocyclic group, a substituted or unsubstituted 6-membered aromatic heterocyclic group, a substituted or unsubstituted 9-membered aromatic heterocyclic group, and a substituted or unsubstituted 10-membered aromatic heterocyclic group (hereinafter referred to as A-6).
R 1 Examples thereof include a 5-membered non-aromatic heterocyclic group which may be substituted with oxo and further substituted with one or more groups, a 6-membered non-aromatic heterocyclic group which may be substituted with oxo and further substituted with one or more groups, a 10-membered non-aromatic heterocyclic group which may be substituted with oxo and further substituted with one or more groups, a substituted or unsubstituted 5-membered aromatic heterocyclic group, a substituted or unsubstituted 6-membered aromatic heterocyclic group, a substituted or unsubstituted 9-membered aromatic heterocyclic group, and a substituted or unsubstituted 10-membered aromatic heterocyclic group (hereinafter referred to as A-7).
R 1 Examples thereof include a 5-membered non-aromatic heterocyclic group which may be substituted with a substituent group C, a 6-membered non-aromatic heterocyclic group which may be substituted with a substituent group C, a 10-membered non-aromatic heterocyclic group which may be substituted with a substituent group C, a 5-membered aromatic heterocyclic group which may be substituted with a substituent group B, a 6-membered aromatic heterocyclic group which may be substituted with a substituent group B, a 9-membered aromatic heterocyclic group which may be substituted with a substituent group B, and a 10-membered aromatic heterocyclic group which may be substituted with a substituent group B (hereinafter referred to as A-8).
R 1 Examples thereof include a 5-membered non-aromatic heterocyclic group which may be substituted by oxo and further substituted by substituent group C, a 6-membered non-aromatic heterocyclic group which may be substituted by oxo and further substituted by substituent group C, a 10-membered non-aromatic heterocyclic group which may be substituted by oxo and further substituted by substituent group C, a 5-membered aromatic heterocyclic group which may be substituted by substituent group B, a 6-membered aromatic heterocyclic group which may be substituted by substituent group B, a 9-membered aromatic heterocyclic group which may be substituted by substituent group B, a 10-membered aromatic heterocyclic group which may be substituted by substituent group B (toHereinafter referred to as A-9).
R 1 Examples thereof include a 5-membered non-aromatic heterocyclic group which may be substituted with oxo and further substituted with the substituent group ω2, a 6-membered non-aromatic heterocyclic group which may be substituted with oxo and further substituted with the substituent group ω2, a 10-membered non-aromatic heterocyclic group which may be substituted with oxo and further substituted with the substituent group ω2, a 5-membered aromatic heterocyclic group which may be substituted with the substituent group ω1, a 6-membered aromatic heterocyclic group which may be substituted with the substituent group ω1, a 9-membered aromatic heterocyclic group which may be substituted with the substituent group ω1, and a 10-membered aromatic heterocyclic group which may be substituted with the substituent group ω1 (hereinafter referred to as a-10).
Substituent group ω1: halogen, cyano, nitro, hydroxy, carboxy, carbamoyl which may be substituted by substituent group ω ', alkoxycarbonyl which may be substituted by substituent group ω ', alkenyloxy which may be substituted by substituent group ω ', alkynyl which may be substituted by substituent group ω ', alkoxyl which may be substituted by substituent group ω ', alkenyloxy which may be substituted by substituent group ω ', alkynyloxy which may be substituted by substituent group ω ', alkylcarbonyl which may be substituted by substituent group ω ', alkenylcarbonyl which may be substituted by substituent group ω ', alkenyloxycarbonyl which may be substituted by substituent group ω ', alkynyloxycarbonyl which may be substituted by substituent group ω ', alkenyloxycarbonyl which may be substituted by substituent group ω ', alkylthio which may be substituted by substituent group ω ', alkenylthio which may be substituted by substituent group ω ', alkynylthioalkyl which may be substituted by substituent group ω ', amino which may be substituted by substituent group ω ', aromatic carbocyclic which may be substituted by substituent group ω ', aromatic heterocyclic which may be substituted by substituent group ω ', heterocyclic which may be substituted by substituent group ω ', aromatic heterocyclic which may be substituted by substituent group ω ' may be substituted by aromatic group ω ', heterocyclic which may be substituted by substituent group ω ', heterocyclic group which may be substituted by substituent group ω ' ω;
Substituent group ω2: substituent groups ω1, oxo and thiooxo.
Substituent group ω': halogen, hydroxy, alkyl, hydroxyalkyl, alkylaminoalkyl, alkylcarbonyl, carbamoyl, aromatic carbocyclyl, and non-aromatic carbocyclyl.
R 1 Examples thereof include a 5-membered non-aromatic heterocyclic group which may be substituted with oxo and further substituted with substituent group C, a 6-membered non-aromatic heterocyclic group which may be substituted with oxo and further substituted with substituent group C, and a 10-membered non-aromatic heterocyclic group which may be substituted with oxo and further substituted with substituent group C (hereinafter referred to as A-11).
R 1 Examples thereof include a 5-membered non-aromatic heterocyclic group which may be substituted with oxo and further substituted with the substituent group ω2, a 6-membered non-aromatic heterocyclic group which may be substituted with oxo and further substituted with the substituent group ω2, and a 10-membered non-aromatic heterocyclic group which may be substituted with oxo and further substituted with the substituent group ω2 (hereinafter referred to as a-12).
R 1 Examples thereof include a 5-membered aromatic heterocyclic group which may be substituted with the substituent group B, a 6-membered aromatic heterocyclic group which may be substituted with the substituent group B, a 9-membered aromatic heterocyclic group which may be substituted with the substituent group B, and a 10-membered aromatic heterocyclic group which may be substituted with the substituent group B (hereinafter referred to as A-13).
R 1 Examples thereof include a 5-membered aromatic heterocyclic group which may be substituted with the substituent group ω1, a 6-membered aromatic heterocyclic group which may be substituted with the substituent group ω1, a 9-membered aromatic heterocyclic group which may be substituted with the substituent group ω1, and a 10-membered aromatic heterocyclic group which may be substituted with the substituent group ω1 (hereinafter referred to as a-14).
R 1 Examples thereof include a substituted or unsubstituted dihydropyridinyl group, a substituted or unsubstituted dihydropyrimidinyl group, a substituted or unsubstituted dihydropyridazinyl group, a substituted or unsubstituted dihydropyrazinyl group, a substituted or unsubstituted dihydroquinolinyl group, a substituted or unsubstituted dihydronaphthyridinyl group, a substituted or unsubstituted dihydrothienopyridinyl group, a substituted or unsubstituted tetrahydropyridinyl group, a substituted or unsubstituted benzopyranyl group, a substituted or unsubstituted pyrrolidinyl group, a substituted or unsubstituted dihydropyrazolyl group, a substituted or unsubstituted pyrazolyl group, a substituted or unsubstituted imidazolyl group, a substituted or unsubstituted triazolyl group, a substituted or unsubstituted oxazolyl group, a substituted or unsubstituted isoxazolyl group, a substituted or unsubstituted thiazolyl group, a substituted or unsubstituted oxadiazolyl group, a substituted or unsubstituted pyridinyl group,
A substituted or unsubstituted imidazopyridinyl group, a substituted or unsubstituted indazolyl group, a substituted or unsubstituted benzisoxadiazolyl group, a substituted or unsubstituted pyrazolopyridinyl group, a substituted or unsubstituted naphthyridinyl group, a substituted or unsubstituted substituted isoquinolinyl group (hereinafter referred to as A-15).
R 1 Examples thereof include a substituted or unsubstituted oxo-dihydropyridinyl group, a substituted or unsubstituted oxo-dihydropyrazinyl group, a substituted or unsubstituted oxo-dihydroquinolinyl group, a substituted or unsubstituted oxo-dihydrothienopyridinyl group, a substituted or unsubstituted dioxotetrahydropyridinyl group, a substituted or unsubstituted oxo-thiotetrahydropyridinyl group, a substituted or unsubstituted dioxodihydropyridazinyl group, a substituted or unsubstituted oxo-benzopyranyl group, a substituted or unsubstituted oxo-pyrrolidinyl group, a substituted or unsubstituted oxo-dihydropyrazolyl group,
Substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted oxadiazolyl, substituted or unsubstituted pyridinyl,
a substituted or unsubstituted imidazopyridinyl group, a substituted or unsubstituted indazolyl group, a substituted or unsubstituted benzisoxadiazolyl group, a substituted or unsubstituted pyrazolopyridinyl group, a substituted or unsubstituted naphthyridinyl group, a substituted or unsubstituted substituted isoquinolinyl group (hereinafter referred to as A-16).
R 1 Examples thereof include a substituted or unsubstituted dihydropyridyl group (hereinafter referred to as A-17).
R 1 Examples thereof include dihydropyridinyl (hereinafter referred to as A-18) which may be substituted with the substituent group ω2.
R 1 Examples thereof include a substituted or unsubstituted dihydronaphthyridinyl group (hereinafter referred to as A-19).
R 1 Examples thereof include a dihydronaphthyridinyl group (hereinafter referred to as A-20) which may be substituted with the substituent group ω2.
R 1 Examples thereof include a substituted or unsubstituted triazolyl group (hereinafter referred to as A-21).
R 1 Examples thereof include a triazolyl group (hereinafter referred to as A-22) substituted with one or more substituents selected from substituent group ω1.
R 1 Examples thereof include a triazolyl group substituted with an alkyl group (hereinafter referred to as A-23).
R 1 An unsubstituted triazolyl group (hereinafter referred to as A-24) may be mentioned.
R 1 Examples thereof include a substituted or unsubstituted pyridyl group (hereinafter referred to as A-25).
R 1 Examples thereof include pyridyl (hereinafter referred to as A-26) substituted with one or more substituents selected from substituent group ω1.
R 1 Examples thereof include pyridyl (hereinafter referred to as A-27) substituted with one or more substituents selected from substituent group ω4.
Substituent group ω4: halogen, alkyl, alkenyl, alkynyl, haloalkyl, and alkoxy.
R 1 An unsubstituted pyridyl group (hereinafter referred to as A-28) may be mentioned.
R 1 Examples thereof include a substituted or unsubstituted isoquinolinyl group (hereinafter referred to as A-29).
R 1 Examples thereof include isoquinolyl groups substituted with one or more substituents selected from substituent group ω1 (hereinafter referred to as A-30).
R 1 An unsubstituted isoquinolinyl group (hereinafter referred to as A-31) may be mentioned.
R 1 The formula may be given:
[ FORMS 54 ]
(wherein Z is CR 1b Or N;
R 1a is a hydrogen atom, halogen, substituted or unsubstituted alkyl;
R 1b is hydrogen, halogen, carboxyl, cyano, nitro, substituted or unsubstituted carbamoyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstitutedUnsubstituted alkynyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted alkynylcarbonyl, substituted or unsubstituted alkoxycarbonyl, substituted or unsubstituted alkenyloxycarbonyl, substituted or unsubstituted alkynyloxycarbonyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted alkenylsulfonyl, substituted or unsubstituted alkynylsulfonyl, substituted or unsubstituted amino, substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic carbocyclyl;
R 1c A group represented by a hydrogen atom, a halogen atom, a carboxyl group, a cyano group, a nitro group, a substituted or unsubstituted carbamoyl group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted alkylcarbonyl group, a substituted or unsubstituted alkenylcarbonyl group, a substituted or unsubstituted alkynyloxycarbonyl group, a substituted or unsubstituted alkoxycarbonyl group, a substituted or unsubstituted alkenylsulfonyl group, a substituted or unsubstituted alkynylsulfonyl group, a substituted or unsubstituted amino group, a substituted or unsubstituted aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted aromatic carbocyclic carbonyl group, a substituted or unsubstituted aromatic heterocyclic carbonyl group, a substituted or unsubstituted non-aromatic carbocyclic carbonyl group, a substituted or unsubstituted non-aromatic heterocyclic carbonyl group (hereinafter referred to as a-32).
R 1 The formula may be given:
[ chemical formula 55 ]
(wherein R is 1a 、R 1b And R is 1c Is synonymous with A-32 described above;
z is CR 1b ;
R 1b And R is 1c May form a group shown as a substituted or unsubstituted aromatic carbocyclic ring or a substituted or unsubstituted aromatic heterocyclic ring together with the bonded carbon atom (hereinafter referred to as A-33).
R 1 The formula may be given:
[ chemical formula 56 ]
(wherein R is 1a Is a hydrogen atom; z is CR 1b ;
R 1b Is a hydrogen atom, halogen, alkyl, haloalkyl, hydroxyalkyl, carbamoyl, alkylcarbamoyl;
R 1c a group represented by a hydrogen atom (hereinafter referred to as A-34).
R 1 The formula may be given:
[ chemical formula 57 ]
(wherein R is 1a Is a hydrogen atom; z is CH; r is R 1c A group represented by a hydrogen atom (hereinafter referred to as A-35).
R 1 The formula may be given:
[ chemical 58 ]
(wherein R is 1d Is a group shown as a substituted or unsubstituted alkyl group (hereinafter referred to as A-36).
R 1 The formula may be given:
[ chemical formula 59 ]
/>
(wherein R is 1d Is an unsubstituted alkyl group) (hereinafter referred to as A-37).
R 1 The formula may be given:
[ chemical formula 60 ]
(wherein R is 1e Is a group represented by halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, amino, alkylamino (hereinafter referred to as A-38).
R 1 The formula may be given:
[ chemical formula 61 ]
(wherein R is 1e A group represented by halogen or unsubstituted alkyl group (hereinafter referred to as A-39).
R 2 Examples thereof include a substituted or unsubstituted aromatic carbocyclyl group, a substituted or unsubstituted non-aromatic carbocyclyl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, and a substituted or unsubstituted alkyl group (hereinafter referred to as B-1).
R 2 Examples thereof include a substituted or unsubstituted aromatic carbocyclic group (excluding 1-p-fluorophenyl, 1-p-chlorophenyl and 1-p-methylphenyl), a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group, and a substituted or unsubstituted non-aromatic heterocyclic group (hereinafter referred to as B-2).
R 2 Examples thereof include a substituted or unsubstituted 6-, 10-or 14-membered aromatic carbocyclic group (except for 1-p-fluorophenyl, 1-p-chlorophenyl and 1-p-methylphenyl), a substituted or unsubstituted 5-, 6-, 9-or 10-membered non-aromatic carbocyclic group, and a substituted or unsubstitutedSubstituted 5-, 6-, 9-or 10-membered aromatic heterocyclic group, substituted or unsubstituted 5-, 6-, 9-or 10-membered non-aromatic heterocyclic group (hereinafter referred to as B-3-1).
R 2 Examples thereof include a substituted or unsubstituted 6-membered aromatic carbocyclyl group (excluding 1-p-fluorophenyl, 1-p-chlorophenyl and 1-p-methylphenyl), a substituted or unsubstituted 6-membered non-aromatic carbocyclyl group, a substituted or unsubstituted 9-10-membered non-aromatic carbocyclyl group, a substituted or unsubstituted 5-6-membered aromatic heterocyclic group, and a substituted or unsubstituted 9-10-membered non-aromatic heterocyclic group (hereinafter referred to as B-3).
R 2 Examples thereof include a substituted or unsubstituted 6-membered aromatic carbocyclic group (excluding 1-p-fluorophenyl, 1-p-chlorophenyl and 1-p-methylphenyl), a substituted or unsubstituted 9-10-membered non-aromatic carbocyclic group, a substituted or unsubstituted 5-6-membered aromatic heterocyclic group, and a substituted or unsubstituted 9-10-membered non-aromatic heterocyclic group (hereinafter referred to as B-4).
R 2 Examples thereof include a 6-membered aromatic carbocyclic group substituted with 1 halogen or cyano group and further substituted with 1, 2, 3 or 4 substituents selected from substituent group G, and a 6-membered aromatic heterocyclic group substituted with 1 halogen or cyano group and further substituted with 1 or 2 substituents selected from substituent group G (hereinafter referred to as B-5).
Substituent group G: halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkenyloxy, alkynyloxy, and haloalkoxy.
R 2 Examples thereof include; m-chlorophenyl; m-cyanophenyl; a 6 membered aromatic carbocyclyl substituted with 1 halogen or cyano and further substituted with 1, 2, 3 or 4 substituents selected from substituent group G; a 6-membered aromatic heterocyclic group substituted with 1 halogen or cyano group and further substituted with 1 or 2 substituents selected from substituent group G (hereinafter referred to as B-15).
R 2 There may be mentioned a 6-membered aromatic carbocyclyl group (hereinafter referred to as B-6) substituted with 1 halogen or cyano group and further substituted with 1, 2, 3 or 4 substituents selected from substituent group G.
R 2 Can be substituted by 1 halogen or cyano and further by 1, 2, 3 or 4 substituents selected from the substituent group G'Substituted 6-membered aromatic carbocyclyl (hereinafter referred to as B-7).
Substituent group G': halogen and cyano.
R 2 There may be mentioned a 6-membered aromatic carbocyclyl group (hereinafter referred to as B-8) substituted with 1 halogen or cyano group and further substituted with 1 or 2 substituents selected from substituent group G.
R 2 There may be mentioned a 6-membered aromatic carbocyclyl group (hereinafter referred to as B-9) substituted with 1 halogen or cyano group and further substituted with 1 or 2 substituents selected from substituent group G'.
R 2 Examples thereof include phenyl (hereinafter referred to as B-10) substituted with 1 halogen or cyano group and further substituted with 1, 2, 3 or 4 substituents selected from substituent group G.
R 2 Examples thereof include phenyl (hereinafter referred to as B-11) substituted with 1 halogen or cyano group and further substituted with 1, 2, 3 or 4 substituents selected from substituent group G'.
R 2 Examples thereof include phenyl (hereinafter referred to as B-12) substituted with 1 halogen or cyano group and further substituted with 1 or 2 substituents selected from substituent group G.
R 2 Examples thereof include phenyl (hereinafter referred to as B-13) substituted with 1 halogen or cyano group and further substituted with 1 or 2 substituents selected from substituent group G'.
R 2 Examples thereof include phenyl groups substituted with 3 halogens (hereinafter referred to as B-14).
R 3 Examples thereof include a substituted or unsubstituted aromatic carbocyclyl group, a substituted or unsubstituted non-aromatic carbocyclyl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, and a substituted or unsubstituted alkyl group (hereinafter referred to as C-1).
R 3 Examples thereof include a substituted or unsubstituted 6-membered aromatic carbocyclyl group, a substituted or unsubstituted 3-10-membered non-aromatic carbocyclyl group, a substituted or unsubstituted 5-6-membered aromatic heterocyclic group, a substituted or unsubstituted 9-10-membered aromatic heterocyclic group, a substituted or unsubstituted 13-15-membered aromatic heterocyclic group, and a substituted or unsubstituted 3-20-membered non-aromatic heterocyclic group (hereinafter referred to as C-2).
R 3 Examples thereof include a substituted or unsubstituted alkyl group (hereinafter referred to as C-33).
R 3 Examples thereof include a substituted or unsubstituted 6-membered aromatic carbocyclyl group, a substituted or unsubstituted 3-10-membered non-aromatic carbocyclyl group, a substituted or unsubstituted 5-6-membered aromatic heterocyclic group, a substituted or unsubstituted 9-10-membered aromatic heterocyclic group, and a substituted or unsubstituted 3-10-membered non-aromatic heterocyclic group (hereinafter referred to as C-3).
R 3 Examples thereof include a substituted or unsubstituted 6-membered aromatic carbocyclyl group, a substituted or unsubstituted 9-10-membered aromatic heterocyclic group, and a substituted or unsubstituted 9-10-membered non-aromatic heterocyclic group (hereinafter referred to as C-4).
R 3 Examples thereof include a substituted or unsubstituted 6-membered aromatic carbocyclyl group (hereinafter referred to as C-5).
R 3 Examples thereof include a substituted or unsubstituted 9-10 membered aromatic heterocyclic group and a substituted or unsubstituted 9-10 membered non-aromatic heterocyclic group (hereinafter referred to as C-6).
R 3 Examples thereof include a 6-membered aromatic carbocyclic group which may be substituted by the substituent group B, a 9-10-membered aromatic heterocyclic group which may be substituted by the substituent group B, and a 9-10-membered non-aromatic heterocyclic group which may be substituted by the substituent group C (hereinafter referred to as C-7).
R 3 Examples thereof include a 6-membered aromatic carbocyclyl group (hereinafter referred to as C-8) which may be substituted with the substituent group B.
R 3 Examples thereof include a 9-10 membered aromatic heterocyclic group which may be substituted with the substituent group B and a 9-10 membered non-aromatic heterocyclic group which may be substituted with the substituent group C (hereinafter referred to as C-9).
R 3 Examples thereof include a 6-membered aromatic carbocyclyl group (hereinafter referred to as C-10) which may be substituted with a substituent group ω3.
Substituent group ω3: halogen, cyano, hydroxy, carboxy, substituted alkyl (halogen as substituent), unsubstituted alkyl, unsubstituted alkoxy (halogen, hydroxy, carboxy, alkoxy, alkoxycarbonyl, carbamoyl, alkylcarbamoyl, alkylamino, aromatic carbocyclyl as substituent), unsubstituted alkoxy, substituted alkylcarbonyl (amino as substituent), unsubstituted alkoxycarbonyl, unsubstituted alkylthio, unsubstituted alkylsulfinyl, unsubstituted alkylsulfonyl, substituted amino (alkylcarbonyl, alkylcarbamoyl, alkylsulfonyl as substituent), substituted carbamoyl (alkyl as substituent), unsubstituted carbamoyl, unsubstituted dialkylsulfoimino, unsubstituted non-aromatic carbocyclyl, substituted aromatic heterocyclic group (alkyl as substituent), unsubstituted aromatic heterocyclic group, substituted non-aromatic heterocyclic group (oxo as substituent), unsubstituted non-aromatic carbocyclyloxy.
R 3 Examples thereof include a 6-membered aromatic carbocyclyl group substituted with halogen and alkoxy, a dihydrobenzofuranyl group substituted with substituent group B, a dihydrobenzofuranyl group substituted with halogen, an unsubstituted dihydrobenzofuranyl group, an indazolyl group substituted with substituent group C, an indazolyl group substituted with halogen and alkyl, an unsubstituted indazolyl group, a benzoxazolyl group substituted with substituent group B, a benzothiazolyl group substituted with substituent group B, and a benzimidazolyl group substituted with substituent group B (hereinafter referred to as C-11).
R 3 Examples thereof include a 6-membered aromatic carbocyclyl group substituted with halogen and alkoxy (hereinafter referred to as C-12).
R 3 Examples thereof include dihydrobenzofuranyl groups (hereinafter referred to as C-13) which may be substituted with the substituent group B.
R 3 Examples thereof include a dihydrobenzofuranyl group substituted with halogen (hereinafter referred to as C-14).
R 3 An unsubstituted dihydrobenzofuranyl group (hereinafter referred to as C-15) may be mentioned.
R 3 An indazolyl group (hereinafter referred to as C-16) which may be substituted by the substituent group C is exemplified.
R 3 Examples thereof include indazolyl groups substituted with halogen and alkyl groups (hereinafter referred to as C-17).
R 3 An unsubstituted indazolyl group (hereinafter referred to as C-18) may be mentioned.
R 3 Examples thereof include benzoxazolyl groups (hereinafter referred to as "C' -1") which may be substituted with the substituent group B.
R 3 Can be mentioned asBenzothiazolyl substituted with substituent group B (hereinafter referred to as C' -2).
R 3 Examples thereof include benzimidazolyl (hereinafter referred to as C' -3) which may be substituted with the substituent group B.
R 3 Examples thereof include benzoxazolyl groups (hereinafter referred to as C' -4) substituted with one or more groups selected from substituent group ω5.
Substituent group ω5: halogen, alkyl, haloalkyl, cycloalkyl, hydroxyalkyl, alkylcarbonylalkyl, alkylamino, alkoxycarbonylamino.
R 3 An unsubstituted benzoxazolyl group (hereinafter referred to as C' -5) may be mentioned.
R 3 Examples thereof include benzothiazolyl (hereinafter, referred to as C' -6) substituted with one or more groups selected from substituent group ω5.
R 3 An unsubstituted benzothiazolyl group (hereinafter referred to as C' -7) may be mentioned.
R 3 There may be mentioned benzimidazolyl (hereinafter referred to as C' -8) substituted with one or more groups selected from substituent group ω5.
R 3 An unsubstituted benzimidazolyl group (hereinafter referred to as C' -9) may be mentioned.
R 3 Examples thereof include a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted aromatic carbocyclic group, and a substituted or unsubstituted non-aromatic carbocyclic group (hereinafter referred to as C-19).
R 3 Examples thereof include a substituted or unsubstituted aromatic heterocyclic group and a substituted or unsubstituted non-aromatic heterocyclic group (hereinafter referred to as C-20).
R 3 Examples thereof include an aromatic heterocyclic group or an unsubstituted aromatic heterocyclic group (hereinafter referred to as C-21) substituted with one or more substituents selected from the group consisting of substituent group d (substituent group d: substituted or unsubstituted alkyl group; substituted or unsubstituted amino group; and halogen).
R 3 Examples include alkyl groups (substituents: halogen, non-aromatic carbocyclyl) or unsubstituted alkyl groups substituted with one or more substituents d '(substituent group d': substituted), substituted amino groups(substituent: alkyl) or unsubstituted amino; and halogen), or an unsubstituted aromatic heterocyclic group (hereinafter referred to as C-22).
R 3 Examples thereof include an aromatic heterocyclic group substituted with an alkyl group and a halogen group or an unsubstituted aromatic heterocyclic group (hereinafter referred to as C-23).
R 3 Examples thereof include an aromatic heterocyclic group substituted with an alkyl group and a halogen (hereinafter referred to as C-24).
R 3 Examples thereof include an aromatic heterocyclic group substituted with an unsubstituted alkyl group and a halogen group or an unsubstituted aromatic heterocyclic group (hereinafter referred to as C-25).
R 3 Examples thereof include an aromatic heterocyclic group substituted with an unsubstituted alkyl group and halogen (hereinafter referred to as C-26).
R 3 Examples thereof include a 9-membered aromatic heterocyclic group substituted with an unsubstituted alkyl group and halogen, and an unsubstituted 9-membered aromatic heterocyclic group (hereinafter referred to as C-27).
R 3 Examples thereof include a 9-aromatic heterocyclic group substituted with an unsubstituted alkyl group and halogen (hereinafter referred to as C-28).
R 3 An indazolyl group substituted with an unsubstituted alkyl group and halogen (hereinafter referred to as C-29) may be mentioned.
R 3 The formula may be given:
[ chemical formula 62 ]
(wherein R is 3a Is a hydrogen atom or a halogen;
R 3b is a group shown as a substituted or unsubstituted alkyl group (hereinafter referred to as C-30).
R 3 The formula may be given:
[ chemical formula 63 ]
(in the formula (I),R 3a is halogen;
R 3b a group represented by a substituted alkyl group (substituent: halogen or non-aromatic carbocyclyl group) or an unsubstituted alkyl group (hereinafter referred to as C-31).
R 3 The formula may be given:
[ chemical 64 ]
(wherein R is 3a Is halogen;
R 3b is an alkyl group substituted with halogen or an unsubstituted alkyl group) (hereinafter referred to as C-32).
As the-X-are mentioned-NR 6 -、-CR 6 R 6’ -, -O-, -S-or a single bond (hereinafter referred to as D-1).
As the-X-are mentioned-NR 6 -, -O-or a single bond (hereinafter referred to as D-2).
X-may be-NH-or a single bond (hereinafter referred to as D-4).
As the-X-there may be mentioned-NH- (hereinafter referred to as D-3).
R 6 And R is 6’ Each independently includes a hydrogen atom or a substituted or unsubstituted alkyl group (hereinafter referred to as E-1).
R 6 And R is 6’ Each independently includes a hydrogen atom (hereinafter referred to as E-2).
m may be 0, 1 or 2 (hereinafter referred to as F-1).
m may be 0 or 1 (hereinafter referred to as F-2).
m is exemplified by 0 (hereinafter, F-3).
m is 1 (hereinafter referred to as F-4).
R 5a Each independently includes a hydrogen atom or a substituted or unsubstituted alkyl group (hereinafter referred to as G-1).
R 5a Each independently includes a hydrogen atom (hereinafter referred to as G-2).
R 5b Each independently of the other, a hydrogen atom or a substituted or unsubstituted alkyl group (hereinafter referred to asG' -1).
R 5b Each independently includes a hydrogen atom (hereinafter referred to as G' -2).
m may be 0, 1 or 2 (hereinafter referred to as H-1).
m may be 0 or 1 (hereinafter referred to as H-2).
m is exemplified by 0 (hereinafter, H-3).
m is 1 (hereinafter, referred to as H-4).
R 4a Each independently includes a hydrogen atom or a substituted or unsubstituted alkyl group (hereinafter referred to as J-1).
R 4a Each independently includes a hydrogen atom or an unsubstituted alkyl group (hereinafter referred to as J-2).
R 4a The hydrogen atoms (hereinafter referred to as J-3) are each independently exemplified.
R 4b Each independently includes a hydrogen atom or a substituted or unsubstituted alkyl group (hereinafter referred to as J' -1).
R 4b Each independently includes a hydrogen atom (hereinafter referred to as J' -2).
“R 4a And R is 4b Together form a substituted or unsubstituted non-aromatic carbocyclic ring (hereinafter referred to as K-1).
Formula (I):
[ chemical 65 ]
/>
The compounds shown exemplify the following embodiments. As the compound represented by the formula (I), embodiments of all combinations of the specific examples shown below are exemplified.
Y is preferably AA-2.
R 1 Preferably A-5, A-6, A-7, A-9, A-10, A-13, A-14, A-15, A-16, A-21, A-22, A-23, A-25, A-26, A-27, A-28, A-36, A-37, A-38 or A-39.
R 2 Preferably B-4, B-5, B-6, B-7, B-8, B-9, B-10, B-11, B-12, B-13 or B-14.
R 3 Preferably C-6, C-9, C-16, C-17, C-19, C-20, C-21, C-22, C-23, C-24, C-25, C-26, C-27, C-28, C-29, C-30, C-31 or C-32.
X is preferably D-3.
m is preferably F-2, F-3 or F-4.
R 5a G-2 is preferred.
R 5b G' -2 is preferred.
n is preferably H-4.
R 4a J-3 is preferred.
R 4b J' -2 is preferred.
Formula (I'):
[ chemical 66 ]
The compound shown (wherein Y is AA-2, X is D-3, R 5a Is G-2, R 5b Is G' -2, n is H-4, R 4a Is J-3, R 4b The embodiment of J' -2) may be the following combination.
(a1)
R 1 Is A-36, A-37, A-38 or A-39,
R 2 Is B-12, B-13 or B-14,
R 3 Is C-30, C-31 or C-32,
m is F-2, F-3 or F-4.
(a2)
R 1 Is A-37,
R 2 Is B-14,
R 3 Is C-32,
m is F-4.
(a3)
R 1 Is A-39,
R 2 Is B-12,
R 3 Is C-30 or C-32,
m is F-3.
The compounds of formula (I), formula (I ') and formula (I') are not limited to specific isomers, but include all possible isomers (e.g., keto-enol isomers, imine-enamine isomers, diastereomers, optical isomers, rotamers, etc.), racemates or mixtures thereof. For example, compounds in formula (I) wherein Y is N, X is NH include the following tautomers.
[ chemical 67 ]
For example, compounds in formula (I) wherein Y is C, X is NH include the following tautomers.
[ chemical formula 68 ]
For example, compound (I-0113) includes the following tautomers.
[ chemical 69 ]
For example, compound (I-0115) includes the following tautomers.
[ chemical 70 ]
One or more hydrogen, carbon and/or other atoms of the compounds represented by formula (I), formula (I') and formula (I "), respectively, may be replaced by isotopes of hydrogen, carbon and/or other atoms. Examples of such isotopes include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine, e.g., respectively 2 H、 3 H、 11 C、 13 C、 14 C、 15 N、 18 O、 17 O、31P、32P、35S、18F、 123 I and 36 cl. The compounds of formula (I), formula (I ') and formula (I') also includeCompounds substituted with such isotopes. The compounds substituted with this isotope may also be used as pharmaceuticals and include all radiolabels of compounds of formula (I), formula (I ') and formula (I'). The invention also includes "radiolabeling methods" for making the "radiolabels" that may be used as research and/or diagnostic tools in metabolic pharmacokinetic studies, binding assays.
Furthermore, the crystal of the present invention may be a deuterium converter. The crystals of the invention may be prepared with isotopes (e.g., 3 H, 14 C, 35 S, 125 I), etc.).
Radiolabels of compounds of formula (I), formula (I ') and formula (I') may be prepared by methods well known in the art. For example, tritium-labeled compounds of formula (I), formula (I ') and formula (I' ') can be prepared by introducing tritium into specific compounds of formula (I), formula (I') and formula (I '') using catalytic dehalogenation reactions with tritium. The process comprises reacting compounds of formula (I), formula (I ') and formula (I ' ') suitably with a halogen substituted precursor and tritium in the presence of a suitable catalyst, such as Pd/C, in the presence or absence of a base. Other suitable methods for preparing tritium-labeled compounds can be found in "Isotopes in the Physical and Biomedical Sciences, vol.1, labeled Compounds (Part a), chapter 6 (1987)". 14 The C-labelled compound may be prepared by using a compound having the following properties 14 C, raw materials of the catalyst.
Examples of pharmaceutically acceptable salts of the compounds represented by the formulae (I), (I ') and (I') include salts of the compounds represented by the formulae (I), (I ') and (I'), with alkali metals (e.g., lithium, sodium, potassium, etc.), alkaline earth metals (e.g., calcium, barium, etc.), magnesium, transition metals (e.g., zinc, iron, etc.), ammonia, organic bases (e.g., trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, pyridine, picoline, quinoline, etc.), and amino acids, or salts of inorganic acids (e.g., hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid, etc.), and organic acids (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, succinic acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, trifluoroacetic acid, etc.). These salts may be formed by conventional methods.
Pharmaceutically acceptable salts of the compounds of formula (I-A) are, for example, composed of the compounds of formula (I-A) and a counter-molecule or counter-ion, and may contain any number of counter-molecules or counter-ions. Pharmaceutically acceptable salts of the compounds of formula (I-A) refer to salts that mediate ionic bonding through proton transfer between the compound and the counter molecule or counter atom.
The compounds of formula (I), formula (I ') and formula (I') of the present invention or pharmaceutically acceptable salts thereof are present in the form of solvates (e.g., hydrates, etc.), co-crystals and/or polymorphs, and the present invention also includes such various solvates, co-crystals and polymorphs. For compounds of formula (I), formula (I'), and formula (I "), the" solvate "may be coordinated to any number of solvent molecules (e.g., water molecules, etc.). In addition, there are cases where the compounds represented by the formula (I), the formula (I ') and the formula (I') or pharmaceutically acceptable salts thereof are recrystallized to form polymorphs.
As used herein, "crystal" means a solid in which atoms, ions, molecules, and the like, which constitute the structure, are regularly arranged in three dimensions, and is distinguished from an amorphous solid that does not have such a regular internal structure. The crystals of the present invention may be single crystal, bicrystal, polycrystal, etc.
Further, "polymorphs" of the same composition but different crystal arrangements may exist in the "crystal", and these are included as "crystal forms".
In addition, the compounds represented by formula (I), formula (I ') and formula (I') may be converted into pharmaceutically acceptable salts thereof or pharmaceutically acceptable solvates thereof. The crystals of the present invention may be any one of these salts, hydrates, solvates, polymorphs, or even a mixture of two or more, and are intended to be included in the scope of the present invention.
The crystal morphology and crystallinity may be determined by a number of techniques including, for example, X-ray powder diffraction measurement, raman spectroscopy, infrared absorption spectrometry, moisture adsorption and desorption measurement, differential scanning calorimetric measurement, dissolution profile.
As used herein, "co-crystal" means, for example, that the compound represented by formula (I-B) and the counter molecule are regularly arranged in the same crystal lattice, and may contain any number of counter molecules. In addition, co-crystals refer to intermolecular interactions of compounds with counter molecules mediated by non-covalent and non-ionic chemical interactions such as hydrogen bonding and van der Waals forces. Co-crystals differ from salts in that the compound remains essentially uncharged or neutral. Co-crystals differ from hydrates or solvates in that the counter-molecule is not water or solvent.
Complexes comprising the compounds of formula (I-B) of the invention include salts, co-crystals and clathrates or solvates thereof in a broad sense.
As used herein, "solvate" refers to a substance in which compounds of, for example, formula (I), formula (I'), formula (I-A), and formula (I-B) are regularly aligned with any number of solvent molecules.
Examples of the solvent molecule include acetonitrile, chlorobenzene, chloroform, cyclohexane, 1, 2-dichloroethane, dichloromethane, 1, 2-dimethoxyethane, N-dimethylacetamide, N, N-dimethylformamide, 1, 4-dioxane, 2-ethoxyethanol, ethylene glycol, formamide, hexane, methanol, 2-methoxyethanol, methylbutyl ketone, methylcyclohexane, N-methylpyrrolidone, nitromethane, pyridine, sulfolane, tetralin, toluene, 1, 2-trichloroethylene, xylene, acetic acid, anisole, 1-butanol, 2-butanol, N-butyl acetate, t-butylmethyl ether, cumene, dimethyl sulfoxide, ethyl acetate, diethyl ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, tetrahydrofuran, water (i.e., hydrates), ethanol, acetone, 1-diethoxypropane, 1-dimethoxymethane, 2-dimethoxypropane, isooctane, isopropyl ether, methyl isopropyl ketone, methyl tetrahydrofuran, petroleum ether, trichloroacetic acid and trifluoroacetic acid; preferred examples thereof include acetic acid, anisole, 1-butanol, 2-butanol, n-butyl acetate, t-butyl methyl ether, cumene, dimethyl sulfoxide, ethyl acetate, diethyl ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, tetrahydrofuran, water (i.e., hydrate), ethanol, acetone, 1-diethoxypropane, 1-dimethoxymethane, 2-dimethoxypropane, isooctane, isopropyl ether, methyl isopropyl ketone, methyl tetrahydrofuran, petroleum ether, trichloroacetic acid and trifluoroacetic acid; more preferably, water (i.e., hydrate), ethanol, acetone, 1-diethoxypropane, 1-dimethoxymethane, 2-dimethoxypropane, isooctane, isopropyl ether, methyl isopropyl ketone, methyl tetrahydrofuran, petroleum ether, trichloroacetic acid, trifluoroacetic acid, and the like are mentioned.
In addition, by leaving the compounds represented by the formula (I), the formula (I ') and the formula (I') or pharmaceutically acceptable salts, co-crystals and complexes thereof in the atmosphere, moisture may be absorbed, there may be a case where adsorbed water is attached thereto, or a case where a hydrate is formed.
The compounds of formula (I), formula (I ') and formula (I') of the present invention or pharmaceutically acceptable salts thereof are useful in the formation of prodrugs and the present invention also includes such various prodrugs. Prodrugs are derivatives of the compounds of the invention which have a chemically or metabolically cleavable group and which become pharmaceutically active compounds of the invention in vivo by solvolysis or under physiological conditions. Prodrugs are compounds that are converted to compounds of formula (I), formula (I ') and formula (I ") by enzymatic oxidation, reduction, hydrolysis, etc., under physiological conditions in a living body, compounds that are converted to compounds of formula (I), formula (I') and formula (I") by hydrolysis with gastric acid, etc., and the like. Methods of selection and manufacture of suitable prodrug derivatives are described, for example, in "Design of Prodrugs, elsevier, amsterdam, 1985". Prodrugs are also active themselves.
In the case where the compounds represented by the formula (I), the formula (I ') and the formula (I') or pharmaceutically acceptable salts thereof have a hydroxyl group, for example, a prodrug such as an acyloxy derivative, a sulfonyloxy derivative is produced by reacting a compound having a hydroxyl group with an appropriate acyl halide, an appropriate acid anhydride, an appropriate sulfonyl chloride, an appropriate sulfonyl anhydride and a mixed acid anhydride, or by reacting them with a condensing agent. For example, CH can be mentioned 3 COO-、C 2 H 5 COO-、tert-BuCOO-、C 15 H 31 COO-、PhCOO-、(m-NaOOCPh)COO-、NaOOCCH 2 CH 2 COO-、CH 3 CH(NH 2 )COO-、CH 2 N(CH 3 ) 2 COO-、CH 3 SO 3 -、CH 3 CH 2 SO 3 -、CF 3 SO 3 -、CH 2 FSO 3 -、CF 3 CH 2 SO 3 -、p-CH 3 O-PhSO 3 -、PhSO 3 -、p-CH 3 PhSO 3 -。
(X-ray powder diffraction (XRPD))
X-ray powder diffraction (XRPD) is one of the most sensitive analytical methods for determining solid crystal morphology and crystallinity. When the X-ray is irradiated onto the crystal, it is reflected by the lattice plane and interferes with each other, exhibiting ordered diffraction lines corresponding to the structural period. On the other hand, with amorphous solids, there is typically no ordered repetition period in their structure, so no diffraction occurs, and they exhibit a broad XRPD pattern (also known as a halo pattern) without features.
The crystal forms of the compounds represented by the formulas (I-A) and (I-B) can be identified by X-ray powder diffraction patterns and characteristic diffraction peaks. The crystal forms of the compounds represented by the formulas (I-A) and (I-B) can be distinguished from other crystal forms by the presence of characteristic diffraction peaks.
The characteristic diffraction peak used in the present specification is a peak selected from the diffraction patterns observed. The characteristic diffraction peaks are preferably selected from about 10, more preferably about 5, and even more preferably about 3 of the diffraction patterns.
When a plurality of crystals are distinguished, a peak identified in the crystal but not identified in other crystals is preferably a characteristic peak that identifies the crystal, rather than a peak intensity. As long as it is such a characteristic peak, one or both peaks can characterize the crystal. Comparing the graphs obtained by the measurement, it can be said that the X-ray powder diffraction patterns are substantially identical when these characteristic peaks are identical.
In general, since an error may occur in the diffraction angle (2θ) in the X-ray powder diffraction in the range of ±0.2°, it is to be understood that the value of the diffraction angle in the X-ray powder diffraction also includes a value in the range of ±0.2°. Therefore, the present invention includes not only crystals in which diffraction angles of peaks in diffraction of an X-ray powder are completely uniform, but also crystals in which diffraction angles of peaks are uniform within an error of about.+ -. 0.2 ℃.
It is known that the peak intensities represented in the tables and figures below may generally vary due to factors such as the effect of the crystals on the selective orientation of the X-ray beam, the influence of coarse particles, the purity of the substance being analyzed, or the crystallinity of the sample. In addition, the peak position may be shifted based on the variation in the sample height. Further, when measurements are made using different wavelengths, different displacements are obtained according to the bragg equation (nλ=2dsinθ), but such different XRPD patterns obtained using different wavelengths are also included within the scope of the present invention.
(analysis of Single Crystal Structure)
Single crystal structure analysis is one of methods for determining a crystal, and can obtain crystallographic parameters in the crystal, and further obtain atomic coordinates (values indicating spatial positional relationships of atoms) and a three-dimensional structural model. See, for example, the publication of Shanghai, X-ray Structure analysis Manual, stout & Jensen, X-Ray Structure Determination: A Practical Guide, macmillan Co., new York (1968), et cetera. Single crystal structure analysis can be used to identify the crystal structure of complexes, salts, optical isomers, tautomers and geometric isomers as in the present invention.
(Raman Spectroscopy)
Raman spectroscopy reveals the vibrational characteristics of a molecule or composite system. The origin is inelastic collisions between molecules and photons, which are particles of light containing light rays. The collision of molecules and photons results in an energy exchange, with a consequent change in energy, and hence in the wavelength of the photons. That is, raman spectrum is a spectral line with an extremely narrow wavelength emitted when photons are incident on a target molecule, and thus laser light or the like can be used as a light source. The wavelength of each raman line is represented by the shift in wave number from the incident light, which is the difference between the raman line and the inverse of the wavelength of the incident light. Raman spectroscopy determines the vibrational state of a molecule, which is determined by the molecular structure.
In general, due to Raman spectral peaks (cm -1 ) At + -2 cm -1 Errors may occur within the range of (2), and it is therefore to be understood that the values of the Raman spectrum peaks also include + -2 cm -1 Values within the left and right ranges. Therefore, the invention not only includes the crystal with the completely consistent Raman spectrum peak in the Raman spectrum, but also includes the crystal with the Raman spectrum peak within + -2 cm -1 Crystals consistent within left and right errors.
(differential scanning calorimetry (DSC))
DSC is one of the main measurement methods of thermal analysis, and is a method for measuring thermal properties of a substance that is an aggregate of atoms and molecules.
The change in calories of the pharmaceutically active ingredient with temperature or time is measured by DSC and the data obtained is plotted against temperature or time to obtain a differential scanning calorimetric curve. From the differential scanning calorimetric curve, information about the initial temperature at which the pharmaceutically active ingredient is melted, the maximum value of the endothermic peak curve accompanying the melting, and the enthalpy can be obtained.
Regarding DSC, it is known that the observed temperature may depend on the rate of temperature change as well as the sample preparation technique and the particular device used. Thus, the "melting point" in DSC refers to the onset temperature that is not susceptible to sample preparation techniques. The error range of the starting temperature obtained from the differential scanning calorimetric curve is about ±2 ℃. Not only the melting point, the overall map is important in identifying the identity of the crystals, and may vary somewhat depending on the assay conditions or assay machinery.
(differential thermal-thermogravimetry Simultaneous assay (TG/DTA))
TG/DTA is one of the main measurement methods of thermal analysis, and is a method for measuring thermal properties of a substance which is an aggregate of atoms and molecules.
TG/DTA is a method of determining the weight and caloric value of a pharmaceutically active ingredient as a function of temperature or time, and TG (thermogravimetric) and DTA (differential thermal) curves are obtained by plotting the obtained data against temperature or time. Information on weight and caloric changes associated with decomposition, dehydration, oxidation, reduction, sublimation, evaporation of the pharmaceutically active ingredient can be obtained from TG/DTA curves.
Regarding TG/DTA, it is known that the observed temperature, weight change may depend on the rate of temperature change as well as the sample preparation technique and the particular device used. Thus, the "melting point" in TG/DTA refers to the onset temperature that is not readily affected by the sample preparation technique. Not only the melting point, the overall map is important in identifying the identity of the crystals, and may vary somewhat depending on the assay conditions or assay machinery.
The compounds of the present invention have coronavirus 3CL protease inhibitory activity and are therefore useful as therapeutic and/or prophylactic agents for diseases associated with coronavirus 3CL protease. The "therapeutic agent and/or prophylactic agent" in the present invention also includes a symptom-improving agent. The disease associated with coronavirus 3CL protease may be a viral infection, and preferably a coronavirus infection.
In one embodiment, coronaviruses may be exemplified as coronaviruses that infect humans. As coronaviruses which infect humans, HCoV-229E, HCoV-NL63, HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV and/or SARS-CoV-2 can be mentioned.
In one embodiment, coronaviruses may be exemplified by alpha and/or beta coronaviruses, more preferably beta coronaviruses.
In one embodiment, the alpha genus coronavirus may be HCoV-229E and HCoV-NL63. HCoV-229E is particularly preferred.
In one embodiment, the beta genus coronavirus may be HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV, and/or SARS-CoV-2. HCoV-OC43 or SARS-CoV-2 is preferred, and SARS-CoV-2 is particularly preferred.
In one embodiment, the genus beta coronavirus may be exemplified by the genus beta coronavirus subgroup A (beta-coronavirus lineage A), the genus beta coronavirus subgroup B (beta-coronavirus lineage B) and the genus beta coronavirus subgroup C (beta-coronavirus lineage C). More preferably, the subgroup B coronavirus A (beta-coronavirus lineage A) and the subgroup B coronavirus B (beta-coronavirus lineage B) are exemplified, and particularly preferably the subgroup B coronavirus B (beta-coronavirus lineage B) is exemplified.
In one embodiment, the genus β coronavirus may be exemplified by the subgenera sabia virus.
As the subgroup (. Beta. -coronavirus lineage A) of the genus coronavirus A, HCoV-HKU1 and HCoV-OC43, preferably HCoV-OC43, are exemplified. Examples of the subgroup B (beta-coronavirus lineage B) of the genus coronavirus include SARS-CoV and SARS-CoV-2, and SARS-CoV-2 is preferred. The subgroup C of the genus beta coronavirus (. Beta. -coronavirus lineage C) is preferably MERS-CoV.
In one embodiment, the coronavirus may be HCoV-229E, HCoV-OC43 and/or SARS-CoV-2, with SARS-CoV-2 being particularly preferred.
As coronavirus infection, there may be mentioned infection caused by HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, SARS-CoV, MERS-CoV and/or SARS-CoV-2. Preferably, the infection is caused by HCoV-229E, HCoV-OC43 and/or SARS-CoV-2, and particularly preferably by SARS-CoV-2.
The coronavirus infection is particularly preferably a novel coronavirus infection (COVID-19).
(Process for producing the Compound of the invention)
The compounds represented by the formula (I), the formula (I ') and the formula (I') according to the present invention can be produced, for example, by the following general synthesis methods. The method is carried out by adopting common organic chemistry experiments such as extraction, purification and the like.
The compounds of the present invention may be manufactured by reference to methods well known in the art. For example, reference may be made to WO 2010092966, WO 2012020749, WO 2013089212, WO 2014200078, WO 2012020742 and WO 2013118855.
(method A) Y is N, XNR 6 Or O time
[ chemical formula 71 ]
(wherein Alk is a C1-C3 alkyl group, lg 1 Other symbols are synonymous with the foregoing as leaving groups. )
(step 1)
In a solvent such as N, N-dimethylformamide, N-dimethylacetamide, N '-dimethylimidazolidinone, dimethylsulfoxide, THF, etc., the compound (a-1) or its hydrochloride or bromate is reacted with isocyanate (a-2) or 1-carbamoylimidazole (a-2') in the presence of a base such as DBU, triethylamine, N-diisopropylethylamine, pyridine, etc., preferably DBU, at-20℃to 50℃and preferably-10℃to ice-cooling. Subsequently, the reaction mixture is reacted with a carbonylation agent such as 1,1' -carbonyldiimidazole, phosgene, triphosgene, etc., and a base such as DBU, triethylamine, N-diisopropylethylamine, pyridine, etc. (preferably DBU), at-20℃to 50℃and preferably-10℃to ice-cooling, whereby the compound (a-3) can be produced.
(step 2)
Compound (a-5) can be produced by reacting compound (a-3) with compound (a-4) in the presence of a base such as potassium carbonate, sodium carbonate, N-diisopropylethylamine, etc., in a solvent such as acetonitrile, acetone, DMF, DMSO, etc., under 50℃to heating reflux, preferably heating reflux.
Examples of leaving groups include halogen and-OSO 2 (C t F 2t+1 ) (wherein t is an integer of 1 to 4), and the like. Halogen is preferably chlorine, iodine and bromine; -OSO 2 (C t F 2t+1 ) The radical is preferably an-OTf radical (triflate).
(step 3)
The compound represented by the compound (I-a) can be produced by reacting the compound (a-5) with the compound (a-6) or the compound (a-6') in a solvent such as NMP, DMF, DMA, DMSO, t-butanol or 2-methyl-2-butanol in the presence or absence of an acid such as acetic acid at 60℃to 150℃and preferably 80℃to 120 ℃.
The compound represented by the optically active compound (I-a) can be produced by using the optically active isocyanate (a-2).
(method B) Y is N, X is-S-or-CR 6 R 6’ -time of day
[ chemical formula 72 ]
(in which the symbols are synonymous with the foregoing.)
(step 1)
In the same manner as in step 1 of the method A, the compound (b-2) can be produced by reacting the compound (b-1) with the compound (a-2) or (a-2').
(step 2)
The compound represented by the compound (I-b) can be produced in the same manner as in the step 2 of the method A.
(method C) when Y is N, X a single bond
[ chemical 73 ]
(in which the symbols are synonymous with the foregoing.)
(step 1)
In the same manner as in step 1 of the method A, the compound (c-2) can be produced by reacting the compound (c-1) with the compound (a-2) or (a-2').
(step 2)
The compound represented by the compound (I-c) can be produced in the same manner as in the step 2 of the method A.
(method D) when Y is N, m and 0
[ chemical 74 ]
(in the formula (I),pro is C1-C4 alkyl or t-butoxycarbonyl, lg 2 Other symbols are synonymous with the foregoing as leaving groups. )
(step 1)
In the same manner as in step 2 of the above method A, the compound (d-2) can be produced from the compound (d-1).
(step 2)
Compound (d-3) can be produced by treating compound (d-2) with a strong acid such as TFA at-20℃to room temperature, preferably at room temperature, in the presence or absence of an organic solvent.
(step 3)
In the same manner as in step 3 of the above method A, the compound (d-4) can be produced from the compound (d-3).
(step 4)
The compound (I-D) can be produced by Goldberg amination using the compound (D-4) and the compound (D-5).
The leaving group may be the one described in step 1 of method A.
As the catalyst, for example, commercially available copper catalysts such as copper iodide, copper cyanide, copper bromide and the like can be used.
As the ligand, 1, 2-dimethylethylenediamine, trans-N, N' -dimethylcyclohexane-1, 2-diamine and the like can be used.
As the base, potassium carbonate, potassium phosphate and the like can be used.
NMP, dioxane, DMSO, and the like can be used as the solvent.
The reaction temperature is preferably from room temperature to the reflux temperature of the solvent, preferably by heating the reaction.
(method E) when Y is N, m or 1 or 2
[ chemical formula 75 ]
(wherein Alk is a C1-C3 alkyl group, lg 3 Other symbols are synonymous with the foregoing as leaving groups. )
(step 1)
The compound (e-2) can be produced in the same manner as in step 2 of the method A.
The leaving group may be the one described in step 1 of method A.
(step 2)
The compound represented by the compound (I-E) can be produced in the same manner as in the step 3 of the method A.
(method F) when Y is C
[ chemical formula 76 ]
(wherein Lg 4 Other symbols are synonymous with the foregoing as leaving groups. )
(step 1)
Compound (f-2) can be produced by reacting compound (f-1) with compound (a-4) in the presence of a base and an organolithium reagent.
The leaving group may be the one described in step 1 of method A.
Sodium hydride and the like can be used as the base.
Lithium bromide, lithium iodide, and the like can be used as the organolithium reagent.
As the solvent, DMF, DMA, etc. can be used.
The reaction temperature is from-20deg.C to room temperature, preferably from 0deg.C to room temperature.
(step 2)
The compound (f-3) can be produced in the same manner as in the step 1 of the method E.
(step 3)
Compound (I-F) can be produced by reacting compound (F-3) with compound (a-6) in the presence of a palladium catalyst, a phosphine ligand and a base.
Pd can be used as the palladium catalyst 2 (dba) 3 、PdCl 2 dppf、PdCl 2 (PPh 3 ) 2 、Pd(OAc) 2 、Pd(PPh 3 ) 4 、Pd/C、PdCl 2 、Pd-PEPPSI TM -IPr、Bis[cinnamyl palladium Cl]、PdCl 2 (Xantphos) or Pd (OH) 2 Etc.
As phosphine ligands, xantphos, P (2-furyl) can be used 3 、PPh 3 、P(o-tol) 3 、P(OPh) 3 、P(OMe) 3 、dppp、dppb、dppf、BINAP、X-Phos、P(t-Bu) 3 、P(Oi-Pr) 3 、P(p-MeOPh) 3 Or DPEPhos, etc.
Examples of the base include cesium carbonate, potassium carbonate, sodium carbonate, and potassium phosphate.
As the solvent, 1, 4-dioxane, THF, etc. can be used.
The reaction temperature is preferably from room temperature to the reflux temperature of the solvent, preferably by heating the reaction.
The compounds of the present invention have coronavirus 3CL protease inhibitory activity and are therefore useful as therapeutic and/or prophylactic agents for coronavirus infection.
Further, the compound of the present invention has usefulness as a medicament, and preferably has any one or more of the following excellent characteristics.
a) The inhibition effect on CYP enzymes (such as CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and the like) is weak.
b) Shows good pharmacokinetics with high bioavailability, moderate clearance rate and the like.
c) High metabolic stability.
d) No irreversible inhibition was exhibited by CYP enzyme (e.g., CYP3 A4) over the concentration range of the assay conditions described in the present specification.
e) Has no mutagenicity.
f) The risk of cardiovascular systems is low.
g) Exhibit high solubility.
h) High protein non-binding rate (fu value).
i) Has high selectivity of coronavirus 3CL protease.
j) Has high coronavirus proliferation inhibiting activity. For example, when Human Serum (HS) or Human Serum Albumin (HSA) is added, the coronavirus growth inhibitory activity is high.
Examples of the coronavirus proliferation inhibitor include, for example, in the CPE inhibition effect confirmation test (SARS-CoV-2) described later, for example, EC 50 An embodiment of 10. Mu.M or less, preferably 1. Mu.M or less, more preferably 100nM or less.
The salt, crystal, complex and co-crystal of the compound according to the present invention are useful as a pharmaceutical, and preferably have any one or more of the following excellent characteristics.
bb) shows good pharmacokinetic properties of high bioavailability, moderate clearance, high AUC, high maximum blood drug concentration, etc.
gg) exhibit high solubility, high chemical stability and low hygroscopicity.
The pharmaceutical compositions of the present invention may be administered by any of the methods of oral or parenteral administration. Methods of parenteral administration may be mentioned: transdermal, subcutaneous, intravenous, intraarterial, intramuscular, intraperitoneal, transmucosal, inhalation, nasal, eye drops, ear drops, vaginal administration, and the like.
For oral administration, the composition may be formulated into any of commonly used dosage forms such as solid preparations for internal use (e.g., tablets, powders, granules, capsules, pills, films, etc.), solutions for internal use (e.g., suspensions, emulsions, elixirs, syrups, lemonades, alcoholic solutions, aromatic solutions, extractants, decoction, tinctures, etc.), and the like, by a conventional method. The tablet can be sugar-coated tablet, film coated tablet, enteric coated tablet, sustained release tablet, buccal tablet, sublingual tablet, buccal tablet, chewable tablet or orally disintegrating tablet; powders and granules can be dry syrups; the capsule can be soft capsule, microcapsule or slow release capsule.
For parenteral administration, the composition may be suitably administered in any of commonly used forms such as injections, drops, external preparations (for example, eye drops, nasal drops, ear drops, aerosols, inhalants, lotions, injections, spreads, gargles, enemas, ointments, plasters, gels, creams, patches, external ointments, external powders, suppositories, etc.). The injection may be O/W, W/O, O/W/O, W/O/W type emulsion, etc.
To an effective amount of the compound of the present invention, various pharmaceutical additives such as excipients, binders, disintegrants, lubricants and the like suitable for the dosage form thereof are mixed as needed, whereby a pharmaceutical composition can be prepared. The pharmaceutical composition can be prepared into a pharmaceutical composition for children, the elderly, patients with severe symptoms or for surgery by appropriately changing the effective amount, dosage form and/or various pharmaceutical additives of the compound of the present invention. For example, a pharmaceutical composition for children may be administered to a neonate (less than 4 weeks after birth), an infant (4 weeks after birth to less than 1 year old), a child (1 to 7 years old), a child (7 to less than 15 years old), or a patient of 15 to 18 years old. For example, a pharmaceutical composition for the elderly may be administered to a patient over 65 years old.
The amount of the pharmaceutical composition of the present invention (for example, a pharmaceutical composition of the p-toluenesulfonate crystal form I comprising the compound represented by the formula (I-A) or a pharmaceutical composition of the fumaric acid co-crystal form I comprising the compound represented by the formula (I-B)) to be administered should be set in consideration of the age, weight, kind or extent of the disease, administration route and the like of the patient, but is usually in the range of 0.05 to 200 mg/kg/day, preferably 0.1 to 100 mg/kg/day, when orally administered. Parenteral administration is usually 0.005-200 mg/kg/day, preferably in the range of 0.01-100 mg/kg/day, although there are large differences depending on the route of administration. It can also be administered in 1-several times per day.
The compound of the present invention can be used in combination with, for example, other novel therapeutic agents for coronavirus infection (covd-19) including agents already in the batch and agents under development or to be developed in the future (hereinafter simply referred to as concomitant agents) for the purpose of enhancing the effect of the compound or reducing the amount of the compound to be administered, etc. In this case, the administration timing of the compound of the present invention and the concomitant drug is not limited, and these may be administered simultaneously to the administration subject or may be administered with a time difference therebetween. The compound of the present invention and the concomitant drug may be administered in the form of a preparation containing 2 or more of the respective active ingredients, or may be administered in the form of a single preparation containing all the active ingredients.
The amount of the drug to be administered is appropriately selected based on the clinically used amount. In addition, the mixing ratio of the compound of the present invention and the concomitant agent may be appropriately selected according to the administration subject, the administration route, the subject disease, symptoms, combinations, and the like. For example, when the subject to be administered is a human, the compound of the present invention may be used in an amount of 0.01 to 100 parts by weight based on 1 part by weight of the compound.
[ example ]
The present invention will be described in further detail with reference to examples, reference examples and test examples, but the present invention is not limited thereto.
In addition, abbreviations used in the present specification represent the following meanings.
Boc: boc-group
CDI: carbonyl diimidazoles
DBU:1, 8-diazabicyclo [5.4.0] undec-7-ene
DIEA: n, N-diisopropylethylamine
DMA: n, N-dimethylacetamide
DMF: n, N-dimethylformamide
DMSO: dimethyl sulfoxide
DTT: dithiothreitol
EDC: 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide
EDT:1, 2-ethanedithiol
EDTA: ethylenediamine tetraacetic acid
FBS: fetal bovine serum
HOBT: 1-hydroxybenzotriazoles
LHMDS: lithium bis (trimethylsilyl) amide
MEM: eagle minimum essential medium
NMP: n-methylpyrrolidone
Pd(OAc) 2 : palladium acetate
TFA: trifluoroacetic acid
THF: tetrahydrofuran (THF)
TMSCL: trimethylchlorosilane
Xantphos:4,5 '-bis (diphenylphosphino) -9,9' -dimethylxanthene
mM:mmol/L
μM:μmol/L
nM:nmol/L
(method for identifying Compound)
NMR analyses obtained in each example were all performed at 400MHz and DMSO-d was used 6 、CDCl 3 、MeOH-d 4 The measurement was performed. In addition, when NMR data is displayed, all peaks measured may not be described.
In the specification, RT represents a retention time in LC/MS (liquid chromatography-mass spectrometry) and is measured under the following conditions.
(measurement condition 1)
Chromatographic column: ACQUITYBEH C18(1.7μm、i.d.2.1x50mm)(Waters)
Flow rate: 0.8 mL/min
UV detection wavelength: 254nm
Mobile phase: [A] the solution was an aqueous solution containing 0.1% formic acid, and [ B ] was an acetonitrile solution containing 0.1% formic acid.
Gradient elution: after 3.5 minutes of elution with a linear gradient of 5% -100% solvent [ B ], 0.5 minutes was maintained with 100% solvent [ B ].
(measurement condition 2)
Chromatographic column: ACQUITYBEH C18(1.7μm、i.d.2.1x50mm)(Waters)
Flow rate: 0.55 mL/min
UV detection wavelength: 254nm
Mobile phase: [A] the solution was an aqueous solution containing 0.1% formic acid, and [ B ] was an acetonitrile solution containing 0.1% formic acid.
Gradient elution: after 3 minutes of elution with a linear gradient of 5% -100% solvent [ B ], 0.5 minutes was maintained with 100% solvent [ B ].
(measurement condition 3)
Chromatographic column: shim-pack XR-ODS (2.2 μm, i.d. 3.0x50mm) (Shimadzu)
Flow rate: 1.6 mL/min
UV detection wavelength: 254nm
Mobile phase: [A] the solution was an aqueous solution containing 0.1% formic acid, and [ B ] was an acetonitrile solution containing 0.1% formic acid.
Gradient elution: the elution was performed with a linear gradient of 10% -100% solvent [ B ] for 3 min and 100% solvent [ B ] was used for 0.5 min.
(measurement condition 4)
Chromatographic column: ACQUITYBEH C18(1.7μm、i.d.2.1x50mm)(Waters)
Flow rate: 0.8 mL/min
UV detection wavelength: 254nm
Mobile phase: [A] is an aqueous solution containing 10mmol/L ammonium carbonate, [ B ] is acetonitrile
Gradient elution: after 3.5 minutes of elution with a linear gradient of 5% -100% solvent [ B ], 0.5 minutes was maintained with 100% solvent [ B ].
(measurement condition 5)
Chromatographic column: shim-pack XR-ODS (2.2 μm, i.d. 3.0x50mm) (Shimadzu)
Flow rate: 1.6 mL/min
UV detection wavelength: 254nm
Mobile phase: [A] the solution was an aqueous solution containing 0.1% formic acid, and [ B ] was an acetonitrile solution containing 0.1% formic acid.
Gradient elution: the elution was performed with a linear gradient of 10% -100% solvent [ B ] for 8 min and 100% solvent [ B ] was used for 0.5 min.
In the specification, MS (m/z) means a value observed by mass analysis.
(determination of X-ray powder diffraction pattern)
The crystals obtained in each example were subjected to X-ray powder diffraction measurement according to the X-ray powder diffraction measurement method described in the Japanese pharmacopoeia general test method. The measurement conditions are as follows.
(apparatus)
SmartLab manufactured by Japanese Physics Co., ltd
(method of operation)
Assay: reflection method
The wavelength is used: cuK alpha rays
Tube current: 200mA
Tube voltage: 45kV
Sample plate: aluminum (Al)
Incidence angle of X-rays: 2.5 degree
Sampling width: 0.02 degree
A detector: hyPix-3000 (two-dimensional detection mode)
(method for measuring and analyzing single crystal Structure analysis)
The measurement conditions and analysis methods for analyzing the single crystal structure are as follows.
(apparatus)
XtaLAB P200 MM007 manufactured by Japanese Physics Co., ltd
(measurement conditions)
Measuring temperature: 25 DEG C
The wavelength is used: cuK alpha rays
Software: crysalisPro 1.171.39.46e (Rigaku Oxford Diffraction, 2018)
(data processing)
Software: crysalisPro 1.171.39.46e (Rigaku Oxford Diffraction, 2018)
The data is subjected to lorentz, polarization correction and absorption correction.
(analysis of Crystal Structure)
The phase determination was performed using the direct method program sheldxt (g.m., 2015), and the full-matrix least squares method was performed using sheldxl (g.m., 2015) for refinement. The temperature factors of the non-hydrogen atoms are all refined in an anisotropic manner. The hydrogen atom is introduced by calculation using the default parameters of ShellXL and treated as a riding atom (riding atom). All hydrogen atoms were refined with isotropic parameters.
The diagrams of FIGS. 2 and 4 use PLATON (Spek, 1991)/ORTEP (Johnson, 1976).
(measurement of Raman Spectroscopy)
The raman spectrum of the crystals obtained in each example was measured. The measurement conditions are as follows.
The measuring machine: RAMANTouch Vis2-NIR-SNU (manufactured by Nanophoton Corporation)
The measuring method comprises the following steps: laser micro-Raman spectroscopy
Laser wavelength: 671nm
Diffraction grating: 600grooves/mm
A detector: CCD detector
An objective lens: 50× (NA 0.80)
Cumulative number of times: 3-10 times
Exposure time: 1-10 seconds
(measurement of Differential Scanning Calorimeter (DSC))
The DSC of the crystals obtained in each example was measured. Samples were weighed approximately 3mg into aluminum pans and crimped for measurement. The measurement conditions are as follows. Further, measurement by Differential Scanning Calorimeter (DSC) may cause an error in the range of ±0.2 ℃.
The device comprises: TA Instrument Q1000/TA Instrument
Measuring temperature range: 0-295 DEG C
Heating rate: 10 ℃/min
Atmosphere: n (N) 2 50 mL/min
(measurement of TG/DTA data)
About 3mg of the crystals obtained in each example were weighed, charged into an aluminum pan, and measured in an open system. The measurement conditions were as follows.
(measurement condition 1)
The device comprises: hitachi High-Tech TG/DTA STA7200RV
Measuring temperature range: room temperature-400 DEG C
Heating rate: 10 ℃/min
[ example 1 ]
Synthesis of Compound (I-0001)
[ chemical 77 ]
Process 1 Synthesis of Compound 1
DMA (50 mL) was added to [ (2-methoxypyridin-3-yl) methyl ] amine (10.0 g, 72.4 mmol) under a nitrogen atmosphere and cooled with ice. CDI (12.9 g, 80.0 mmol) was slowly added to the reaction solution and stirred at room temperature for 50 minutes. The reaction solution was cooled with ice, 1-amidinopyrazole hydrochloride (10.6 g, 72.4 mmol) and DBU (11.5 mL, 76.0 mmol) were added, and stirred at room temperature for 17 hours. The reaction solution was cooled with ice, CDI (17.6 g, 109 mmol) and DBU (16.4 mL, 109 mmol) were added, and stirred at room temperature for 2 hours. The reaction solution was cooled with ice, CDI (11.7 g, 72.4 mmol) and DBU (10.9 mL, 72.4 mmol) were added, and stirred at room temperature for 2 hours.
The reaction solution was poured into 2mol/L aqueous hydrochloric acid (362 mL, 724 mmol) under ice bath and stirred at 0deg.C for 1 hour. The resulting solid was filtered off and washed with water. The obtained solid was dried under reduced pressure to obtain compound 1 (17.5 g, 58.3mmol, yield 81%).
LC/MS(ESI):m/z=301[M+H] + Rt=1.27 min, LC/MS assay condition 1
Process 2 Synthesis of Compound 2
Compound 1 (5.0 g, 16.7 mmol) was dissolved in DMA (50 mL), DIEA (3.78 mL, 21.7 mmol) and 3,4, 5-trifluorobenzyl bromide (2.33 mL, 17.5 mmol) were added, and stirred at 60℃for 3 hours. The reaction solution was cooled to room temperature and ice water (200 mL) was added. The precipitate formed was filtered off and dissolved in ethyl acetate. The resulting solution was dried over sodium sulfate and filtered. The solvent was distilled off under reduced pressure, and the residue was washed with a diisopropyl ether/hexane mixed solution to give compound 2 (5.46 g, 12.3mmol, yield 74%). The filtrate of the diisopropyl ether/hexane mixed solution was concentrated, and the obtained residue was washed with the diisopropyl ether/hexane mixed solution to obtain compound 2 (1.19 g, 2.68mmol, yield 22%).
LC/MS(ESI):m/z=445[M+H] + Rt=2.27 min, LC/MS assay condition 1
Process 3 Synthesis of Compound 3
2-chloro-4-fluoroaniline (16.0. Mu.L, 0.135 mmol) and Compound 2 were dissolved in NMP (0.5 mL) under a nitrogen atmosphere. Methanesulfonic acid (7.31. Mu.L, 0.113 mmol) was added to the reaction solution and stirred at 80℃for 1 hour and 35 minutes. Ethyl acetate (5 mL) and water (5 mL) were added to the reaction solution, extracted with ethyl acetate, and the organic layer was washed with water and saturated brine, dried over sodium sulfate, and filtered. The solvent was distilled off under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate=2:1), and the solvent was distilled off under reduced pressure to obtain compound 3 (33.6 mg, 0.064mmol, yield 57.2%).
LC/MS(ESI):m/z=522[M+H] + Rt=2.51 min, LC/MS assay condition 3
Process 4 Synthesis of Compound (I-0001)
Compound 3 (32.7 mg, 0.063 mmol) and sodium iodide (18.8 mg, 0.125 mmol) were dissolved in acetonitrile (0.7 mL) at room temperature under nitrogen atmosphere. TMSCl (0.016 mL, 0.125 mmol) was added to the reaction solution and stirred at 65℃for 50 min. Ethyl acetate (5 mL) and a 10% aqueous solution of sodium thiosulfate (5 mL) were added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with water and saturated brine, dried over sodium sulfate, and filtered. The solvent was distilled off under reduced pressure, and the obtained solid was washed with a hexane/ethyl acetate mixed solution (hexane: ethyl acetate=5:1) to obtain compound (I-0001) (28.8 mg, 0.057mmol, yield 91%).
1 H-NMR(CDCl 3 )δ:4.63(s,2H),5.13(s,2H),6.15(t,1H,J=6.7Hz),6.96(brs,1H),7.13(brs,1H),7.30(d,1H,J=6.0Hz),7.31-7.40(m,2H),7.40-7.47(m,2H),11.01(brs,1H),11.69(s,1H)
LC/MS(ESI):m/z=507[M+H] + Rt=2.05 min, LC/MS assay condition 3
[ example 2 ]
Synthesis of Compound (I-0135)
[ chemical formula 78 ]
Process 1 Synthesis of Compound 5
Compound 4 (20.0 g, 87.0 mmol) (synthesis see WO 2012020749, WO 2013089212 and WO 2014200078), acetonitrile (160 mL), potassium carbonate (15.7 g, 113 mmol) and 3,4, 5-trifluorobenzyl bromide (21.6 g, 96.0 mmol) were mixed under nitrogen atmosphere and the resulting solution was stirred at 80 ℃ for 1 hour 25 minutes. After cooling to room temperature, it was diluted with ethyl acetate (50 mL). After the precipitate produced was filtered off, it was washed with ethyl acetate. The solution was concentrated, a mixed solution (30 mL) of ethyl acetate: hexane=1:10 was added, and the resultant precipitate was collected by filtration and washed with a mixed solution of ethyl acetate: hexane=1:10. The obtained residue was dried under reduced pressure to obtain compound 5 (31.0 g, 83.0mmol, yield 95%).
LC/MS (ESI): m/z=374, rt=2.65 min, LC/MS measurement condition 1
Process 2 Synthesis of Compound 6
Trifluoroacetic acid (45.0 mL) was added to compound 5 (15.0 g,40.2 mmol) under nitrogen atmosphere and stirred at room temperature for 2 hours and 20 minutes. The reaction solution was concentrated and azeotroped with toluene (20 mL) to remove trifluoroacetic acid. Diisopropyl ether (15 mL) was added to the residue, and the resulting precipitate was collected by filtration and washed with diisopropyl ether. The obtained residue was dried under reduced pressure to obtain compound 6 (12.2 g, 38.5mmol, yield 96%).
LC/MS (ESI): m/z=318, rt=1.88 min, LC/MS assay condition 1
Process 3 Synthesis of Compound 7
Compound 6 (515 mg, 1.62 mmol), p-anisole (300 mg, 2.44 mmol), t-butanol (5.2 mL) and acetic acid (1.39 mL, 24.4 mmol) were mixed and the resulting solution was stirred at 100 ℃ for 2 hours 15 minutes. The reaction solution was cooled in an ice bath, and the resulting precipitate was collected by filtration and washed with t-butanol. The obtained residue was dried under reduced pressure to obtain compound 7 (473 mg, 1.25mmol, yield 77%). The filtrate was concentrated, and the obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate=8:2-4:6), and the solvent was distilled off under reduced pressure to give compound 7 (129 mg, 0.341mmol, yield 21%).
LC/MS (ESI): m/z=379, rt=1.85 min, LC/MS assay condition 1
Process 4 Synthesis of Compound (I-0135)
Compound 7 (10.0 mg, 0.026 mmol), 3-bromopyridine (5.01 mg, 0.032 mmol), copper iodide (1.51 mg, 7.93 μmol), trans-N, N' -dimethylcyclohexane-1, 2-diamine (rac, 2.26mg, 0.016 mmol) and DMA (400 μl) were mixed under a nitrogen atmosphere, and the resulting solution was stirred at 100 ℃ for 17 hours. Saturated aqueous ammonium chloride (10 mL) was added to the reaction solution, and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate and filtered. The filtrate was concentrated to give compound (I-0135) (8.0 mg, 0.018mmol, yield 67%).
1 H-NMR(DMSO-d6)δ:3.75(s,3H),5.25(s,2H),6.88-7.00(m,2H),7.19-7.32(m,2H),7.42-7.54(m,2H),7.80(d,J=6.1Hz,1H),8.48-8.69(m,2H),9.31(s,1H)
LC/MS (ESI): m/z=456, rt=1.85 min, LC/MS assay condition 1
[ example 3 ]
Synthesis of Compound (I-0335)
[ chemical 79 ]
Process 1 Synthesis of Compound 8
Compound 6 (100 mg, 0.315 mmol), potassium carbonate (56.6 mg, 0.410 mmol), 3- (chloromethyl) -1-methyl-1H-1, 2, 4-triazole (45.6 mg, 0.347 mmol)) and DMF (1.0 mL) were mixed, and the resulting solution was stirred at 60 ℃ for 2 hours. Saturated aqueous ammonium chloride (5 mL) was added to the reaction solution, and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate and filtered. The filtrate was concentrated to give compound 8 (109 mg, 0.264mmol, yield 84%). The obtained compound 8 was used in the next step without purification.
LC/MS (ESI): m/z=413, rt=1.82 min, LC/MS assay condition 1
Process 2 Synthesis of Compound (I-0335)
The procedure of example 2 was followed in the same manner as in step 3 to give compound (I-0335) (26.5 mg, 0.056mmol, yield 46%).
1 H-NMR(DMSO-d6)δ:3.75(s,3H),3.79(s,3H),4.94(s,2H),5.27(s,2H),6.93(d,J=7.8Hz,2H),7.22(d,7.8Hz,2H),7.33(dd,J=6.5,9.0Hz,2H),8.35(s,1H),9.28(s,1H)
LC/MS (ESI): m/z= 474.15, rt=1.78 min, LC/MS assay condition 1
[ example 4 ]
Synthesis of Compound (I-0329)
[ 80 ] the preparation method
Process 1 Synthesis of Compound 9
[ (2-methoxypyridin-3-yl) methyl ] amine (200 mg, 1.45 mmol) and DMA (2.0 mL) were mixed, and the resulting solution was cooled to 0 ℃. CDI (258 mg, 1.60 mmol) was added to the solution and stirred at room temperature for 10 min. Benzamidine hydrochloride (227 mg, 1.45 mmol) and DBU (240. Mu.L, 1.59 mmol) were added to the reaction solution at room temperature and stirred for 30 minutes. CDI (352 mg, 2.17 mmol) and DBU (327. Mu.L, 2.17 mmol) were added, stirred at room temperature for 10 minutes, and left to stand for 3 days. Ice water was added to the reaction solution, the pH was adjusted to 3-4 with 2mol/L aqueous hydrochloric acid, and the resulting precipitate was collected by filtration, washed with water and diisopropyl ether. The residue was dried under reduced pressure at 40℃to give Compound 9 (324 mg, 1.04mmol, yield 72%).
LC/MS (ESI): m/z=311, rt=1.41 min, LC/MS measurement condition 1
Process 2 Synthesis of Compound 10
The procedure of example 1 was repeated in the same manner as in step 2 to obtain a crude product of Compound 10.
LC/MS (ESI): m/z=455, rt=2.32 min, LC/MS measurement condition 1
The obtained compound 10 was used in the next step without purification.
Process 3 Synthesis of Compound (I-0329)
In the same manner as in step 4 of example 1, compound (I-0329) was obtained.
1 H-NMR(DMSO-d6)δ:4.76(s,2H),4.87(s,2H),6.16(t,J=6.4Hz,1H),7.25(dd,J=6.8,9.2Hz,2H),7.31-7.35(m,2H),7.44-7.56(m,5H),11.71,(brs,1H).
LC/MS (ESI): m/z=441, rt=1.89 min, LC/MS assay condition 1
[ example 5 ]
Synthesis of Compound (I-0326)
[ chemical formula 81 ]
Process 1 Synthesis of Compound 11
6-chlorouracil (600 mg, 4.09 mmol) was dissolved in DMF (6000. Mu.L) and cooled to 0deg.C. Sodium hydride (197 mg, 4.91 mmol) was added and stirred at 0deg.C for 5 min. Lithium bromide (356 mg, 4.09 mmol) was added and stirred at 0deg.C for 30 min. Further, 5- (bromomethyl) -1,2, 3-trifluorobenzene (1013 mg, 4.50 mmol) was added thereto, and the mixture was stirred at room temperature overnight. Saturated aqueous ammonium chloride and water were added to the obtained reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with water and saturated brine, dried over sodium sulfate, and filtered. The filtrate was concentrated, and the residue was suspended in a mixed solution of ethyl acetate/diisopropyl ether and filtered. The residue was washed with a mixed solution of ethyl acetate/diisopropyl ether to give compound 11 (202 mg, 0.695mmol, yield 17%).
LC/MS (ESI): m/z=296, rt=1.76 min, LC/MS assay condition 1
Process 2 Synthesis of Compound 12
Compound 11 (100 mg, 0.344 mmol), 3- (chloromethyl) -2-methoxypyridine (65.1 mg, 0.413 mmol), potassium carbonate (71.3 mg, 0.516 mmol) and sodium iodide (77 mg, 0.516 mg) were mixed in DMF (1000. Mu.L). The resulting reaction solution was stirred at 60℃for 4 hours and extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over sodium sulfate, and filtered. The filtrate was concentrated, and the residue was purified by column chromatography (hexane/ethyl acetate) to give compound 12 (119.4 mg, 0.29mmol, yield 84%).
LC/MS (ESI): m/z=412, rt=2.33 min, LC/MS assay condition 1
Process 3 Synthesis of Compound 13
Compound 12 (94 mg, 0.228 mmol), p-anisole (30.9 mg, 0.251 mmol), pd (OAc) 2 (5.13 mg, 0.023 mmol), xantphos (19.81 mg, 0.034 mmol) and cesium carbonate (112 mg, 0.342 mmol) were mixed in 1, 4-dioxane (1880. Mu.L). The resulting reaction solution was stirred at 120℃for 4 hours and extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over sodium sulfate, and filtered. The filtrate was concentrated, and the resulting residue was pulverized with ethyl acetate and filtered. The residue was washed with diisopropyl ether and hexane to give compound 13 (62.1 mg, 0.125mmol, yield 55%).
LC/MS (ESI): m/z=499, rt=2.27 min, LC/MS assay condition 1
Process 4 Synthesis of Compound (I-0326)
In the same manner as in step 4 of example 1, compound (I-0326) was obtained.
1 H-NMR(DMSO-d6)δ:3.77(s,3H),4.49(s,1H),4.68(s,2H),5.26(s,2H),6.05-6.11(m,1H),6.87-6.89(m,1H),6.97-7.02(m,2H),7.12-7.18(m,2H),7.22-7.31(m,3H),8.51(s,1H),11.6(brs,1H)
LC/MS (ESI): m/z=485, rt=1.83 min, LC/MS assay condition 1
[ example 6 ]
Synthesis of Compound (I-0113)
[ chemical formula 82 ]
Process 1 Synthesis of Compound 14
3,4, 5-Trifluorobenzylamine (3.34 g, 20.7 mmol) was dissolved in dichloromethane (33.4 mL) and cooled in a water bath. Benzoyl isothiocyanate (2.93 mL, 21.8 mmol) was added to the reaction solution and stirred at room temperature for 30 minutes.
The solvent was removed by distillation, the residue was diluted with methanol, and 1mol/L aqueous sodium hydroxide solution (7.45 mL, 7.45 mmol) was added. The reaction solution was stirred at room temperature for 30 minutes, and 2mol/L aqueous hydrochloric acid was added. The aqueous layer was extracted with ethyl acetate, and the organic layer was washed with saturated aqueous sodium bicarbonate and saturated brine. The organic layer was dried over sodium sulfate, and the solvent was distilled off under reduced pressure to give a crude product (8.3 g) of compound 14. The crude product was used in the next step as 100% yield without further purification.
LC/MS (ESI): m/z=221, rt=1.45 min, LC/MS assay condition 3
Process 2 Synthesis of Compound 15
The crude product of compound 14 (8.3 g), DMF (85 mL) and methyl iodide (4.84 mL, 77 mmol) were mixed and the reaction solution stirred at 50℃for 40 min. Water was added to the reaction solution, extracted with ethyl acetate, and washed with water. 2mol/L aqueous sodium hydroxide solution was added to the aqueous layer, and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, and dried over sodium sulfate. The solvent was distilled off under reduced pressure to give a crude product (3.86 g, 16.5mmol, yield 80%) of compound 15.
LC/MS (ESI): m/z=235, rt=0.84 min, LC/MS assay condition 3
Process 3 Synthesis of Compound 16
Triphosgene (0.507 g, 1.71 mmol) and THF (6 mL) were mixed and the reaction solution was cooled in an ice bath. 3-amino-5-methylpyridine (0.462 g, 4.27 mmol) and triethylamine (1.48 mL, 10.7 mmol) were mixed in THF (6 mL), and the resulting solution was added dropwise to the reaction solution. After stirring the reaction solution at room temperature for 40 minutes, it was cooled in an ice bath. Compound 15 (1 g, 4.27 mmol) was added to the reaction solution and stirred at room temperature for 55 minutes. Water was added, the aqueous layer was extracted with ethyl acetate, and the organic layer was washed with water. The organic layer was dried over magnesium sulfate, and the solvent was distilled off under reduced pressure to give a crude product (1.57 g, 4.26mmol, yield: quantitative) of compound 16.
LC/MS (ESI): m/z=369, rt=1.52 min, LC/MS assay condition 1
Process 4 Synthesis of Compound 17
CDI (2.78 g, 17.2 mmol), compound 16 (1.58 g, 4.29 mmol) and DMF (12.6 mL) were mixed. Diisopropylethylamine (3.00 mL, 17.2 mmol) was added to the reaction solution, and the mixture was irradiated with microwaves for 30 minutes while stirring at 110 ℃. The reaction solution was poured into ice, and the resulting precipitate was filtered off and washed with water. The obtained residue was dried under reduced pressure to obtain a crude product (649 mg, 1.51mmol, yield 35%) of compound 17.
LC/MS (ESI): m/z=395, rt=1.74 min, LC/MS assay condition 1
Process 5 Synthesis of Compound (I-0113)
6-chloro-2-methyl-2H-indazole-5-ammonia (55.3 mg, 0.304 mmol), compound 17 (100 mg, 0.254 mmol) and THF (1 mL) were mixed. The reaction solution was cooled in an ice bath and LHMDS (0.761 mL, 0.761 mmol) was added. The reaction solution was stirred in an ice bath for 40 minutes, and a saturated aqueous ammonium chloride solution was added. The organic layer was extracted with ethyl acetate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol) to give compound (I-0113) (80 mg, 0.145mmol, yield 57.4%).
1 H-NMR(Methanol-d4)δ:8.43(d,J=1.0Hz,1H),8.36(d,J=2.0Hz,1H),8.18(s,1H),7.74(s,1H),7.72(br s,1H),7.48-7.35(m,3H),5.32(s,2H),4.20(s,3H),2.42(s,3H).
LC/MS (ESI): m/z=528, rt=1.93 min, LC/MS assay condition 1
[ example 7 ]
Synthesis of Compound (I-0115)
[ chemical formula 83 ]
Process 1 Synthesis of Compound 18
Compound 4 (926 mg, 4.04 mmol), acetonitrile (7.41 mL), potassium carbonate (726 mg, 5.25 mmol) and 2,4, 5-trifluorobenzyl bromide (1000 mg, 4.44 mmol) were mixed. The reaction solution was stirred at 80 ℃ for 40 minutes, cooled, and then diluted with ethyl acetate. After insoluble matter was filtered off, the filtrate was concentrated to give a crude product (1.51 g, 4.04mmol, yield: quantitative) of compound 18.
LC/MS (ESI): m/z=374, rt=2.54 min, LC/MS assay condition 1
Process 2 Synthesis of Compound 19
Compound 18 (1.51 g, 4.04 mmol) and TFA (3.02 mL) were mixed. The reaction solution was stirred at room temperature for 4 hours and allowed to stand overnight. TFA was removed by distillation under the reduced pressure, and toluene was added to the residue to azeotrope. Isopropyl ether was added to the residue to suspend it, and then filtered to give compound 19 (1.22 g, 3.84mmol, yield 95%).
LC/MS (ESI): m/z=318, rt=1.68 min, LC/MS assay condition 1
Process 3 Synthesis of Compound 20
Compound 19 (200 mg, 0.63 mmol), DMF (1.8 mL), potassium carbonate (261 mg, 1.89 mmol) and 3- (chloromethyl) -1-methyl-1H-1, 2, 4-triazole hydrochloride (159 mg, 0.946 mmol) were mixed. The reaction solution was stirred at 60℃for 2 hours, and a saturated aqueous ammonium chloride solution was added. The aqueous layer was extracted with ethyl acetate, and the organic layer was washed with saturated brine. The organic layer was dried over magnesium sulfate, filtered and concentrated. The residue was suspended in a mixed solvent of isopropyl ether, hexane, ethyl acetate and chloroform and filtered. The residue was mixed with DMF (1.8 mL), potassium carbonate (261 mg, 1.89 mmol) and 3- (chloromethyl) -1-methyl-1H-1, 2, 4-triazole hydrochloride (159 mg, 0.946 mmol). The reaction solution was stirred at 60℃for 6 hours, and a saturated aqueous ammonium chloride solution was added. The aqueous layer was extracted with ethyl acetate, and the organic layer was washed with saturated brine. The organic layer was dried over magnesium sulfate, filtered and concentrated. The residue was suspended in a mixed solvent of isopropyl ether, hexane, ethyl acetate and chloroform and collected by filtration to give compound 20 (116 mg, 0.281mmol, yield 45%).
LC/MS (ESI): m/z=413, rt=1.84 min, LC/MS measurement conditions: 1
Process 4 Synthesis of Compound (I-0115)
Compound 20 (115 mg, 0.279 mmol), THF (2.30 mL) and 6-chloro-2-methyl-2H-indazole-5-ammonia (60.8 mg, 0.335 mmol) were mixed. LHMDS (558. Mu.L, 0.558 mmol) was added dropwise to the reaction solution at 0 ℃. The reaction solution was stirred at 0 ℃ for 2.5 hours and at room temperature for 40 minutes, and a saturated aqueous ammonium chloride solution was added. The organic layer was extracted with chloroform and concentrated. The residue was purified by silica gel column chromatography (chloroform/methanol) to give compound (I-0115) (61.8 mg, 0.116mmol, yield 42%).
1 H-NMR(CDCl 3 )δ:7.96(s,1H),7.82(d,J=2.5Hz,2H),7.48(br s,1H),7.45-7.37(m,1H),7.08(s,1H),6.97-6.88(m,1H),5.35(s,2H),5.17(s,2H),4.21(s,3H),3.89(s,3H).
LC/MS (ESI): m/z=532, rt=1.70 min, LC/MS assay condition 1
The following compounds were synthesized according to the methods described in the general synthesis methods and examples. The structure and physical properties (LC/MS and NMR data) are shown in the following table.
Amino structures in the table:
[ chemical formula 84 ]
The compound of formula (I) wherein Y N, X is NH may also have an imino structure:
[ chemical formula 85 ]
And the compound shown in the imino structure may also have an amino structure.
That is, even the same compound may have an imino structure and an amino structure depending on crystallization conditions and the like; even in the case of forming a salt or a complex, there are cases where the salt or the complex has an imino structure and an amino structure depending on the kind of a counter molecule; even with the same counter molecule, there are cases where the molecule has an imino structure and an amino structure depending on the crystal conditions and the like. Further, a mixture of a compound having an imino structure, a salt thereof, or a complex thereof and a compound having an amino structure, a salt thereof, or a complex thereof may be used.
Also, in the structural formulae, "wedge" and "broken line" indicate a stereoscopic configuration. In particular, among the compounds describing the steric configuration, the compound described as "a" in the "steric" item means that the steric property is determined as shown in the chemical structure.
Further, among the compounds described in solid lines as bonds forming asymmetric carbons, the compound described as "b" in the "steric" item is a racemic compound.
[ Table 1 ]
[ Table 2 ]
[ Table 3 ]
[ Table 4 ]
[ Table 5 ]
[ Table 6 ]
[ Table 7 ]
[ Table 8 ]
[ Table 9 ]
[ Table 10 ]
[ Table 11 ]
[ Table 12 ]
[ Table 13 ]
[ Table 14 ]
[ Table 15 ]
[ Table 16 ]
[ Table 17 ]
[ Table 18 ]
[ Table 19 ]
[ Table 20 ]
[ Table 21 ]
[ Table 22 ]
[ Table 23 ]
[ Table 24 ]
[ Table 25 ]
[ Table 26 ]
[ Table 27 ]
[ Table 28 ]
[ Table 29 ]
[ Table 30 ]
[ Table 31 ]
[ Table 32 ]
[ Table 33 ]
[ Table 34 ]
[ Table 35 ]
[ Table 36 ]
[ Table 37 ]
[ Table 38 ]
[ Table 39 ]
[ Table 40 ]
[ Table 41 ]
[ Table 42 ]
[ Table 43 ]
[ Table 44 ]
[ Table 45 ]
[ Table 46 ]
[ Table 47 ]
[ Table 48 ]
[ Table 49 ]
[ Table 50 ]
[ Table 51 ]
[ Table 52 ]
[ Table 53 ]
[ Table 54 ]
[ Table 55 ]
[ Table 56 ]
[ Table 57 ]
[ Table 58 ]
[ Table 59 ]
[ Table 60 ]
[ Table 61 ]
[ Table 62 ]
[ Table 63 ]
[ Table 64 ]
[ Table 65 ]
[ Table 66 ]
[ Table 67 ]
[ Table 68 ]
[ Table 69 ]
[ Table 70 ]
[ Table 71 ]
[ Table 72 ]
[ Table 73 ]
[ Table 74 ]
[ Table 75 ]
[ Table 76 ]
[ Table 77 ]
[ Table 78 ]
[ Table 79 ]
[ Table 80 ]
[ Table 81 ]
[ Table 82 ]
[ Table 83 ]
[ Table 84 ]
[ Table 85 ]
[ Table 86 ]
[ Table 87 ]
[ Table 88 ]
[ Table 89 ]
[ Table 90 ]
[ Table 91 ]
[ Table 92 ]
[ Table 93 ]
[ Table 94 ]
[ Table 95 ]
[ Table 96 ]
[ Table 97 ]
[ Table 98 ]
[ Table 99 ]
[ Table 100 ]
[ Table 101 ]
[ Table 102 ]
[ Table 103 ]
[ Table 104 ]
[ Table 105 ]
[ Table 106 ]
[ Table 107 ]
[ Table 108 ]
[ Table 109 ]
[ Table 110 ]
[ Table 111 ]
[ Table 112 ]
[ Table 113 ]
[ Table 114 ]
[ Table 115 ]
[ Table 116 ]
[ Table 117 ]
[ Table 118 ]
[ Table 119 ]
[ Table 120 ]
[ Table 121 ]
[ Table 122 ]
[ Table 123 ]
[ Table 124 ]
[ Table 125 ]
[ Table 126 ]
[ Table 127 ]
[ Table 128 ]
[ Table 129 ]
[ Table 130 ]
[ Table 131 ]
[ Table 132 ]
[ Table 133 ]
[ Table 134 ]
[ Table 135 ]
[ Table 136 ]
[ Table 137 ]
[ Table 138 ]
[ Table 139 ]
[ Table 140 ]
[ Table 141 ]
[ Table 142 ]
[ Table 143 ]
[ Table 144 ]
[ Table 145 ]
[ Table 146 ]
[ Table 147 ]
[ Table 148 ]
[ Table 149 ]
[ Table 150 ]
[ Table 151 ]
[ Table 152 ]
[ Table 153 ]
[ Table 154 ]
[ Table 155 ]
[ Table 156 ]
[ Table 157 ]
[ Table 158 ]
[ Table 159 ]
[ Table 160 ]
[ Table 161 ]
[ Table 162 ]
[ Table 163 ]
[ Table 164 ]
[ Table 165 ]
[ Table 166 ]
[ Table 167 ]
[ Table 168 ]
[ Table 169 ]
[ Table 170 ]
[ Table 171 ]
[ Table 172 ]
[ Table 173 ]
[ Table 174 ]
[ Table 175 ]
[ Table 176 ]
[ Table 177 ]
[ Table 178 ]
[ Table 179 ]
[ Table 180 ]
[ Table 181 ]
[ Table 182 ]
[ Table 183 ]
[ Table 184 ]
[ Table 185 ]
[ Table 186 ]
[ example 8 ]
7mL of ethyl acetate and 557. Mu.L (1.05 eq) of 5mol/L aqueous p-toluenesulfonic acid were added to 1400mg of compound (I-0113). After stirring at 60℃for 15 minutes, stirring was carried out at 25℃for 2 hours. The solid was collected by filtration and dried to obtain p-toluenesulfonate crystal form I (1289.6 mg, 69%) of the compound represented by formula (I-A).
The results of single crystal structure analysis of the p-toluenesulfonate crystal form I of the compound of formula (I-A) are shown below.
R1 (I > 2.00s (I)) was 0.0444, and it was confirmed by the final difference Fourier that there were no defects or dislocation in electron density.
The crystallographic data are shown in table 187.
[ Table 187 ]
Here, volume means a unit cell Volume, and Z means the number of molecules in the unit cell.
In addition, atoms other than hydrogen atoms are listed in tables 188-189. Here, U (eq) means an equivalent isotropic temperature factor.
[ Table 188 ]
Atoms | X | y | Z | U(eq) |
S1 | 5557.0(7) | 5570.9(7) | 3382.5(3) | 58.54(18) |
CI1 | 9613.3(8) | 973.2(6) | 9196.1(4) | 65.77(19) |
O0AA | 9535.3(19) | 4701.0(16) | 6926.8(8) | 53.6(4) |
O2 | 6849(2) | 439.0(17) | 5545.6(8) | 60.9(4) |
N6 | 8276(2) | 2541.7(17) | 6223.6(9) | 40.7(4) |
N5 | 7041.4(19) | 1025.1(16) | 6857.9(9) | 39.7(4) |
F2 | -141.7(19) | -251.9(19) | 7226.8(11) | 92.1(6) |
N2 | 8829(2) | 5271.5(19) | 11119.0(9) | 48.5(4) |
N3 | 7195(2) | 1663.4(19) | 8176.4(9) | 48.2(4) |
N4 | 8541(2) | 3184.9(17) | 7562.2(9) | 42.4(4) |
F3 | 887(2) | 430(2) | 5999.5(12) | 97.1(6) |
N1 | 7812(2) | 6077.8(19) | 11018(1) | 50.4(4) |
O4 | 4537(2) | 6507(2) | 3385.2(11) | 77.0(5) |
N7 | 7564(2) | 3712.1(19) | 4481.8(10) | 51.8(5) |
F1 | 1789(2) | -1005(2) | 8247.6(11) | 106.2(7) |
O3 | 5276(3) | 4797(2) | 3958.3(11) | 84.0(6) |
O5 | 7190(2) | 6153(3) | 3452.2(12) | 88.9(7) |
C9 | 7583(2) | 1982(2) | 7574.6(11) | 40.1(4) |
C11 | 7341(2) | 1270(2) | 6163.6(11) | 42.9(5) |
C7 | 7658(2) | 2633(2) | 8912.6(11) | 43.2(5) |
C10 | 8834(2) | 3579(2) | 6910.2(11) | 40.9(4) |
C13 | 4424(2) | -281(2) | 6933.5(11) | 41.9(4) |
C4 | 8567(2) | 4339(2) | 10420.3(11) | 42.0(4) |
C3 | 7411(2) | 4585(2) | 9881.8(11) | 43.7(5) |
C19 | 8494(2) | 2887(2) | 5509.3(11) | 41.9(4) |
C12 | 6089(2) | -316(2) | 6838.6(12) | 43.8(5) |
C6 | 8796(3) | 2385(2) | 9477.2(12) | 45.7(5) |
C8 | 6978(3) | 3725(2) | 9112.3(12) | 46.5(5) |
C23 | 9844(3) | 2769(2) | 5216.8(11) | 45.0(5) |
C21 | 8868(3) | 3604(2) | 4179.9(12) | 50.6(5) |
C22 | 10048(3) | 3130(2) | 4531.1(12) | 48.5(5) |
C5 | 9266(3) | 3215(2) | 10214.4(11) | 46.2(5) |
C20 | 7340(3) | 3359(2) | 5136.1(12) | 48.6(5) |
C25 | 5003(3) | 4321(2) | 2476.2(13) | 50.7(5) |
C2 | 6957(3) | 5725(2) | 10300.8(13) | 51.0(5) |
C18 | 3415(3) | 91(2) | 6402.6(14) | 54.5(6) |
[ Table 189 ]
Atoms | X | y | Z | U(eq) |
C14 | 3868(3) | -662(2) | 7553.5(13) | 53.7(5) |
C16 | 1347(3) | -281(3) | 7124.4(16) | 60.7(6) |
C17 | 1900(3) | 94(2) | 6512.6(16) | 61.2(6) |
C30 | 6119(3) | 3983(3) | 2035.5(14) | 55.9(6) |
C26 | 3439(3) | 3640(3) | 2211.0(15) | 61.5(6) |
C15 | 2335(3) | -663(3) | 7636.1(15) | 62.9(6) |
C29 | 5673(3) | 3002(3) | 1334.5(15) | 61.3(6) |
C28 | 4124(3) | 2306(3) | 1062.3(15) | 60.2(6) |
C1 | 7696(3) | 7183(3) | 11670.0(15) | 66.2(7) |
C27 | 3021(3) | 2642(3) | 1519.6(17) | 66.8(7) |
C24 | 11523(3) | 3005(3) | 4204.0(16) | 68.8(7) |
C31 | 3666(4) | 1199(3) | 313.7(19) | 86.6(9) |
Next, the atomic coordinates of the hydrogen atom are shown in Table 190. Here, U (iso) means an isotropic temperature factor. The numbers of hydrogen atoms in table 190 are added in association with the numbers of bonded non-hydrogen atoms.
[ Table 190 ]
Atoms | X | y | Z | U(iso) |
H4 | 8997.31 | 3740.96 | 8003.33 | 51 |
H7 | 6846.9 | 4018.17 | 4247.85 | 62 |
H12A | 6580 | -646.73 | 7249.93 | 53 |
H12B | 6080.56 | -961.06 | 6347.82 | 53 |
H8 | 6243.08 | 3903.21 | 8750.78 | 56 |
H23 | 10622.43 | 2448.15 | 5474.97 | 54 |
H21 | 8972.67 | 3855.23 | 3723.18 | 61 |
H5 | 10022.27 | 3041.45 | 10567.4 | 55 |
H20 | 6421.35 | 3433.73 | 5331.94 | 58 |
H2 | 6205.25 | 6159.69 | 10118.28 | 61 |
H18 | 3760.99 | 335.18 | 5978 | 65 |
H14 | 4530.93 | -915.45 | 7912.92 | 64 |
H30 | 7172.24 | 4418.9 | 2212.04 | 67 |
H26 | 2676.66 | 3860.81 | 2502.17 | 74 |
H29 | 6431.77 | 2800.81 | 1036.17 | 74 |
H1A | 7407.56 | 6810.87 | 12085.34 | 99 |
H1B | 6911.8 | 7647.04 | 11507.76 | 99 |
H1C | 8694.25 | 7819.65 | 11846.48 | 99 |
H27 | 1975.25 | 2179.81 | 1353.37 | 80 |
H24A | 12424.61 | 3497.89 | 4594.3 | 103 |
H24B | 11517.08 | 3380.23 | 3764.48 | 103 |
H24C | 11568.94 | 2056.87 | 4044.69 | 103 |
H31A | 4413.51 | 1353.07 | -17.7 | 130 |
H31B | 2638.62 | 1210.23 | 61.36 | 130 |
H31C | 3652.49 | 325.83 | 417.97 | 130 |
Further, the interatomic bond length (units: angstrom) is shown in Table 191.
[ Table 191 ]
Regarding the p-toluenesulfonate crystal form I of the compound of formula (I-A), in the asymmetric unit, the compound of formula (I-A) has 1 molecule. The structure in the asymmetric unit of the compound represented by formula (I-A) is shown in FIG. 2.
The non-hydrogen atom numbers in tables 188 to 189 and 191 correspond to the numbers described in fig. 2, respectively.
As noted in Table 191, the bond lengths of N3-C9 are shown to be aboutThe bond length of N4-C9 is shown to be about +.>
Due to the bond length of N3-C9 (about) Longer than the bond of N4-C9 (about +.>) Short, the compound of formula (I-A) in the p-toluenesulfonate crystal form I was thus identified as an imino structure:
[ formation 86 ]
In addition, X-ray powder diffraction results of the p-toluenesulfonate crystal form I of the compound of formula (I-A) are also shown.
In the X-ray powder diffraction pattern, at diffraction angle (2θ): peaks were observed at 9.1±0.2°, 11.5±0.2°, 14.6±0.2°, 15.2±0.2°, 18.8±0.2°, 20.2±0.2°, 23.6±0.2°, 24.2±0.2°, 24.9±0.2° and 26.9±0.2°.
In the above-mentioned X-ray powder diffraction peak, at the diffraction angle (2θ): peaks at 9.1.+ -. 0.2 °, 15.2.+ -. 0.2 °, 18.8.+ -. 0.2 °, 23.6.+ -. 0.2 ° and 24.9.+ -. 0.2 ° are particularly characteristic as the p-toluenesulfonate crystal form I of the compound represented by formula (I-A).
[ example 9 ]
278mg (1.1 eq) of fumaric acid and 5.85mL of ethyl acetate were added to 1170mg of compound (I-0115) and stirred at room temperature for 45 minutes. The solid was collected by filtration and dried to give fumaric acid co-crystal form I crystals (1369.4 mg, 94.6%) of the compound represented by the formula (I-B).
The results of single crystal structure analysis of fumaric acid co-crystal form I of the compound represented by the formula (I-B) are shown below.
R1 (I > 2.00s (I)) was 0.0470, and it was confirmed by the final difference Fourier that there were no defects or dislocation in electron density.
The crystallographic data are shown in table 192.
[ Table 192 ]
Here, volume means a unit cell Volume, and Z means the number of molecules in the unit cell.
In addition, atoms other than hydrogen atoms are noted in tables 193-194. Here, U (eq) means an equivalent isotropic temperature factor.
[ Table 193 ]
Atoms | X | y | Z | U(eq) |
Cl36 | 8115.3(9) | 8341.6(8) | 5010.7(5) | 79.9(3) |
F32 | 8958.5(19) | 7981.3(17) | 307.5(9) | 78.5(5) |
O35 | 7267(2) | 5961.4(16) | 1399.9(10) | 56.3(5) |
O34 | 5322(3) | 4254.8(16) | 4098.2(11) | 63.3(5) |
O38 | 3536(2) | 9367.5(19) | 8936.3(12) | 64.2(5) |
N12 | 6506(2) | 7056.8(18) | 2611.0(12) | 44.2(5) |
F33 | 13870(2) | 7642(2) | 1402.1(13) | 100.3(7) |
N16 | 5475(2) | 6174.4(18) | 3988.1(12) | 48.2(5) |
N14 | 6120(3) | 5115.3(18) | 2713.0(12) | 47.3(5) |
N9 | 2815(3) | 8924(2) | 7397.8(13) | 55.4(6) |
N10 | 5772(3) | 8146(2) | 3856.1(13) | 55.1(6) |
N1 | 1276(3) | 8864(2) | 7324.6(14) | 60.2(6) |
F31 | 12197(3) | 7751(3) | 3084.6(13) | 124.9(9) |
N23 | 3644(3) | 4434(2) | 1818.7(15) | 64.5(6) |
N20 | 3122(3) | 4249(2) | 1061.4(15) | 64.9(6) |
C11 | 6673(3) | 6043(2) | 2193.8(15) | 44.7(6) |
C9 | 5879(3) | 7178(2) | 3527.6(15) | 44.2(6) |
C10 | 5619(3) | 5119(2) | 3639.3(15) | 48.4(6) |
N22 | 5784(3) | 3621(2) | 814.1(15) | 67.8(7) |
O39 | 6151(3) | 8893(3) | 8285.8(15) | 109.2(10) |
C12 | 6985(3) | 8068(2) | 2049.4(15) | 47.2(6) |
C20 | 5248(3) | 4044(2) | 1633.9(16) | 50.7(6) |
C7 | 5022(3) | 8298(2) | 4770.9(15) | 50.8(6) |
C4 | 3693(3) | 8762(2) | 6554.3(16) | 49.4(6) |
C13 | 8823(3) | 7976(2) | 1872.6(16) | 48.8(6) |
C5 | 5385(3) | 8700(2) | 6267.8(17) | 56.4(7) |
C19 | 6380(3) | 4009(2) | 2279.5(17) | 54.5(7) |
C14 | 9741(3) | 7934(2) | 1013.2(16) | 54.7(7) |
C3 | 2685(3) | 8593(2) | 5965.2(17) | 54.4(7) |
C6 | 6015(3) | 8469(2) | 5392.0(16) | 54.3(7) |
C23 | 5121(4) | 9287(3) | 8898.3(18) | 62.1(7) |
041 | 1842(3) | 4874(3) | 3529.1(18) | 119.8(10) |
C8 | 3370(3) | 8376(2) | 5054.8(17) | 57.4(7) |
C24 | 5542(3) | 9730(3) | 9679.7(17) | 61.9(7) |
C18 | 9684(4) | 7917(3) | 2570.7(18) | 67.1(8) |
C15 | 11431(3) | 7827(3) | 831.3(19) | 67.8(8) |
C16 | 12217(3) | 7760(3) | 1541(2) | 67.9(8) |
C2 | 1134(4) | 8667(3) | 6497.1(18) | 67.4(8) |
[ Table 194 ]
Atoms | X | y | Z | U(eq) |
C17 | 11360(4) | 7806(3) | 2405(2) | 75.0(9) |
C21 | 4400(4) | 3767(3) | 485.7(19) | 70.6(8) |
O43 | -464(4) | 4618(4) | 3203.2(19) | 154.2(15) |
C1 | 9(4) | 8943(3) | 8139(2) | 81.7(10) |
C26 | 307(4) | 4766(4) | 3745(2) | 93.6(12) |
C25 | -384(4) | 4909(4) | 4700(2) | 92.1(11) |
C22 | 1397(4) | 4562(4) | 963(3) | 102.7(13) |
Next, the atomic coordinates of the hydrogen atom are shown in Table 195. Here, U (iso) means an isotropic temperature factor. The numbers of hydrogen atoms in table 195 are added in association with the numbers of bonded non-hydrogen atoms.
[ Table 195 ]
Atoms | X | y | Z | U(iSo) |
H38 | 3370.9 | 9206.88 | 8452.86 | 96 |
H16 | 5092.25 | 6215.55 | 4554.71 | 58 |
H12A | 6452.59 | 8783.45 | 2347.49 | 57 |
H12B | 6603.63 | 8119.01 | 1479.7 | 57 |
H5 | 6053.99 | 8811.71 | 6658.45 | 68 |
H19A | 6229.72 | 3381.57 | 2741.61 | 65 |
H19B | 7509.94 | 3824.57 | 1962.58 | 65 |
H41 | 2202.36 | 4700.41 | 3007.94 | 180 |
H8 | 2702.01 | 8287.11 | 4656.27 | 69 |
H24 | 6652.83 | 9619.42 | 9719.44 | 74 |
H18 | 9115.24 | 7953.15 | 3160.4 | 81 |
H15 | 12010.7 | 7800.84 | 243.55 | 81 |
H2 | 176.44 | 8593.16 | 6310.6 | 81 |
H21 | 4344.44 | 3553.57 | -79.51 | 85 |
H1A | 260.69 | 8258.79 | 8539.89 | 122 |
H1B | -1049.48 | 8985.26 | 7978.29 | 122 |
H1C | -14.15 | 9635.57 | 8433.78 | 122 |
H25 | -1486.76 | 4863.66 | 4886.06 | 110 |
H22A | 719.4 | 4375.73 | 1521.91 | 154 |
H22B | 1225.91 | 4127.33 | 499 | 154 |
H22C | 1105.77 | 5390.24 | 801.98 | 154 |
Further, the interatomic bond length (in angstroms) is shown in Table 196.
[ Table 196 ]
Regarding fumaric acid co-crystal form I of the compound represented by the formula (I-B), in the asymmetric unit, the compound represented by the formula (I-B) exists in 1 molecule. The structure in the asymmetric unit of fumaric acid co-crystal form I of the compound of formula (I-B) is shown in FIG. 4.
The non-hydrogen atom numbers in tables 193 to 194 and 196 correspond to the numbers described in fig. 4, respectively.
As set forth in Table 196, the bond lengths of N10-C9 are shown to be aboutThe bond length of N16-C9 is shown to be about
Due to the bond length of N10-C9 (about) Longer than the bond of N19-C9 (about +.>) Short, the compound of formula (I-B) of fumaric acid co-crystal form I was identified as an imino structure:
[ chemical formula 87 ]
In addition, the X-ray powder diffraction results of fumaric acid co-crystal form I crystals of the compound represented by the formula (I-B) are also shown.
In the X-ray powder diffraction pattern, at diffraction angle (2θ): peaks were observed at 7.8±0.2°, 9.5±0.2°, 10.1±0.2°, 10.9±0.2°, 13.8±0.2°, 14.7±0.2°, 18.6±0.2°, 22.6±0.2°, 23.5±0.2° and 24.6±0.2°.
In the above-mentioned X-ray powder diffraction peak, at the diffraction angle (2θ): peaks at 9.5.+ -. 0.2 °, 10.9.+ -. 0.2 °, 18.6.+ -. 0.2 °, 23.5.+ -. 0.2 ° and 24.6.+ -. 0.2 ° are particularly characteristic as fumaric acid co-crystal form I crystals of the compound represented by formula (I-B).
The result of the raman spectrum of the fumaric acid co-crystal form I crystal of the compound represented by the formula (I-B) is shown in fig. 5.
At 637.3cm -1 ±2cm -1 、676.3cm -1 ±2cm -1 、688.8cm -1 ±2cm -1 、748.0cm -1 ±2cm -1 、758.1cm -1 ±2cm -1 、1029.3cm -1 ±2cm -1 、1114.4cm -1 ±2cm -1 、1281.3cm -1 ±2cm -1 、1332.1cm -1 ±2cm -1 、1374.4cm -1 ±2cm -1 、1456.0cm -1 ±2cm -1 、1515.5cm -1 ±2cm -1 、1636.0cm -1 ±2cm -1 、1665.7cm -1 ±2cm -1 、1715.7cm -1 ±2cm -1 、1739.1cm -1 ±2cm -1 、2951.2cm -1 ±2cm -1 、3068.3cm -1 ±2cm -1 3126.2cm -1 ±2cm -1 Where the main raman spectral peak is observed.
In one embodiment, the fumaric acid co-crystal form I of the compound of formula (I-B) is in the range of 676.3cm -1 ±2cm -1 、748.0cm -1 ±2cm -1 、1029.3cm -1 ±2cm -1 、1374.4cm -1 ±2cm -1 、1515.5cm -1 ±2cm -1 、1665.7cm -1 ±2cm -1 、1715.7cm -1 ±2cm -1 1739.1cm -1 ±2cm -1 With raman spectral peaks.
In one embodiment, the fumaric acid co-crystal form I of the compound of formula (I-B) is in the range of 676.3cm -1 ±2cm -1 With raman spectral peaks.
In one embodiment, the fumaric acid co-crystal form I of the compound of formula (I-B) is a compound of formula (I-B) having a crystal size of 748.0cm -1 ±2cm -1 With raman spectral peaks.
In one embodiment, the fumaric acid co-crystal form I of the compound of formula (I-B) is a compound of formula (I-B) having a crystal size of 1029.3cm -1 ±2cm -1 With raman spectral peaks.
In one embodiment, the fumaric acid co-crystal form I of the compound of formula (I-B) is a compound of formula (I-B) having a crystal size of 1374.4cm -1 ±2cm -1 With raman spectral peaks.
In one embodiment, the fumaric acid co-crystal form I of the compound of formula (I-B) is a compound of formula (I-B) having a crystal size of 1515.5cm -1 ±2cm -1 With raman spectral peaks.
In one embodiment, the fumaric acid co-crystal form I of the compound of formula (I-B) is a compound of formula (I-B) having a crystal size of 1665.7cm -1 ±2cm -1 With raman spectral peaks.
In one embodiment, the fumaric acid co-crystal form I of the compound of formula (I-B) is a compound of formula (I-B) having a crystal size of 1715.7cm -1 ±2cm -1 With raman spectral peaks.
In one embodiment, the fumaric acid co-crystal form I of the compound of formula (I-B) is a compound of formula (I-B) having a crystal size of 1739.1cm -1 ±2cm -1 With raman spectral peaks.
In one embodiment, the fumaric acid co-crystal form I of the compound of formula (I-B) has one or more crystals selected from the group consisting of those of 676.3cm -1 ±2cm -1 Raman spectrum peak at 748.0cm -1 ±2cm -1 Raman spectrum peak at 1029.3cm -1 ±2cm -1 Raman spectrum peak at 1374.4cm -1 ±2cm -1 Raman spectrum peak at 1515.5cm -1 ±2cm -1 Raman spectrum peak at 1665.7cm -1 ±2cm -1 Raman spectrum peak at 1715.7cm -1 ±2cm -1 Raman spectrum peak at 1739.1cm -1 ±2cm -1 Raman spectral peaks of the group consisting of raman spectral peaks at.
The DSC analysis result of the fumaric co-crystal form I crystal of the compound represented by the formula (I-B) is shown in FIG. 6. The onset temperature (endothermic peak) shows about 272 ℃.
[ example 10 ]
395. Mu.L (1.05 eq) of a 1mol/L aqueous potassium hydroxide solution and 2mL of acetonitrile were added to 200mg of compound (I-0115), and solvent-dried and solidified. 1mL of ethyl acetate was added, and after stirring at 60℃for 10 minutes, stirring was continued overnight at 25 ℃. The solid was collected by filtration and dried to obtain the potassium salt crystal form I of the compound represented by the formula (I-B). Regarding the potassium salt crystal form I of the compound represented by the formula (I-B), the molecular structure (amino/imino) has not been identified.
The X-ray powder diffraction result of the potassium salt crystal form I of the compound represented by the formula (I-B) is shown in FIG. 7.
In the X-ray powder diffraction pattern, at diffraction angle (2θ): peaks were observed at 7.7.+ -. 0.2 °, 8.1.+ -. 0.2 °, 12.6.+ -. 0.2 °, 16.7.+ -. 0.2 °, 18.5.+ -. 0.2 °, 19.4.+ -. 0.2 °, 20.7.+ -. 0.2 °, 22.0.+ -. 0.2 °, 23.7.+ -. 0.2 ° and 25.3.+ -. 0.2 °.
In the above-mentioned X-ray powder diffraction peak, at the diffraction angle (2θ): peaks at 8.1.+ -. 0.2 °, 16.7.+ -. 0.2 °, 20.7.+ -. 0.2 °, 22.0.+ -. 0.2 ° and 25.3.+ -. 0.2 ° are particularly characteristic as the potassium salt crystal form I of the compound represented by the formula (I-B).
The result of the raman spectrum of the potassium salt crystal form I of the compound represented by the formula (I-B) is shown in fig. 8.
At 638.4cm -1 ±2cm -1 、676.3cm -1 ±2cm -1 、724.1cm -1 ±2cm -1 、749.1cm -1 ±2cm -1 、876.9cm -1 ±2cm -1 、1008.7cm -1 ±2cm -1 、1105.9cm -1 ±2cm -1 、1294.8cm -1 ±2cm -1 、1363.1cm -1 ±2cm -1 、1409.2cm -1 ±2cm -1 、1457.0cm -1 ±2cm -1 、1506.4cm -1 ±2cm -1 、1526.5cm -1 ±2cm -1 、1577.4cm -1 ±2cm -1 、1624.1cm -1 ±2cm -1 、1688.3cm -1 ±2cm -1 、2952.0cm -1 ±2cm -1 、2980.5cm -1 ±2cm -1 、3073.7cm -1 ±2cm -1 3121.6cm -1 ±2cm -1 Where the main raman spectral peak is observed.
In one embodiment, the potassium salt of the compound of formula (I-B) is in crystalline form I at 749.1cm -1 ±2cm -1 、1008.7cm -1 ±2cm -1 、1363.1cm -1 ±2cm -1 、1506.4cm -1 ±2cm -1 、1577.4cm -1 ±2cm -1 1624.1cm -1 ±2cm -1 Having a Raman spectrum peak at。
[ example 11 ]
46.4mg (1.1 eq) of succinic acid and 3.8mL of acetonitrile were added to 190mg of compound (I-0115) and stirred at room temperature for 1 hour. The solid was collected by filtration and dried to obtain succinic acid co-crystal form I of the compound represented by the formula (I-B). Regarding the succinic acid co-crystal form I of the compound represented by the formula (I-B), the molecular structure (amino/imino) has not been identified.
The results of X-ray powder diffraction of succinic acid co-crystal form I of the compound represented by the formula (I-B) are shown in FIG. 9.
In the X-ray powder diffraction pattern, at diffraction angle (2θ): peaks were observed at 9.5±0.2°, 10.9±0.2°, 11.3±0.2°, 13.4±0.2°, 14.4±0.2°, 18.7±0.2°, 19.4±0.2°, 22.6±0.2°, 23.4±0.2° and 24.4±0.2°.
In the above-mentioned X-ray powder diffraction peak, at the diffraction angle (2θ): peaks at 10.9.+ -. 0.2 °, 18.7.+ -. 0.2 °, 22.6.+ -. 0.2 °, 23.4.+ -. 0.2 ° and 24.4.+ -. 0.2 ° are particularly characteristic as the succinic acid co-crystal form I of the compound represented by formula (I-B).
The results of the raman spectrum of succinic acid co-crystal form I of the compound represented by formula (I-B) are shown in fig. 10.
At 631.6cm -1 ±2cm -1 、676.4cm -1 ±2cm -1 、748.1cm -1 ±2cm -1 、812.3cm -1 ±2cm -1 、1025.2cm -1 ±2cm -1 、1114.6cm -1 ±2cm -1 、1229.2cm -1 ±2cm -1 、1331.3cm -1 ±2cm -1 、1374.6cm -1 ±2cm -1 、1515.7cm -1 ±2cm -1 、1636.3cm -1 ±2cm -1 、1665.0cm -1 ±2cm -1 、1712.1cm -1 ±2cm -1 、1737.5cm -1 ±2cm -1 、2953.3cm -1 ±2cm -1 、2982.6cm -1 ±2cm -1 、3069.5cm -1 ±2cm -1 3127.5cm -1 ±2cm -1 Where the main raman spectral peak is observed.
In one embodiment, the compound of formula (I-B)Succinic acid co-crystal form I of the compound is 676.4cm -1 ±2cm -1 、748.1cm -1 ±2cm -1 、1025.2cm -1 ±2cm -1 、1374.6cm -1 ±2cm -1 、1515.7cm -1 ±2cm -1 1665.0cm -1 ±2cm -1 With raman spectral peaks.
[ example 12 ]
750 μl of ethyl acetate was added to 150mg of compound (I-0115) and stirred at 60deg.C overnight. The solid was collected by filtration and dried to give the anhydrous crystalline form I of the compound represented by formula (I-B). Regarding the anhydrous crystalline form I of the compound represented by the formula (I-B), the molecular structure (amino/imino) has not been identified.
The results of the X-ray powder diffraction of the anhydrous crystalline form I of the compound of formula (I-B) are shown in FIG. 11.
In the X-ray powder diffraction pattern, at diffraction angle (2θ): peaks were observed at 6.6.+ -. 0.2 °, 9.6.+ -. 0.2 °, 12.2.+ -. 0.2 °, 13.2.+ -. 0.2 °, 16.2.+ -. 0.2 °, 17.5.+ -. 0.2 °, 19.8.+ -. 0.2 °, 23.3.+ -. 0.2 °, 24.5.+ -. 0.2 ° and 26.1.+ -. 0.2 °.
In the above-mentioned X-ray powder diffraction peak, at the diffraction angle (2θ): peaks at 6.6.+ -. 0.2 °, 9.6.+ -. 0.2 °, 13.2.+ -. 0.2 °, 17.5.+ -. 0.2 ° and 19.8.+ -. 0.2 ° are particularly characteristic as the anhydrous crystalline form I of the compound represented by formula (I-B).
The results of the raman spectrum of the anhydrous crystalline form I of the compound represented by formula (I-B) are shown in fig. 12.
At 630.4cm -1 ±2cm -1 、672.8cm -1 ±2cm -1 、744.6cm -1 ±2cm -1 、805.4cm -1 ±2cm -1 、997.8cm -1 ±2cm -1 、1020.7cm -1 ±2cm -1 、1297.9cm -1 ±2cm -1 、1335.2cm -1 ±2cm -1 、1362.0cm -1 ±2cm -1 、1461.0cm -1 ±2cm -1 、1505.4cm -1 ±2cm -1 、1527.5cm -1 ±2cm -1 、1629.1cm -1 ±2cm -1 、1645.9cm -1 ±2cm -1 、1755.7cm -1 ±2cm -1 、2943.3cm -1 ±2cm -1 、2982.1cm -1 ±2cm -1 、3060.5cm -1 ±2cm -1 、3104.7cm -1 ±2cm -1 3123.2cm -1 ±2cm -1 Where the main raman spectral peak is observed.
In one embodiment, the anhydrous crystalline form I of the compound of formula (I-B) is at 630.4cm -1 ±2cm -1 、744.6cm -1 ±2cm -1 、997.8cm -1 ±2cm -1 、1362.0cm -1 ±2cm -1 、1461.0cm -1 ±2cm -1 、1505.4cm -1 ±2cm -1 1755.7cm -1 ±2cm -1 With raman spectral peaks.
[ example 13 ]
187. Mu.L (1.05 eq) of 1mol/L aqueous sodium hydroxide solution and 1mL of acetonitrile were added to 95mg of compound (I-0115) and the mixture was solvent dried and solidified. 100 μl acetonitrile was added to 5mg of the resulting solid and stirred overnight at 25deg.C. The solid was collected by filtration and dried to give the sodium salt of the compound of formula (I-B) as crystalline form I. Regarding the sodium salt crystal form I of the compound represented by the formula (I-B), the molecular structure (amino/imino) has not been identified.
The results of X-ray powder diffraction of the sodium salt crystal form I of the compound represented by formula (I-B) are shown in FIG. 13.
In the X-ray powder diffraction pattern, at diffraction angle (2θ): peaks were observed at 6.6.+ -. 0.2 °, 8.1.+ -. 0.2 °, 10.9.+ -. 0.2 °, 11.6.+ -. 0.2 °, 13.2.+ -. 0.2 °, 16.0.+ -. 0.2 °, 22.1.+ -. 0.2 °, 23.4.+ -. 0.2 °, 26.6.+ -. 0.2 ° and 28.9.+ -. 0.2 °.
In the above-mentioned X-ray powder diffraction peak, at the diffraction angle (2θ): peaks at 8.1.+ -. 0.2 °, 10.9.+ -. 0.2 °, 13.2.+ -. 0.2 °, 23.4.+ -. 0.2 ° and 26.6.+ -. 0.2 ° are particularly characteristic as the sodium salt crystal form I of the compound represented by formula (I-B).
The results of the raman spectrum of the sodium salt crystal form I of the compound represented by formula (I-B) are shown in fig. 14.
At 638.4cm -1 ±2cm -1 、675.1cm -1 ±2cm -1 、746.8cm -1 ±2cm -1 、1013.0cm -1 ±2cm -1 、1106.9cm -1 ±2cm -1 、1126.2cm -1 ±2cm -1 、1299.0cm -1 ±2cm -1 、1367.2cm -1 ±2cm -1 、1407.1cm -1 ±2cm -1 、1457.0cm -1 ±2cm -1 、1504.4cm -1 ±2cm -1 、1526.5cm -1 ±2cm -1 、1581.3cm -1 ±2cm -1 、1629.1cm -1 ±2cm -1 、1711.8cm -1 ±2cm -1 、2959.1cm -1 ±2cm -1 、3062.0cm -1 ±2cm -1 3125.5cm -1 ±2cm -1 Where the main raman spectral peak is observed.
In one embodiment, the sodium salt of the compound of formula (I-B) is in crystalline form I at 746.8cm -1 ±2cm -1 、1013.0cm -1 ±2cm -1 、1367.2cm -1 ±2cm -1 、1504.4cm -1 ±2cm -1 、1526.5cm -1 ±2cm -1 1581.3cm -1 ±2cm -1 With raman spectral peaks.
The results of the simultaneous differential thermal-thermogravimetry (TG/DTA) analysis of the crystalline form I of the sodium salt of the compound of formula (I-B) are shown in FIG. 15. As a result, it was confirmed that the weight was reduced by 8.1% from about 72℃to about 105℃with the endothermic peak.
From the above measurement results, it is considered that the sodium salt crystal form I of the compound represented by the formula (I-B) is a crystal containing water corresponding to 2.5 to 3 water.
Hereinafter, biological test examples of the compounds of the present invention are described.
The compounds represented by the formula (I), the formula (I ') and the formula (I') have the effect of inhibiting coronavirus 3CL protease and can inhibit coronavirus 3CL protease.
Specifically, in the following evaluation method, the IC50 is preferably 50. Mu.M or less, more preferably 1. Mu.M or less, and still more preferably 100nM or less.
Test example 1: assay for confirming Cytopathic effect (CPE) inhibition Using Vero E6 cells expressing human TMPRSS2 (Vero E6/TMPRSS2 cells)
< procedure >
Dilution and dispensing of the test sample
Test samples were diluted in DMSO to appropriate concentrations in advance, and after preparing a 2-5-fold stepwise dilution series, dispensed into 384-well plates.
Dilution and partitioning of cells and SARS-CoV-2
VeroE6/TMPRSS2 cells (JCRB 1819, 5×10) 3 cells/well) and SARS-CoV-2 (100-300 TCID 50 Well) in a medium (MEM, 2% FBS, penicillin-streptomycin), and dispensing into wells into which test samples have been placed, and then in CO 2 Culturing in an incubator for 3 days.
·CellTiter-2.0 dispensing and luminescence Signal determination
After the plate cultured for 3 days was returned to room temperature, cellTiter-2.0 was dispensed into each well and mixed with a plate mixer. After a period of time, luminescence signals (Lum) were measured with a plate reader.
< calculation of measurement item values >
50% concentration of inhibition of death of SARS-CoV-2 infected cells (EC 50 ) Calculation of
When x is the logarithmic value of the compound concentration and y is%efficiency, the inhibition curve is approximated by the following Logistic regression equation, and the value of x when y=50 (%) is substituted is calculated as EC 50 。
y=min+(max-min)/{1+(X50/x)^Hill}
%Efficacy={(Sample-virus control)/(cell control-virus control)}*100%
cell control:the average of Lum of cell control wells
virus control:the average of Lum of virus control wells
min: y-axis lower limit, max: y-axis upper limit, X50: the x-coordinate of the inflection point, hill: slope of curve at midpoint of min and max
The compounds of the present invention were tested essentially as described above. The results are shown in the following table.
And, EC (EC) 50 A value of "A" is less than 1. Mu.M, and B is greater than or equal to 1. Mu.M and less than 10. Mu.M.
[ Table 197 ]
Numbering of compounds | EC50[μM] | Numbering of compounds | EC50[μM] | Numbering of compounds | EC50[μM] | Numbering of compounds | EC50[μM] |
I-0031 | 4.06 | II-0014 | 22.1 | II-0278 | 0.170 | II-0460 | 19.0 |
I-0110 | 0.321 | II-0015 | 0.0350 | II-0282 | 0.260 | II-0482 | 44.5 |
I-0113 | 0.177 | II-0034 | 0.234 | II-0284 | 0.184 | II-0483 | 20.9 |
I-0115 | 0.328 | II-0036 | 0.355 | II-0288 | 2.40 | II-0484 | 14.2 |
I-0180 | 6.41 | II-0043 | 0.232 | II-0289 | 16.0 | II-0490 | 8.70 |
I-0237 | 3.39 | II-0045 | 0.218 | II-0290 | 0.210 | II-0493 | 0.0680 |
I-0239 | 0.225 | II-0055 | 0.180 | II-0292 | 0.434 | II-0494 | 0.878 |
I-0247 | 3.54 | II-0074 | 0.248 | II-0299 | 0.202 | II-0499 | 0.680 |
I-0281 | 4.18 | II-0087 | 0.0690 | II-0304 | 0.213 | II-0521 | 0.220 |
I-0288 | 0.747 | II-0089 | 0.182 | II-0306 | 0.410 | II-0522 | 15.0 |
I-0318 | 1.36 | II-0090 | 0.355 | II-0329 | 11.5 | II-0523 | 0.240 |
I-0329 | 5.10 | II-0093 | 0.487 | II-0330 | 42.2 | II-0525 | 0.533 |
I-0339 | 8.00 | II-0109 | 0.798 | II-0332 | 0.0540 | II-0543 | 0.0870 |
I-0351 | 0.0747 | II-0111 | 1.91 | II-0334 | 0.620 | II-0545 | 0.750 |
I-0353 | 0.306 | II-0118 | 0.121 | II-0335 | 0.241 | II-0548 | 0.533 |
I-0354 | 0.107 | II-0119 | 0.183 | II-0343 | 4.14 | II-0550 | 6.42 |
I-0355 | 0.339 | II-0120 | 0.127 | II-0347 | 0.190 | II-0559 | 0.246 |
I-0358 | 7.45 | II-0125 | 0.220 | II-0369 | 1.16 | II-0566 | 0.898 |
I-0361 | 0.131 | II-0130 | 0.0950 | II-0370 | 28.9 | II-0567 | 0.650 |
I-0377 | 0.0729 | II-0132 | 49.8 | II-0371 | 13.3 | II-0568 | 0.132 |
I-0383 | 0.0960 | II-0163 | 0.342 | II-0372 | 6.52 | II-0569 | 0.419 |
I-0390 | 3.16 | II-0164 | 0.195 | II-0375 | 21.6 | II-0570 | 0.600 |
I-0391 | 0.460 | II-0173 | 0.272 | II-0376 | 7.13 | II-0571 | 0.190 |
I-0421 | 0.450 | II-0192 | 0.454 | II-0377 | 0.0490 | II-0572 | 0.925 |
I-0426 | 1.03 | II-0223 | 22.5 | II-0389 | 4.40 | II-0573 | 0.340 |
I-0433 | 0.720 | II-0226 | 2.77 | II-0392 | 20.8 | II-0574 | 0.200 |
I-0444 | 3.94 | II-0228 | 5.00 | II-0393 | 6.08 | II-0576 | 0.530 |
I-0457 | 5.30 | II-0233 | 0.0650 | II-0394 | 44.9 | II-0577 | 0.0850 |
I-0465 | 3.27 | II-0241 | 1.39 | II-0401 | 2.33 | II-0579 | 0.0670 |
I-0480 | 0.0726 | II-0255 | 1.52 | II-0407 | 15.0 | II-0584 | 0.750 |
I-0481 | 0.0432 | II-0257 | 9.14 | II-0410 | 0.201 | II-0595 | 8.22 |
I-0482 | 0.385 | II-0258 | 7.87 | II-0415 | 0.870 | II-0596 | 0.0620 |
I-0a83 | 0.395 | II-0259 | 36.3 | II-0418 | 6.24 | II-0604 | 9.76 |
II-0001 | 0.466 | II-0272 | 1.59 | II-0422 | 0.290 | ||
II-0003 | 17.8 | II-0273 | 6.60 | II-0425 | 5.85 | ||
II-0010 | 0.940 | II-0275 | 7.28 | II-0455 | 0.750 |
[ Table 198 ]
Numbering of compounds | EC50[μM] | Numbering of compounds | EC50[μM] |
II-0608 | 0.487 | II-0609 | 2.04 |
[ Table 199 ]
Numbering of compounds | EC50 | Numbering of compounds | EC50 | Numbering of compounds | EC50 | Numbering of compounds | EC50 |
I-0007 | B | I-0447 | B | I4-0184 | B | II-0391 | B |
I-0008 | B | I-0450 | B | II-0185 | A | II-0395 | A |
I-0009 | A | I-0451 | B | II-0186 | B | II-0396 | A |
I-0011 | A | I-0452 | B | II-0187 | A | II-0397 | A |
I-0012 | B | I-0454 | B | II-0188 | A | II-0398 | A |
I-0013 | B | I-0455 | B | II-0189 | B | II-0399 | A |
I-0016 | A | I-0456 | B | II-0190 | B | II-0400 | B |
I-0019 | B | I-0459 | B | II-0191 | A | II-0402 | A |
I-0020 | B | I-0460 | B | II-0193 | B | II-0403 | A |
I-0025 | B | I-0461 | B | II-0194 | A | II-0404 | A |
I-0026 | B | I-0462 | B | II-0195 | B | II-0405 | A |
I-0029 | A | I-0465 | B | II-0196 | A | II-0406 | A |
I-0031 | B | I-0466 | A | II-0197 | A | II-0408 | B |
I-0033 | A | I-0467 | B | II-0198 | A | II-0409 | B |
I-0035 | A | I-0468 | B | II-0199 | A | II-0412 | B |
I-0038 | A | I-0470 | B | II-0200 | B | II-0413 | B |
I-0042 | B | I-0471 | B | II-0201 | A | II-0414 | B |
I-0064 | B | I-0472 | A | II-0202 | B | II-0416 | B |
I-0066 | B | II-0002 | B | II-0203 | A | II-0417 | B |
I-0069 | B | II-0005 | B | II-0204 | B | II-0419 | A |
I-0077 | A | II-0006 | B | II-0205 | B | II-0420 | A |
I-0079 | B | II-0007 | A | II-0207 | B | II-0421 | A |
I-0081 | A | II-0008 | B | II-0208 | B | II-0423 | B |
I-0084 | B | II-0011 | B | II-0210 | B | II-0424 | B |
I-0094 | B | II-0017 | A | II-0212 | A | II-0426 | A |
I-0095 | B | II-0018 | B | II-0213 | B | II-0429 | B |
I-0100 | B | II-0020 | B | II-0214 | B | II-0430 | B |
I-0111 | B | II-0022 | A | II-0215 | B | II-0431 | A |
I-0112 | A | II-0023 | A | II-0217 | B | II-0433 | A |
I-0114 | B | II-0024 | B | II-0218 | B | II-0434 | A |
I-0116 | B | II-0025 | B | II-0219 | B | II-0435 | B |
I-0128 | A | II-0027 | A | II-0220 | B | II-0436 | A |
I-0129 | B | II-0028 | A | II-0221 | B | II-0437 | A |
I-0132 | A | II-0029 | B | II-0222 | A | II-0438 | B |
I-0133 | A | II-0030 | A | II-0227 | A | II-0439 | A |
I-0134 | A | II-0031 | B | II-0232 | A | II-0440 | B |
I-0135 | B | II-0032 | A | II-0234 | A | II-0442 | A |
I-0136 | B | II-0035 | A | II-0235 | B | II-0446 | B |
[ Table 200 ]
Numbering of compounds | EC50 | Numbering of compounds | EC50 | Numbering of compounds | EC50 | Numbering of compounds | EC50 |
I-0152 | A | II-0037 | B | II-0236 | A | II-0448 | A |
I-0165 | B | II-0038 | B | II-0237 | A | II-0449 | A |
I-0166 | A | II-0039 | B | II-0238 | B | II-0450 | B |
I-0194 | B | II-0041 | B | II-0239 | B | II-0452 | B |
I-0196 | B | II-0044 | A | II-0240 | B | II-0453 | B |
I-0213 | B | II-0046 | A | II-0242 | A | II-0454 | B |
I-0214 | A | II-0047 | A | II-0243 | B | II-0458 | A |
I-0226 | B | II-0048 | A | II-0244 | B | II-0459 | B |
I-0227 | B | II-0049 | A | II-0245 | A | II-0461 | B |
I-0231 | B | II-0050 | A | II-0246 | B | II-0462 | A |
I-0236 | A | II-0051 | B | II-0247 | A | II-0463 | A |
I-0242 | A | II-0052 | B | II-0249 | B | II-0464 | A |
I-0245 | B | II-0053 | A | II-0250 | B | II-0466 | B |
I-0247 | B | II-0054 | A | II-0251 | A | II-0468 | B |
I-0248 | B | II-0056 | B | II-0252 | B | II-0469 | A |
I-0249 | B | II-0057 | B | II-0253 | B | II-0475 | B |
I-0250 | B | II-0058 | A | II-0254 | B | II-0477 | B |
I-0251 | B | II-0059 | B | II-0260 | A | II-0478 | B |
I-0252 | B | II-0060 | B | II-0261 | A | II-0479 | B |
I-0253 | B | II-0061 | B | II-0262 | B | II-0485 | A |
I-0254 | B | II-0063 | B | II-0263 | B | II-0486 | B |
I-0255 | A | II-0064 | B | II-0264 | B | II-0487 | B |
I-0256 | B | II-0065 | A | II-0265 | A | II-0489 | B |
I-0260 | B | II-0066 | B | II-0267 | B | II-0491 | B |
I-0264 | B | II-0067 | A | II-0269 | B | II-0492 | A |
I-0267 | B | II-0068 | A | II-0270 | B | II-0495 | A |
I-0269 | B | II-0069 | B | II-0271 | B | II-0496 | A |
I-0271 | B | II-0070 | B | II-0279 | B | II-0497 | A |
I-0272 | A | II-0071 | A | II-0281 | B | II-0498 | B |
I-0279 | B | II-0072 | B | II-0283 | A | II-0500 | B |
I-0284 | A | II-0073 | B | II-0285 | A | II-0501 | A |
I-0285 | B | II10075 | A | II-0286 | B | II-0503 | B |
I-0286 | B | II-0076 | A | II-0287 | B | II-0504 | A |
I-0290 | B | II-0077 | A | II-0291 | B | II-0505 | B |
I-0301 | A | II-0078 | A | II-0294 | B | II-0506 | A |
I-0306 | B | II-0079 | A | II-0295 | B | II-0507 | B |
I-0307 | A | II-0080 | B | II-0296 | A | II-0508 | B |
I-0310 | B | II-0082 | B | II-0297 | B | II-0509 | B |
[ Table 201 ]
Numbering of compounds | EC50 | Numbering of compounds | EC50 | Numbering of compounds | EC50 | Numbering of compounds | EC50 |
I-0316 | B | II-0084 | A | II-0298 | B | II-0510 | B |
I-0318 | B | II-0088 | B | II-0300 | B | II-0512 | B |
I-0320 | B | II-0092 | A | II-0301 | A | II-0513 | A |
I-0321 | A | II-0094 | B | II-0302 | B | II-0514 | B |
I-0330 | B | II-0095 | A | II-0303 | A | II-0515 | B |
I-0331 | B | II-0096 | A | II-0305 | B | II-0516 | B |
I-0332 | B | II-0097 | A | II-0307 | B | II-0517 | B |
I-0335 | B | II-0098 | B | II-0308 | A | II-0518 | B |
I-0339 | B | II-0099 | B | II-0309 | B | II-0519 | B |
I-0344 | A | II-0100 | A | II-0311 | B | II-0520 | B |
I-0346 | A | II-0101 | A | II-0312 | A | II-0524 | B |
I-0348 | A | II-0102 | B | II-0313 | A | II-0526 | B |
I-0349 | B | II-0104 | B | II-0316 | B | II-0527 | A |
I-0350 | A | II-0105 | A | II-0318 | A | II-0528 | A |
I-0352 | A | II-0106 | B | II-0320 | A | II-0529 | A |
I-0355 | A | II-0107 | B | II-0322 | B | II-0533 | B |
I-0357 | B | II-0108 | B | II-0323 | A | II-0534 | B |
I-0359 | B | II-0110 | A | II-0326 | B | II-0535 | A |
I-0364 | B | II-0112 | B | II-0333 | A | II-0536 | B |
I-0365 | B | II-0114 | A | II-0336 | A | II-0537 | B |
I-0366 | B | II-0115 | A | II-0337 | A | II-0538 | B |
I-0368 | B | II-0116 | A | II-0339 | A | II-0539 | B |
I-0369 | B | II-0117 | A | II-0341 | B | II-0541 | A |
I-0370 | B | II-0121 | A | II-0342 | B | II-0544 | A |
I-0372 | A | II-0122 | B | II-0344 | B | II-0546 | A |
I-0374 | B | II-0123 | B | II-0345 | A | II-0547 | A |
I-0378 | A | II-0126 | B | II-0346 | A | II-0551 | A |
I-0379 | A | II-0127 | B | II-0348 | B | II-0552 | A |
I-0380 | A | II-0128 | B | II-0349 | B | II-0553 | B |
I-0381 | B | II-0129 | B | II-0350 | B | II-0554 | B |
I-0382 | B | II-0131 | A | II-0351 | A | II-0555 | B |
I-0384 | A | II-0140 | B | II-0352 | A | II-0556 | B |
I-0385 | A | II-0144 | A | II-0353 | B | II-0560 | B |
I-0390 | B | II-0154 | A | II-0354 | B | II-0562 | B |
I-0392 | B | II-0156 | A | II-0355 | A | II-0563 | B |
I-04400 | B | II-0158 | B | II-0356 | B | II-0564 | A |
I-04401 | B | II-0159 | A | II-0359 | B | II-0565 | B |
I-04402 | B | II-0160 | A | II-0360 | B | II-0578 | B |
[ Table 202 ]
Numbering of compounds | EC50 | Numbering of compounds | EC50 | Numbering of compounds | FC50 | Numbering of compounds | FC50 |
I-0404 | B | II-0161 | A | II-0361 | A | II-0580 | A |
I-0406 | B | II-0162 | A | II-0362 | A | II-0581 | A |
I-0408 | B | II-0165 | A | II-0363 | A | II-0582 | A |
I-0421 | A | II-0166 | A | II-0364 | A | II-0583 | A |
I-0422 | B | II-0167 | A | II-0365 | A | II-0585 | B |
I-0423 | B | II-0168 | A | II-0366 | A | II-0586 | A |
I-0424 | B | II-0169 | A | II-0367 | A | II-0587 | A |
I-0425 | B | II-0171 | A | II-0368 | B | II-0588 | A |
I-0428 | A | II-0172 | A | II-0378 | B | II-0589 | B |
I-0429 | A | II-0174 | A | II-0380 | B | II-0590 | A |
I-0430 | A | II-0175 | A | II-0381 | A | II-0591 | A |
I-0431 | A | II-0176 | A | II-0382 | A | II-0592 | B |
I-0432 | B | II-0177 | A | II-0383 | A | II-0593 | B |
I-0433 | A | II-0178 | A | II-0384 | B | II-0597 | A |
I-0434 | B | II-0179 | B | II-0385 | A | II-0598 | A |
I-0435 | B | II-0180 | A | II-0386 | B | II-0599 | A |
I-0436 | A | II-0181 | A | II-0387 | A | II-0600 | A |
I-0437 | B | II-0182 | A | II-0388 | A | II-0601 | A |
I-0444 | B | II-0183 | A | II-0390 | B | II-0602 | A |
Reference example 1
Compounds I-0679, I-0683, I-0685 and I-1603 of International publication No. 2012/020749 (patent document 1), compounds I-575 and I-580 of International publication No. 2013/089212 (patent document 2), and compound I-066 of International publication No. 2010/092966 (patent document 3) were subjected to tests substantially as shown in test example 1. The results are shown in the following table.
[ Table 203 ]
[ Table 204 ]
Compounds I-0679, I-0683, I-0685 and I-1603 of International publication No. 2012/020749 (patent document 1), compounds I-575 and I-580 of International publication No. 2013/089212 (patent document 2), and compound I-066 of International publication No. 2010/092966 (patent document 3) do not exhibit coronavirus proliferation inhibitory activity at a concentration of up to 50. Mu.M.
Test example 2: inhibition Activity assay for SARS-CoV-2 3CL protease
< Material >
Commercial Recombinant SARS-CoV-2 3CL Protease
Commercial substrate peptide
Dabcyl-Lys-Thr-Ser-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-Lys-Met-Glu (Edans) -NH2 (SEQ ID NO: 1)
Internal Standard peptide
Dabcyl-Lys-Thr-Ser-Ala-Val-Leu (13C 6, 15N) -Gln (SEQ ID NO: 2)
Dabcyl-Lys-Thr-Ser-Ala-Val-Leu (13C 6, 15N) -Gln can be synthesized by reference (Athereton, E.; shelppard, R.C., "In Solid Phase Peptide Synthesis, A Practical Approach", IRL Press at Oxford University Pres,1989. And Bioorg. Med. Chem., volume 5, no. 9, 1997, pages 1883-1891, etc.). An example is shown below.
H-Lys-Thr-Ser-Ala-Val-Leu (13C 6, 15N) -Glu (resin) -OαOtBu (Lys side chain protected by Boc, thr side chain protected by tert-butyl, ser side chain protected by tert-butyl, C-terminal OH of Glu protected by tert-butyl, condensing carboxylic acid of Glu side chain to resin) was synthesized by Fmoc solid phase synthesis using Rink amide resin. Modification of the N-terminal Dabcyl group involves condensing 4-dimethylaminoazobenzene-4' -carboxylic acid (Dabcyl-OH) on the resin using EDC/HOBT. Final deprotection and cleavage from resin was performed by treatment with TFA/edt=95:5. After that, purification was performed by reverse phase HPLC.
·RapidFire Cartridge C4 typeA
< procedure >
Preparation of detection buffer
The assay used a detection buffer consisting of 20mM Tris-HCl, 100mM sodium chloride, 1mM EDTA, 10mM DTT, 0.01% BSA. With respect to IC 50 Compounds having a value of 10nM or less were detected using a detection buffer composed of 20mM Tris-HCl, 1mM EDTA, 10mM DTT, and 0.01% BSA.
Dilution and dispensing of the test sample
Test samples were diluted in DMSO to appropriate concentrations in advance, and after preparing a 2-5-fold stepwise dilution series, dispensed into 384-well plates.
Addition of enzyme and substrate, enzymatic reaction
To the prepared compound plate, 8. Mu.M substrate and 6 or 0.6nM enzyme solution were added and incubated at room temperature for 3-5 hours. Thereafter, a reaction terminator (0.067 μ M Internal Standard, 0.1% formic acid, 10 or 25% acetonitrile) was added to terminate the enzymatic reaction.
Determination of the reaction products
The completed plates were assayed using a RapidFire System 360 and a mass spectrometer (Agilent, 6550 ifennel Q-TOF) or Rapid Fire System 365 and a mass spectrometer (Agilent, 6495C Triple Quadrupole). The measurement was performed using a solution A (75% isopropanol, 15% acetonitrile, 5mM ammonium formate) and a solution B (0.01% trifluoroacetic acid, 0.09% formic acid) as mobile phases.
The reaction Product detected by the mass spectrometer was calculated as a Product area value using RapidFire Integrator or a program capable of equivalent analysis. Furthermore, internal Standard detected at the same time was also calculated as Internal Standard area value.
< calculation of measurement item values >
Calculation of P/IS
The P/IS IS calculated by calculating the area value obtained in the previous item by the following formula.
P/is=product area value/Internal Standard area value
50% SARS-CoV-2 3CL protease inhibition concentration (IC 50 ) Calculation of
When x is the logarithmic value of the compound concentration and y is% Inhibition, the Inhibition is approximated by the following Logistic regression equationCurve is made and the value of x when y=50 (%) is substituted is calculated as IC 50 。
y=min+(max-min)/{1+(X50/x)^Hill}
%Inhibition={1-(Sample-Control(-))/Control(+)-Control(-))}*100
Control(-):the average of P/IS of enzyme inhibited condition wells
Control(+):the average of P/IS of DMSO control wells
min: y-axis lower limit, max: y-axis upper limit, X50: the x-coordinate of the inflection point, hill: slope of curve at midpoint of min and max
The compounds of the present invention were tested essentially as described above. The results are shown in the following table.
And, IC 50 A value of "A" is 0.1. Mu.M or more and 1. Mu.M or less, B is 1. Mu.M or more and 10. Mu.M or less.
[ Table 205 ]
Numbering of compounds | IC50[μM] | Numbering of compounds | IC50[μM] | Numbering of compounds | IC50[μM] | Numbering of compounds | IC50[μM] |
I-0031 | 0.13 | I-0396 | 3.1 | II-0223 | 0.78 | II-0389 | 0.045 |
I-0033 | 5.6 | I-0397 | 0.73 | II-0224 | 1.9 | II-0392 | 1.0 |
I-0035 | 35 | I-0403 | 0.31 | II-0225 | 2.7 | II-0393 | 3.1 |
I-0038 | 1.3 | I-0412 | 5.1 | II-0226 | 0.13 | II-0394 | 3.9 |
I-0048 | 0.44 | I-0414 | 0.25 | II-0227 | 0.63 | II-0401 | 0.29 |
I-0083 | 1.8 | I-0415 | 3.0 | II-0228 | 0.24 | II-0407 | 0.0038 |
I-0102 | 0.85 | I-0416 | 3.5 | II-0229 | 0.25 | II-0410 | 0.0047 |
I.0106 | 1.9 | I.0421 | 0.010 | II-0229 | 0.25 | II-0415 | 0.015 |
I-0110 | 0.0042 | I-0426 | 0.0063 | II-0230 | 0.55 | II-0418 | 0.11 |
I-0113 | 0.014 | I-0433 | 0.010 | II-0231 | 0.88 | II-0422 | 0.0064 |
I-0115 | 0.010 | I-0438 | 0.74 | II-0232 | 3.7 | II-0425 | 0.26 |
I-0128 | 9.7 | I-0444 | 0.0051 | II-0233 | 0.0015 | II-0428 | 0.84 |
I-0132 | 2.3 | I-0457 | 0.0072 | II-0241 | 0.024 | II-0455 | 0.019 |
I-0133 | 3.4 | I-0465 | 0.0042 | II-0255 | 0.10 | II-0460 | 0.022 |
I.0134 | 4.0 | I-0480 | 0.0065 | II-0256 | 0.16 | II-0481 | 0.10 |
I-0149 | 3.5 | I-0481 | 0.0027 | II-0257 | 0.97 | II-0482 | 0.41 |
I-0151 | 0.97 | I-0482 | 0.015 | II-0258 | 0.95 | II-0483 | 1.8 |
I-0154 | 1.3 | I-0483 | 0.0098 | II-0259 | 3.4 | II-0484 | 3.4 |
I-0180 | 0.058 | II-0001 | 0.0034 | II-0272 | 0.18 | II-0490 | 0.083 |
I-0204 | 0.61 | II-0003 | 0.0060 | II-0273 | 0.36 | II-0492 | 1.0 |
I-0207 | 1.9 | II-0010 | 0.019 | II-0274 | 3.0 | II-0493 | 0.0013 |
I-0208 | 0.23 | II-0014 | 2.4 | II-0275 | 0.36 | II-0494 | 0.024 |
I-0223 | 4.3 | II-0015 | 0.0015 | II-0278 | 0.0031 | II-0499 | 0.012 |
I-0237 | 0.0042 | II-0021 | 3.6 | II-0282 | 0.0088 | II-0521 | 0.0034 |
I-0239 | 0.0039 | II-0034 | 0.0073 | II-0284 | 0.0092 | II-0522 | 0.0041 |
I-0247 | 0.025 | II-0036 | 0.0083 | II-0288 | 0.099 | II-0523 | 0.011 |
I-0257 | 2.9 | II-0043 | 0.0058 | II-0289 | 0.24 | II-0525 | 0.016 |
I-0258 | 3.5 | II-0045 | 0.0047 | II-0290 | 0.0035 | II-0543 | 0.0028 |
I-0281 | 0.0038 | II-0055 | 0.0045 | II-0292 | 0.0039 | II-0545 | 0.0086 |
I-0288 | 0.0058 | II-0074 | 0.0036 | II-0299 | 0.0033 | II-0548 | 0.014 |
I-0301 | 3.8 | II-0085 | 9.2 | II-0304 | 0.0045 | II-0550 | 1.1 |
I-0307 | 0.44 | II-0086 | 3.4 | II-0306 | 0.0051 | II-0559 | 0.0064 |
I-0318 | 0.11 | II-0087 | 0.0025 | II-0327 | 1.5 | II-0566 | 0.027 |
I-0321 | 2.1 | II-0089 | 0.0036 | II-0329 | 0.14 | II-0567 | 0.0088 |
I-0326 | 0.065 | II-0090 | 0.016 | II-0330 | 3.6 | II-0568 | 0.0021 |
I-0329 | 2.0 | II-0093 | 0.012 | II-0332 | 0.0020 | II-0569 | 0.0042 |
I-0334 | 0.87 | II-0109 | 0.040 | II-0334 | 0.0028 | II-0570 | 0.0044 |
I-0339 | 0.61 | II-0111 | 0.078 | II-0335 | 0.0032 | II-0571 | 0.0054 |
I-03a0 | 0.84 | II-0118 | 0.0045 | II-0343 | 0.31 | II-0572 | 0.0056 |
I-0351 | 0.0043 | II-0119 | 0.0089 | II-0347 | 0.0070 | II-0573 | 0.0061 |
I-0353 | 0.0054 | II-0120 | 0.0090 | II-0369 | 0.63 | II-0574 | 0.0092 |
I-0354 | 0.0050 | II-0124 | 3.3 | II-0370 | 0.52 | II-0576 | 0.017 |
[ Table 206 ]
Numbering of compounds | IC50[μM] | Numbering of compounds | IC50[μM] | Numbering of compounds | IC50[μM] | Numbering of compounds | IC50[μM] |
I-0355 | 0.0087 | II-0125 | 0.0048 | II-0371 | 0.54 | II-0577 | 0.0011 |
I-0358 | 0.12 | II-0130 | 0.0019 | II-0372 | 3.4 | II-0579 | 0.0021 |
I-0361 | 0.0091 | II-0132 | 0.0025 | II-0373 | 0.43 | II-0584 | 0.0048 |
I-0377 | 0.0080 | II-0163 | 0.0088 | II-0374 | 3.5 | II-0594 | 0.27 |
I-0383 | 0.0034 | II-0164 | 0.0090 | II-0375 | 3.8 | II-0595 | 0.53 |
I-0390 | 0.0040 | II-0173 | 0.015 | II-0376 | 1.0 | II-0596 | 0.0016 |
I-0391 | 0.0076 | II-0192 | 0.037 | II-0377 | 0.0030 | II-0604 | 0.47 |
[ Table 207 ]
Numbering of compounds | IC50[μM] | Numbering of compounds | IC50[μM] | Numbering of compounds | IC50[μM] | Numbering of compounds | IC50[μM] |
II-0608 | 0.019 | II-0609 | 0.12 | II-0643 | 1.0 | II-0644 | 3.5 |
[ Table 208 ]
Numbering of compounds | IC50 | Numbering of compounds | IC50 | Numbering of compounds | IC50 | Numbering of compounds | IC50 |
I-0001 | B | I-0421 | A | II-0149 | A | II-0380 | A |
I-0005 | A | I-0422 | A | II-0150 | A | II-0381 | A |
I-0006 | A | I-0423 | A | II-0151 | A | II-0382 | A |
I-0007 | A | I-0424 | A | II-0152 | A | II-0383 | A |
I-0008 | A | I-0425 | A | II-0153 | A | II-0384 | A |
I-0009 | A | I-0427 | A | II-0154 | A | II-0385 | A |
I-0010 | A | I-0428 | A | II-0155 | A | II-0386 | A |
I-0011 | A | I-0429 | A | II-0156 | A | II-0387 | A |
I-0012 | A | I-0430 | A | II-0158 | A | II-0388 | A |
I-0013 | A | I-0431 | A | II-0159 | A | II-0390 | A |
I-0016 | A | I-0432 | A | II-0160 | A | II-0391 | A |
I-0019 | A | I-0433 | A | II-0161 | A | II-0395 | A |
I-0020 | A | I-0434 | A | II-0162 | A | II-0396 | A |
I-0025 | A | I-0435 | A | II-0165 | A | II-0397 | A |
I-0026 | A | I-0436 | A | II-0166 | A | II-0398 | A |
I-0027 | A | I-0437 | A | II-0167 | A | II-0400 | A |
I-0029 | A | I-0438 | B | II-0168 | A | II-0402 | A |
I-0031 | B | I-0439 | A | II-0169 | A | II-0403 | A |
I-0033 | C | I-0440 | A | II-0170 | A | II-0404 | A |
I-0035 | C | I-0441 | A | II-0171 | A | II-0405 | A |
I-0038 | C | I-0442 | A | II-0172 | A | II-0406 | A |
I-0042 | A | I-0443 | A | II-0174 | A | II-0408 | A |
I-0048 | B | I-0444 | A | II-0175 | A | II-0409 | A |
I-0056 | A | I-0445 | A | II-0176 | A | II-0411 | A |
I-0063 | A | I-0446 | A | II-0177 | A | II-0412 | A |
I-0064 | A | I-0447 | A | II-0178 | A | II-0413 | A |
I-0066 | A | I-0448 | A | II-0179 | A | II-0414 | A |
I-0069 | A | I-0449 | A | II-0180 | A | II-0416 | A |
I-0072 | A | I-0450 | A | II-0181 | A | II-0417 | A |
I-0074 | A | I-0451 | A | II-0182 | A | II-0419 | A |
I-0077 | A | I-0445 | A | II-0183 | A | II-0420 | A |
I-0078 | A | I-0446 | A | II-0184 | A | II-0421 | A |
I-0079 | A | I-0447 | A | II-0185 | A | II-0423 | A |
I-0080 | A | I-0448 | A | II-0186 | A | II-0424 | A |
I-0081 | A | I-0449 | A | II-0187 | A | II-0426 | A |
I-0083 | C | I-0450 | A | II-0188 | A | II-0427 | A |
I-0084 | A | I-0451 | A | II-0189 | A | II-0429 | A |
I-0087 | A | I-0452 | A | II-0190 | A | II-0430 | A |
[ Table 209 ]
Numbering of compounds | IC50 | Numbering of compounds | IC50 | Numbering of compounds | IC50 | Numbering of compounds | IC50 |
I-0088 | A | I-0453 | A | II-0191 | A | II-0431 | A |
I-0089 | A | I-0454 | A | II-0193 | A | II-0432 | A |
I-0092 | A | I-0455 | A | II-0194 | A | II-0433 | A |
I-0094 | A | I-0456 | A | II-0195 | A | II-0434 | A |
I-0095 | A | I-0458 | A | II-0196 | A | II-0435 | A |
I-0096 | A | I-0459 | A | II-0197 | A | II-0436 | A |
I-0097 | A | I-0460 | A | II-0198 | A | II-0437 | A |
I-0098 | A | I-0461 | A | II-0199 | A | II-0438 | A |
I-0099 | A | I-0462 | A | II-0200 | A | II-0439 | A |
I-0100 | A | I-0463 | A | II-0201 | A | II-0440 | A |
I-0102 | B | I-0464 | A | II-0202 | A | II-0441 | A |
I-0103 | A | I-0465 | A | II-0203 | A | II-0442 | A |
I-0105 | A | I-0466 | A | II-0204 | A | II-0443 | A |
I-0106 | C | I-0467 | A | II-0205 | A | II-0444 | A |
I-0111 | A | I-0468 | A | II-0206 | A | II-I445 | A |
I-0112 | A | I-0469 | A | II-0207 | A | II-0446 | A |
I-0114 | A | I-0470 | A | II-0208 | A | II-0447 | A |
I-0116 | A | I-0471 | A | II-0209 | A | II-0448 | A |
I-0129 | A | I-0472 | A | II-0210 | A | II-0449 | A |
I-0132 | C | I-0477 | A | II-0211 | A | II-0450 | A |
I-0133 | C | I-0478 | A | II-0212 | A | II-0451 | A |
I-0134 | C | I-0479 | C | II-0213 | A | II-0452 | A |
I-0135 | B | II-0002 | A | II-0214 | A | II-0453 | A |
I-0136 | A | II-0004 | A | II-0215 | A | II-0454 | A |
I-0143 | A | II-0005 | A | II-0216 | A | II-0456 | A |
I-0144 | A | II-0006 | A | II-0217 | A | II-0457 | A |
I-0149 | C | II-0007 | A | II-0218 | A | II-0458 | A |
I-0151 | B | II-0008 | A | I1-0219 | A | II-0459 | A |
I-0152 | A | II-0009 | A | II-0220 | A | II-0461 | A |
I-0154 | C | II-0011 | A | II-0221 | A | II-0462 | A |
I-0165 | A | II-0012 | A | II-0222 | A | II-0463 | A |
I-0166 | A | II-0013 | A | II-0234 | A | II-0464 | A |
I-0194 | A | II-0017 | A | II-0235 | A | II-0465 | A |
I-0196 | A | II-0018 | A | II-0236 | A | II-0466 | A |
I-0204 | B | II-0019 | A | II-0237 | A | II-0467 | A |
I-0207 | C | II-0020 | A | II-0238 | A | II-0468 | A |
I-0208 | B | II-0022 | A | II-0239 | A | II-0469 | A |
I-0213 | A | II-0023 | A | II-0240 | A | II-0470 | A |
[ Table 210 ]
Numbering of compounds | IC50 | Numbering of compounds | IC50 | Numbering of compounds | IC50 | Numbering of compounds | IC50 |
I-0214 | A | II-0024 | A | II-0242 | A | II-0471 | A |
I-0223 | C | II-0025 | A | II-0243 | A | II-0472 | A |
I-0226 | A | II-0027 | A | II-0244 | A | II-0473 | A |
I-0227 | A | II-0028 | A | II-0245 | A | II-0474 | A |
I-0231 | A | II-0029 | A | II-0246 | A | II-0475 | A |
I-02344 | A | II-0030 | A | II-0247 | A | II-0476 | A |
I-0236 | A | II-0031 | A | II-0248 | A | II-0477 | A |
I-0242 | A | II-0032 | A | II-0249 | A | II-0478 | A |
I-0244 | A | II-0033 | A | II-0250 | A | II-0479 | A |
I-02445 | A | II-0035 | A | II-0251 | A | II-0480 | A |
I-0246 | A | II-0037 | A | II-0252 | A | II-0485 | A |
I-0248 | A | II-0038 | A | II-0253 | A | II-0486 | A |
I-0249 | A | II-0039 | A | II-0254 | A | II-0487 | A |
I-0250 | A | II-0040 | A | II-0260 | A | II-0488 | A |
I-0251 | A | II-0041 | A | II-0261 | A | II-0489 | A |
I-0252 | A | II-0042 | A | II-0262 | A | II-0491 | A |
I-0253 | A | II-0044 | A | II-0263 | A | II-0495 | A |
I-0254 | A | II-0046 | A | II-0264 | A | II-0496 | A |
I-0255 | A | II-0047 | A | II-0265 | A | II-0497 | A |
I-0256 | A | II-0048 | A | II-0266 | A | II-0498 | A |
I-0258 | C | II-0049 | A | II-0267 | A | II-0500 | A |
I-0259 | A | II-0050 | A | II-0268 | A | II-0501 | A |
I-0260 | A | II-0051 | A | II-0269 | A | II-0502 | A |
I-0264 | A | II-0052 | A | II-0270 | A | II-0503 | A |
I-0265 | A | II-0053 | A | II-0271 | A | II-0504 | A |
I-0266 | A | II-0054 | A | II-0276 | A | II-0505 | A |
I-0267 | A | II-0056 | A | II-0277 | A | II-0506 | A |
I-0268 | A | II-0057 | A | II-0279 | A | II-0507 | A |
I-0269 | A | II-0058 | A | II-0280 | A | II-0508 | A |
I-0270 | A | II-0059 | A | II-0281 | A | II-0509 | A |
I-0271 | A | II-0060 | A | II-0283 | A | II-0510 | A |
I-0272 | A | II-0061 | A | II-0285 | A | II-0511 | A |
I-0279 | A | II-0062 | A | II-0286 | A | II-0512 | A |
I-0284 | A | II-0063 | A | II-0287 | A | II-0513 | A |
I-0285 | A | II-0064 | A | II-0291 | A | II-0514 | A |
I-0286 | A | II-0065 | A | II-0293 | A | II-0515 | A |
I-0287 | A | II-0066 | A | II-0294 | A | II-0516 | A |
I-0289 | A | II-0067 | A | II-0295 | A | II-0517 | A |
[ Table 211 ]
Numbering of compounds | IC50 | Numbering of compounds | IC50 | Numbering of compounds | IC50 | Numbering of compounds | IC50 |
I-0290 | A | II-0068 | A | II-0296 | A | II-0518 | A |
I-0301 | C | II-0069 | A | II-0297 | A | II-0519 | A |
I-0306 | A | II-0070 | A | II-0298 | A | II-0520 | A |
I-0307 | B | II-0071 | A | II-0300 | A | II-0524 | A |
I-0310 | A | II-0072 | A | II-0301 | A | II-0526 | A |
I-0316 | A | II-0073 | A | II-0302 | A | II-0527 | A |
I-0318 | B | II-0075 | A | II-0303 | A | II-0528 | A |
I-0320 | A | II-0076 | A | II-0305 | A | II-0529 | A |
I-0321 | C | II-0077 | A | II-0307 | A | II-0530 | A |
I-0330 | A | II-0078 | A | II-0308 | A | II-0531 | A |
I-0331 | A | II-0079 | A | II-0309 | A | II-0532 | A |
I-0332 | A | II-0080 | A | II-0310 | A | II-0533 | A |
I-0333 | A | II-0081 | A | II-0311 | A | II-0534 | A |
I-0334 | B | II-0082 | A | II-0312 | A | II-0535 | A |
I-0335 | B | II-0083 | A | II-0313 | A | II-0536 | A |
I-0339 | B | II-0084 | A | II-0314 | A | II-0537 | A |
I-0340 | B | II-0088 | A | II-0315 | A | II-0538 | A |
I-0344 | A | II-0091 | A | II-0316 | A | II-0539 | A |
I-0346 | A | II-0092 | A | II-0317 | A | II-0540 | A |
I-0348 | A | II-0094 | A | II-0318 | A | II-0541 | A |
I-0349 | A | II-0095 | A | II-0319 | A | II-0542 | A |
I-0350 | A | II-0096 | A | II-0320 | A | II-0544 | A |
I-0352 | A | II-0097 | A | II-0321 | A | II-0546 | A |
I-0355 | A | II-0098 | A | II-0322 | A | II-0547 | A |
I-0356 | A | II-0099 | A | II-0323 | A | II-0549 | A |
I-0357 | A | II-0100 | A | II-0324 | A | II-0551 | A |
I-0358 | B | II-0101 | A | II-0325 | A | II-0552 | A |
I-0359 | A | II-0102 | A | II-0326 | A | II-0553 | A |
I-0364 | A | II-0103 | A | II-0328 | A | II-0554 | A |
I-0365 | A | II-0104 | A | II-0331 | C | II-0555 | A |
I-0366 | A | II-0105 | A | II-0333 | A | II-0556 | A |
I-0367 | A | II-0106 | A | II-0336 | A | II-0557 | A |
I-0368 | A | II-0107 | A | II-0337 | A | II-0558 | A |
I-0369 | A | II-0108 | A | II-0338 | A | II-0560 | A |
I-0370 | A | II-0110 | A | II-0339 | A | II-0561 | A |
I-0371 | A | II-0112 | A | II-0340 | A | II-0562 | A |
I-0372 | A | II-0113 | A | II-0341 | A | II-0563 | A |
I-0374 | A | II-0114 | A | II-0342 | A | II-0564 | A |
[ Table 212 ]
Numbering of compounds | IC50 | Numbering of compounds | IC50 | Numbering of compounds | IC50 | Numbering of compounds | IC50 |
I-0378 | A | II-0115 | A | II-0344 | A | II-0565 | A |
I-0379 | A | II-0116 | A | II-0345 | A | II-0575 | A |
I-0380 | A | II-0117 | A | II-0346 | A | II-0578 | A |
I-0381 | A | II-0121 | A | II-0348 | A | II-0580 | A |
I-0382 | A | II-0122 | A | II-0349 | A | II-0581 | A |
I-0384 | A | II-0123 | A | II-0350 | A | II-0582 | A |
I-0385 | A | II-0126 | A | II-0351 | A | II-0583 | A |
I-0386 | A | II-0127 | A | II-0352 | A | II-0585 | A |
I-0390 | A | II-0128 | A | II-0353 | A | II-0586 | A |
I-0392 | A | II-0129 | A | II-0354 | A | II-0587 | A |
I-0396 | C | II-0131 | A | II-0355 | A | II-0588 | A |
I-0397 | B | II-0134 | A | II-0356 | A | II-0589 | A |
I-0399 | A | II-0135 | A | II-0357 | A | II-0590 | A |
I-0400 | A | II-0136 | A | II-0358 | A | II-0591 | A |
I-0401 | A | II-0137 | A | II-0359 | A | II-0592 | A |
I-0402 | A | II-0138 | A | II-0360 | A | II-0593 | A |
I-0403 | B | II-0139 | A | II-0361 | A | II-0597 | A |
I-0404 | A | II-0140 | A | II-0362 | A | II-0598 | A |
I-0405 | A | II-0141 | A | II-0363 | A | II-0599 | A |
I-0406 | A | II-0142 | A | II-0364 | A | II-0600 | A |
I-0407 | A | II-0143 | A | II-0365 | A | II-0601 | A |
I-0408 | A | II-0144 | A | II-0366 | A | II-0602 | A |
I-0412 | C | II-0145 | A | II-0367 | A | II-0603 | A |
I-0414 | B | II-0146 | A | II-0368 | A | II-0605 | C |
I-0415 | C | II-0147 | A | II-0378 | A | II-0606 | B |
I-0416 | C | II-0148 | A | II-0379 | A | II-0607 | B |
[ Table 213 ]
The following examples of the preparation are merely illustrative, and are not intended to limit the scope of the invention at all.
The compounds of the invention may be administered by any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets or capsules; or parenterally, for example in the form of injections or suspensions, topically, for example in the form of lotions, gels, ointments or creams, or nasally or in the form of suppositories, as pharmaceutical compositions. Pharmaceutical compositions comprising a compound of the invention in free form or in pharmaceutically acceptable salt form, together with at least one pharmaceutically acceptable carrier or diluent, may be manufactured by mixing, granulating or coating methods according to conventional methods. For example, the composition for oral administration can be formulated into tablets, granules, capsules containing an excipient, a disintegrant, a binder, a lubricant, etc., and an active ingredient. The injectable composition may be formulated as a solution or suspension, and may be sterilized, and may further contain a preservative, a stabilizer, a buffer, etc.
[ INDUSTRIAL APPLICABILITY ]
The compounds of the present invention are considered to have an inhibitory effect on coronavirus 3CL protease and are useful as therapeutic and/or prophylactic agents for diseases associated with coronavirus 3CL protease.
The application also relates to the following technical scheme.
1. A compound of formula (I):
[ chemical formula 1 ]
(wherein Y is N or CR 7 ;
R 7 Is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 1 is a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, a substituted or unsubstituted carbamoyl group or a substituted or unsubstituted amino group;
R 2 is a substituted or unsubstituted aromatic carbocyclic group (except for 1-p-fluorophenyl, 1-p-chlorophenyl and 1-p-methylphenyl), a substituted or unsubstituted non-aromatic carbocyclic group, a substituted or unsubstituted aromatic heterocyclic group or a substituted or unsubstituted non-aromatic heterocyclic group;
R 3 is a substituted or unsubstituted aromatic carbocyclyl group, a substituted or unsubstituted non-aromatic carbocyclyl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted non-aromatic heterocyclic group, or a substituted or unsubstituted alkyl group;
-X-is-NR 6 -、-CR 6 R 6’ -, -O-, -S-or a single bond;
R 6 and R is 6’ Each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
m is 0, 1 or 2;
R 5a each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 5b each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
n is 0, 1 or 2;
R 4a each independently is a hydrogen atom or a substituted or unsubstituted alkyl group;
R 4b each independently is a hydrogen atom or a substituted or unsubstituted alkyl group (but the following compounds:
[ chemical formula 2 ]
Except for) or a pharmaceutically acceptable salt thereof.
2. The compound of item 1, or a pharmaceutically acceptable salt thereof, wherein Y is N.
3. The compound of clause 1 or 2, or a pharmaceutically acceptable salt thereof, wherein, -X-is-NH-.
4. The compound according to any one of items 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R 2 Is a substituted or unsubstituted 6-14 membered aromatic carbocyclyl, a substituted or unsubstituted 5-10 membered non-aromatic carbocyclyl, a substituted or unsubstituted 5-10 membered aromatic heterocyclyl or a substituted or unsubstituted 5-10 membered non-aromatic heterocyclyl.
5. The compound according to any one of items 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 2 A 6-membered aromatic carbocyclic group substituted by 1 halogen or cyano group and further substituted by 1, 2, 3 or 4 substituents selected from substituent group G or a 6-membered aromatic heterocyclic group substituted by 1 halogen or cyano group and further substituted by 1 or 2 substituents selected from substituent group G;
The substituent group G is a group consisting of halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkenyloxy, alkynyloxy, and haloalkoxy.
6. The compound according to any one of items 1 to 5, or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1.
7. The compound according to any one of items 1 to 6, or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.
8. The compound according to any one of items 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R 4a Each independently is a hydrogen atom or an unsubstituted alkyl group, R 4b Each independently is a hydrogen atom.
9. The compound according to any one of items 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R 5a Each independently is a hydrogen atom, R 5b Each independently is a hydrogen atom.
10. The compound according to any one of items 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R 1 Is a substituted or unsubstituted aromatic heterocyclic group.
11. The compound according to any one of items 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R 1 Is a substituted or unsubstituted aromatic heterocyclic group, m is 1, R 5a Is a hydrogen atom, R 5b Is a hydrogen atom.
12. The compound according to any one of items 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R 1 And m is 0, which is a substituted or unsubstituted aromatic heterocyclic group.
13. The compound according to any one of clauses 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R 3 Is a substituted or unsubstituted 6-membered aromatic carbocyclyl, a substituted or unsubstituted 3-10-membered non-aromatic carbocyclyl, a substituted or unsubstituted 5-6-membered aromatic heterocyclyl, a substituted or unsubstituted 9-10-membered aromatic heterocyclyl, a substituted or unsubstituted 13-15-membered aromatic heterocyclyl, or a substituted or unsubstituted 3-20-membered non-aromatic heterocyclyl.
14. The compound according to any one of clauses 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R 3 Is a substituted or unsubstituted 6-membered aromatic carbocyclyl, a substituted or unsubstituted 9-10-membered aromatic heterocyclyl, or a substituted or unsubstituted 9-13-membered non-aromatic heterocyclyl.
15. The compound according to item 1, or a pharmaceutically acceptable salt thereof, wherein formula (I) is
Formula (I'):
[ chemical 3 ]
(wherein R is 1’ Is of the formula:
[ chemical formula 4 ]
A group shown;
R 2’ is of the formula:
[ chemical 5 ]
A group shown;
R 3’ is of the formula:
[ 6 ] A method for producing a polypeptide
The radicals shown).
16. The compound according to item 1, or a pharmaceutically acceptable salt thereof, wherein formula (I) is formula (I'):
[ chemical 7 ]
(wherein R is 1’ Is of the formula:
[ chemical formula 8 ]
A group shown;
R 2’ is of the formula:
[ chemical formula 9 ]
A group shown;
R 3’ is of the formula:
[ chemical formula 10 ]
The radicals shown).
17. The compound of item 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
[ chemical formula 11 ]
A group of groups.
18. A pharmaceutical composition comprising a compound of any one of items 1-17, or a pharmaceutically acceptable salt thereof.
19. A coronavirus 3CL protease inhibitor comprising a compound of any one of items 1 to 17 or a pharmaceutically acceptable salt thereof.
20. A coronavirus proliferation inhibitor comprising a compound of any one of items 1 to 17 or a pharmaceutically acceptable salt thereof.
21. The coronavirus propagation inhibitor according to item 20, wherein the coronavirus is an alpha genus coronavirus and/or a beta genus coronavirus.
22. The coronavirus propagation inhibitor according to item 20, wherein the coronavirus is SARS-CoV-2.
23. A method of treatment and/or prophylaxis of a disease associated with coronavirus 3CL protease, characterized by administering a compound of any one of items 1 to 17 or a pharmaceutically acceptable salt thereof.
24. A compound according to any one of items 1 to 17, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of a disease associated with coronavirus 3CL protease.
25. A compound of formula (I-a):
[ chemical formula 12 ]
P-toluenesulfonate salt of the compound shown or a solvate thereof.
26. A compound of formula (I-a):
[ chemical formula 13 ]
Crystals of p-toluenesulfonate salt of the compound shown.
27. The p-toluenesulfonate crystal form I according to item 26, said crystal being at diffraction angle (2θ) in an X-ray powder diffraction spectrum: peaks at 9.1.+ -. 0.2 °, 15.2.+ -. 0.2 °, 18.8.+ -. 0.2 °, 23.6.+ -. 0.2 ° and 24.9.+ -. 0.2 °.
28. The p-toluenesulfonate crystal form I according to item 26, said crystal being at diffraction angle (2θ) in an X-ray powder diffraction spectrum: peaks at 9.1.+ -. 0.2 °, 11.5.+ -. 0.2 °, 14.6.+ -. 0.2 °, 15.2.+ -. 0.2 °, 18.8.+ -. 0.2 °, 20.2.+ -. 0.2 °, 23.6.+ -. 0.2 °, 24.2.+ -. 0.2 °, 24.9.+ -. 0.2 ° and 26.9.+ -. 0.2 °.
29. A pharmaceutical composition comprising the crystal of any one of items 26 to 28.
30. A composition comprising formula (I-B):
[ chemical formula 14 ]
Complexes of the compounds shown and fumaric acid.
31. The complex according to item 30, wherein formula (I-B):
[ 15 ] A method of producing a polypeptide
The compounds shown and fumaric acid are present in a molar ratio of 1:1.
32. A fumaric acid co-crystal according to item 30 or 31.
33. The fumaric acid co-crystal form I of clause 32, wherein in the X-ray powder diffraction spectrum, the co-crystal is at diffraction angle (2Θ): peaks at 9.5.+ -. 0.2 °, 10.9.+ -. 0.2 °, 18.6.+ -. 0.2 °, 23.5.+ -. 0.2 ° and 24.6.+ -. 0.2 °.
34. The fumaric acid co-crystal form I of clause 32, wherein in the X-ray powder diffraction spectrum, the co-crystal is at diffraction angle (2Θ): peaks at 7.8.+ -. 0.2 °, 9.5.+ -. 0.2 °, 10.1.+ -. 0.2 °, 10.9.+ -. 0.2 °, 13.8.+ -. 0.2 °, 14.7.+ -. 0.2 °, 18.6.+ -. 0.2 °, 22.6.+ -. 0.2 °, 23.5.+ -. 0.2 ° and 24.6.+ -. 0.2 °.
35. The fumaric acid co-crystal form I of clause 32, wherein the co-crystal is at 676.3cm in Raman spectroscopy -1 ±2cm -1 、748.0cm -1 ±2cm -1 、1029.3cm -1 ±2cm -1 、1374.4cm -1 ±2cm -1 、1515.5cm -1 ±2cm -1 、1665.7cm -1 ±2cm -1 、1715.7cm -1 ±2cm -1 1739.1cm -1 ±2cm -1 With raman spectral peaks.
36. A pharmaceutical composition comprising the co-crystal of any one of items 32 to 35.
Claims (10)
1. Formula (I'):
the compound shown or a pharmaceutically acceptable salt thereof,
in the method, in the process of the invention,
R 1 is that
Wherein R is 1d R is a substituted or unsubstituted alkyl group 1e Is halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, amino, alkylamino;
R 2 Phenyl substituted by 1 halogen or cyano and further substituted by 1 or 2 substituents selected from substituent group G;
the substituent group G is a group consisting of halogen, cyano, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, alkenyloxy, alkynyloxy, and haloalkoxy;
R 3 is that
Wherein R is 3a Is a hydrogen atom or halogen, R 3b Is a substituted or unsubstituted alkyl group;
m is 0 or 1;
wherein one or more hydrogen, carbon and/or other atoms of the compound are optionally replaced with isotopes of hydrogen, carbon and/or other atoms, respectively.
2. The compound according to claim 1, wherein,
R 1 is that
R 1d Is unsubstituted alkyl.
3. The compound according to claim 1, wherein,
R 1 is that
R 1e Is halogen or unsubstituted alkyl.
4. A compound according to any one of claims 1 to 3, wherein R 2 Phenyl substituted with 3 halogens.
5. The compound according to any one of claims 1 to 4, wherein R 3 Is that
Wherein R is 3a Is halogen; r is R 3b Is an alkyl group substituted with halogen or an unsubstituted alkyl group.
6. The compound of any one of claims 1-5, wherein m is 0.
7. The compound of any one of claims 1-5, wherein m is 1.
8. The compound according to any one of claims 1 to 7, wherein one or more hydrogens of the compound are each substituted with 2 H or 3 H is substituted.
9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof.
10. Use of a compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of diseases which are associated with coronavirus 3CL protease.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021068672 | 2021-04-14 | ||
JP2021-068672 | 2021-04-14 | ||
JP2021105802 | 2021-06-25 | ||
JP2021-105802 | 2021-06-25 | ||
JP2021-153819 | 2021-09-22 | ||
JP2021153819 | 2021-09-22 | ||
PCT/JP2022/006495 WO2022138987A1 (en) | 2021-04-14 | 2022-02-17 | Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same |
CN202280000918.9A CN115038696A (en) | 2021-04-14 | 2022-02-17 | Triazine derivatives having virus proliferation inhibitory activity and pharmaceutical composition containing the same |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280000918.9A Division CN115038696A (en) | 2021-04-14 | 2022-02-17 | Triazine derivatives having virus proliferation inhibitory activity and pharmaceutical composition containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117820248A true CN117820248A (en) | 2024-04-05 |
Family
ID=82159864
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311797713.0A Pending CN117820248A (en) | 2021-04-14 | 2022-02-17 | Triazine derivative with virus proliferation inhibition effect and pharmaceutical composition containing triazine derivative |
CN202210742186.2A Active CN115073431B (en) | 2021-04-14 | 2022-02-17 | Triazine derivative with virus proliferation inhibition effect and pharmaceutical composition containing triazine derivative |
CN202310437344.8A Pending CN116650498A (en) | 2021-04-14 | 2022-02-17 | Triazine derivative with virus proliferation inhibition effect and pharmaceutical composition containing triazine derivative |
CN202280000918.9A Pending CN115038696A (en) | 2021-04-14 | 2022-02-17 | Triazine derivatives having virus proliferation inhibitory activity and pharmaceutical composition containing the same |
CN202210983564.6A Pending CN115850249A (en) | 2021-04-14 | 2022-02-17 | Triazine derivatives having virus proliferation inhibitory activity and pharmaceutical composition containing the same |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210742186.2A Active CN115073431B (en) | 2021-04-14 | 2022-02-17 | Triazine derivative with virus proliferation inhibition effect and pharmaceutical composition containing triazine derivative |
CN202310437344.8A Pending CN116650498A (en) | 2021-04-14 | 2022-02-17 | Triazine derivative with virus proliferation inhibition effect and pharmaceutical composition containing triazine derivative |
CN202280000918.9A Pending CN115038696A (en) | 2021-04-14 | 2022-02-17 | Triazine derivatives having virus proliferation inhibitory activity and pharmaceutical composition containing the same |
CN202210983564.6A Pending CN115850249A (en) | 2021-04-14 | 2022-02-17 | Triazine derivatives having virus proliferation inhibitory activity and pharmaceutical composition containing the same |
Country Status (14)
Country | Link |
---|---|
US (2) | US20230128162A1 (en) |
EP (1) | EP4122926A4 (en) |
JP (2) | JPWO2022138987A1 (en) |
KR (2) | KR102494188B1 (en) |
CN (5) | CN117820248A (en) |
AU (1) | AU2022204775B2 (en) |
CA (1) | CA3195272C (en) |
CL (1) | CL2023003041A1 (en) |
CO (1) | CO2022016323A2 (en) |
IL (1) | IL298794B1 (en) |
MX (1) | MX2022014458A (en) |
TW (1) | TWI815396B (en) |
WO (2) | WO2022138988A1 (en) |
ZA (1) | ZA202212526B (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4122926A4 (en) * | 2021-04-14 | 2023-08-30 | Shionogi & Co., Ltd | Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same |
WO2023033098A1 (en) * | 2021-09-03 | 2023-03-09 | 塩野義製薬株式会社 | Bicyclic nitrogen-containing heterocyclic derivative having virus growth inhibitory activity and pharmaceutical composition containing same |
CN116782904A (en) * | 2021-09-28 | 2023-09-19 | 盐野义制药株式会社 | Pharmaceutical composition containing triazine derivative |
TW202320793A (en) * | 2021-09-28 | 2023-06-01 | 日商塩野義製藥股份有限公司 | Pharmaceutical composition comprising triazine derivative |
JP7236065B1 (en) * | 2021-09-28 | 2023-03-09 | 塩野義製薬株式会社 | Pharmaceutical composition containing triazine derivative |
JP7261529B1 (en) | 2021-11-24 | 2023-04-20 | 塩野義製薬株式会社 | Method for producing triazine derivative having virus growth inhibitory action |
KR20230119022A (en) * | 2021-11-24 | 2023-08-14 | 시오노기 앤드 컴파니, 리미티드 | Formulations for oral administration containing triazine derivatives |
WO2023095860A1 (en) * | 2021-11-26 | 2023-06-01 | 塩野義製薬株式会社 | Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug |
TW202339757A (en) * | 2022-01-19 | 2023-10-16 | 日商塩野義製藥股份有限公司 | Medicament for treating novel coronavirus infection |
WO2023165459A1 (en) * | 2022-03-01 | 2023-09-07 | Fochon Biosciences , Ltd. | Compounds as sars-cov-2 inhibitors |
US11655240B1 (en) | 2022-05-10 | 2023-05-23 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases |
CN114805314B (en) * | 2022-04-20 | 2023-12-15 | 杭州国瑞生物科技有限公司 | Synthesis method of Entecavir |
CN117159555A (en) * | 2022-05-27 | 2023-12-05 | 北京远大九和药业有限公司 | Pharmaceutical composition, preparation method and application thereof |
CN117122601A (en) * | 2022-05-27 | 2023-11-28 | 北京远大九和药业有限公司 | Pharmaceutical composition comprising crystalline forms of a compound and fumaric acid, and methods of preparation and use thereof |
WO2023227118A1 (en) * | 2022-05-27 | 2023-11-30 | 广州国家实验室 | 3c-like protease inhibitor |
WO2023227117A1 (en) * | 2022-05-27 | 2023-11-30 | 广州国家实验室 | 3c-like protease inhibitor |
WO2023226679A1 (en) * | 2022-05-27 | 2023-11-30 | 广州国家实验室 | 3c-like protease inhibitor |
CN115260167A (en) * | 2022-08-01 | 2022-11-01 | 陕西盘龙药业集团股份有限公司 | 3-tetrazolylmethyl-1, 3, 5-triazine-2, 4-diketone compound and preparation method and application thereof |
CN116496266A (en) * | 2022-07-08 | 2023-07-28 | 歌礼生物科技(杭州)有限公司 | Triazine derivatives |
US20240025885A1 (en) * | 2022-07-08 | 2024-01-25 | Ascletis BioScience Co., Ltd | Triazine derivatives and methods of use thereof |
CN114989048B (en) * | 2022-07-19 | 2023-05-23 | 郑州大学 | Cyclobut-1-enamine compound, preparation method thereof and application thereof in anti-II-type dengue virus drugs |
CN114933594A (en) * | 2022-07-20 | 2022-08-23 | 北京科翔中升医药科技有限公司 | Fluotriazines compound, pharmaceutical composition and application |
CN115109042B (en) * | 2022-08-30 | 2023-05-26 | 北京科翔中升医药科技有限公司 | Triazine compound or pharmaceutically acceptable salt thereof, pharmaceutical composition and application |
CN115504968B (en) * | 2022-11-21 | 2023-04-18 | 歌礼生物科技(杭州)有限公司 | Triazine derivatives |
CN115819407A (en) * | 2022-12-13 | 2023-03-21 | 浙江乐普药业股份有限公司 | Ensittrelvir analogue, preparation method thereof and new crown resistant application |
CN115785080A (en) * | 2022-12-16 | 2023-03-14 | 陕西盘龙药业集团股份有限公司 | Uracil parent nucleus compound and preparation method and application thereof |
CN116621817B (en) * | 2023-07-20 | 2023-09-29 | 爱斯特(成都)生物制药股份有限公司 | Entecavir fumarate crystal form, preparation method, pharmaceutical composition and application thereof |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1255738E (en) * | 2000-01-25 | 2012-06-19 | Neurocrine Biosciences Inc | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
CA2559302C (en) * | 2004-03-15 | 2012-06-19 | Takeda Pharmaceutical Company Limited | 6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors |
CN1926128A (en) * | 2004-03-15 | 2007-03-07 | 武田药品工业株式会社 | Dipeptidyl peptidase inhibitors |
MX2007011848A (en) * | 2005-03-24 | 2008-04-22 | Johnson & Johnson | Prokineticin 1 receptor antagonists. |
JP5122462B2 (en) * | 2005-09-16 | 2013-01-16 | 武田薬品工業株式会社 | Dipeptidyl peptidase inhibitor |
CN100502868C (en) * | 2005-11-18 | 2009-06-24 | 北京大学 | 3CL protease inhibitor of non-peptide SARS coronavirus and use thereof |
WO2007079163A2 (en) * | 2005-12-29 | 2007-07-12 | Janssen Pharmaceutica N.V. | Prokineticin 1 receptor antagonists |
WO2007112368A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
CN101842361B (en) * | 2007-06-27 | 2013-06-05 | 阿斯利康(瑞典)有限公司 | Pyrazinone derivatives and their use in the treatment of lung diseases |
CA2704185C (en) * | 2007-10-30 | 2016-02-16 | Janssen Pharmaceutica N.V. | Amino-heteroaryl-containing prokineticin 1 receptor antagonists |
PL2399910T3 (en) | 2009-02-13 | 2014-09-30 | Shionogi & Co | Triazine derivatives as p2x3 and/or p2x2/3 receptor antagonists and pharmaceutical composition containing them |
WO2012006004A1 (en) * | 2010-06-28 | 2012-01-12 | Janssen Pharmaceutica Nv | Prokineticin 1 receptor antagonists for the treatment of pain |
US20110319418A1 (en) * | 2010-06-28 | 2011-12-29 | Flores Christopher M | Prokineticin 1 receptor antagonists for the treatment of pain |
WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
KR101867110B1 (en) * | 2010-08-10 | 2018-06-12 | 시오노기 앤드 컴파니, 리미티드 | Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity |
US9212130B2 (en) | 2010-08-10 | 2015-12-15 | Shionogi & Co., Ltd. | Heterocyclic derivative and pharmaceutical composition comprising the same |
CN102807568B (en) * | 2011-05-31 | 2015-11-25 | 正大天晴药业集团股份有限公司 | Thiadiazoles derivative class DPP-IV inhibitor |
CN103159665B (en) * | 2011-12-09 | 2017-01-25 | 天津市国际生物医药联合研究院 | Isatin-5-amide inhibiting agent with inhibition effect against SARS coronavirus main protease |
TW201331188A (en) * | 2011-12-15 | 2013-08-01 | Shionogi & Co | Substituted triazine derivative and pharmaceutical composition comprising the same |
WO2013118855A1 (en) | 2012-02-09 | 2013-08-15 | 塩野義製薬株式会社 | Heterocyclic ring and carbocyclic derivative |
TWI637949B (en) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | Aminotriazine derivative and pharmaceutical composition comprising the same |
MX2016004742A (en) * | 2013-10-25 | 2016-12-09 | Shanghai hengrui pharmaceutical co ltd | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof. |
CN104109147B (en) * | 2014-06-21 | 2016-10-05 | 安徽省逸欣铭医药科技有限公司 | Hydroxyl amidino groups benzene analog derivative and preparation method thereof and medical usage |
JP7116356B2 (en) * | 2017-11-28 | 2022-08-10 | 日産化学株式会社 | Triazine-2,4-dione derivative and method for producing the same |
AU2021253796B2 (en) | 2020-04-05 | 2023-06-01 | Pfizer Inc. | Compounds and methods for the treatment of COVID-19 |
CN112516122A (en) * | 2020-04-21 | 2021-03-19 | 洪楠方 | Application of suramin in preparation of drugs for preventing or treating coronavirus related diseases |
WO2022035911A2 (en) * | 2020-08-11 | 2022-02-17 | Tutela Pharmaceuticals, Inc. | Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
JPWO2022158528A1 (en) * | 2021-01-20 | 2022-07-28 | ||
EP4313097A1 (en) * | 2021-03-29 | 2024-02-07 | Shireen Nature Company for General Trading, Ltd. | Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions |
EP4122926A4 (en) * | 2021-04-14 | 2023-08-30 | Shionogi & Co., Ltd | Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same |
CN113735838B (en) | 2021-09-27 | 2022-07-08 | 成都施贝康生物医药科技有限公司 | Dihydropyrimidine compound, preparation method and application thereof |
CN113666914B (en) | 2021-09-27 | 2022-06-07 | 成都施贝康生物医药科技有限公司 | Dihydropyrimidine compound and preparation method and application thereof |
CN113773300B (en) | 2021-09-27 | 2022-10-11 | 成都施贝康生物医药科技有限公司 | Sulfonamide compound, preparation method and application thereof |
CN113620888B (en) | 2021-09-27 | 2023-06-06 | 成都施贝康生物医药科技有限公司 | Dihydropyrimidine compound and preparation method and application thereof |
CN113801097B (en) | 2021-09-27 | 2022-11-22 | 成都施贝康生物医药科技有限公司 | Dihydropyrimidine compound, preparation method and application thereof |
TW202320793A (en) * | 2021-09-28 | 2023-06-01 | 日商塩野義製藥股份有限公司 | Pharmaceutical composition comprising triazine derivative |
CN116782904A (en) * | 2021-09-28 | 2023-09-19 | 盐野义制药株式会社 | Pharmaceutical composition containing triazine derivative |
KR20230119022A (en) * | 2021-11-24 | 2023-08-14 | 시오노기 앤드 컴파니, 리미티드 | Formulations for oral administration containing triazine derivatives |
TW202339757A (en) * | 2022-01-19 | 2023-10-16 | 日商塩野義製藥股份有限公司 | Medicament for treating novel coronavirus infection |
CN117069708A (en) * | 2022-05-10 | 2023-11-17 | 北京远大九和药业有限公司 | Crystalline form of a compound, preparation method and use thereof |
-
2022
- 2022-02-17 EP EP22733282.2A patent/EP4122926A4/en active Pending
- 2022-02-17 WO PCT/JP2022/006496 patent/WO2022138988A1/en active Application Filing
- 2022-02-17 CN CN202311797713.0A patent/CN117820248A/en active Pending
- 2022-02-17 CN CN202210742186.2A patent/CN115073431B/en active Active
- 2022-02-17 AU AU2022204775A patent/AU2022204775B2/en active Active
- 2022-02-17 JP JP2022571730A patent/JPWO2022138987A1/ja active Pending
- 2022-02-17 CA CA3195272A patent/CA3195272C/en active Active
- 2022-02-17 KR KR1020227018680A patent/KR102494188B1/en active IP Right Grant
- 2022-02-17 US US17/790,358 patent/US20230128162A1/en active Pending
- 2022-02-17 CN CN202310437344.8A patent/CN116650498A/en active Pending
- 2022-02-17 KR KR1020237002784A patent/KR20230159812A/en unknown
- 2022-02-17 CN CN202280000918.9A patent/CN115038696A/en active Pending
- 2022-02-17 CN CN202210983564.6A patent/CN115850249A/en active Pending
- 2022-02-17 MX MX2022014458A patent/MX2022014458A/en unknown
- 2022-02-17 JP JP2022525557A patent/JP7105430B1/en active Active
- 2022-02-17 IL IL298794A patent/IL298794B1/en unknown
- 2022-02-17 WO PCT/JP2022/006495 patent/WO2022138987A1/en unknown
- 2022-04-13 TW TW111113943A patent/TWI815396B/en active
- 2022-04-29 US US17/733,366 patent/US11814368B2/en active Active
- 2022-11-15 CO CONC2022/0016323A patent/CO2022016323A2/en unknown
- 2022-11-16 ZA ZA2022/12526A patent/ZA202212526B/en unknown
-
2023
- 2023-10-11 CL CL2023003041A patent/CL2023003041A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN115850249A (en) | 2023-03-28 |
TWI815396B (en) | 2023-09-11 |
EP4122926A1 (en) | 2023-01-25 |
AU2022204775B2 (en) | 2023-03-30 |
JP7105430B1 (en) | 2022-07-25 |
JPWO2022138988A1 (en) | 2022-06-30 |
CO2022016323A2 (en) | 2023-02-16 |
KR102494188B1 (en) | 2023-01-31 |
KR20220142999A (en) | 2022-10-24 |
US20230212154A1 (en) | 2023-07-06 |
JPWO2022138987A1 (en) | 2022-06-30 |
TW202302571A (en) | 2023-01-16 |
IL298794A (en) | 2023-02-01 |
MX2022014458A (en) | 2023-02-27 |
CN115073431A (en) | 2022-09-20 |
US20230128162A1 (en) | 2023-04-27 |
ZA202212526B (en) | 2023-05-31 |
CL2023003041A1 (en) | 2024-03-15 |
EP4122926A4 (en) | 2023-08-30 |
CN115073431B (en) | 2023-09-05 |
US11814368B2 (en) | 2023-11-14 |
WO2022138987A1 (en) | 2022-06-30 |
CN115038696A (en) | 2022-09-09 |
WO2022138988A1 (en) | 2022-06-30 |
CA3195272A1 (en) | 2022-06-30 |
CN116650498A (en) | 2023-08-29 |
IL298794B1 (en) | 2024-02-01 |
CA3195272C (en) | 2024-02-13 |
KR20230159812A (en) | 2023-11-22 |
AU2022204775A1 (en) | 2022-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115073431B (en) | Triazine derivative with virus proliferation inhibition effect and pharmaceutical composition containing triazine derivative | |
JP7466731B2 (en) | Orally administered preparations containing triazine derivatives | |
EP4292594A2 (en) | Inhibitors of ret | |
BRPI0716918A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, PACKAGED PHARMACEUTICAL COMPOSITION, METHOD OF TREATING A PATIENT WHO HAS A DISEASE RESPONSIBLE FOR BTK ACTIVITY, METHOD OF TREATING A PATIENT WHO HAS A CLEAR ALTERNATIVE DISEASE, CUSTOMS DISEASE INCREASING SENSITIVITY OF CANCER CELLS TO CHEMOTHERAPY, METHOD OF REDUCING MEDICATION ERROR AND IMPROVING THERAPEUTIC PATIENT DISEASE BY BEING TREATED TO A DISEASE RESPONSIBLE FOR BTK MÉTIR DE MÉDID ACTIVITY INHIBITION BTK IN A SAMPLE, METHOD OF INHIBITING B-CELL ACTIVITY | |
WO2023054292A1 (en) | Pharmaceutical composition containing triazine derivative | |
KR20080091294A (en) | Viral polymerase inhibitors | |
JP7261529B1 (en) | Method for producing triazine derivative having virus growth inhibitory action | |
JP2021536436A (en) | A novel inhibitor prepared from quinoline derivatives | |
WO2023042879A1 (en) | Bicyclic heterocyclic derivative having viral growth inhibitory activity and pharmaceutical composition containing same | |
CN116782904A (en) | Pharmaceutical composition containing triazine derivative | |
MX2009000882A (en) | Viral polymerase inhibitors. | |
JP7236065B1 (en) | Pharmaceutical composition containing triazine derivative | |
WO2023095860A1 (en) | Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug | |
RU2806042C1 (en) | Triazine derivatives having inhibitory activity against virus replication, and pharmaceutical composition containing them | |
CN117999257A (en) | Bicyclic heterocyclic derivatives having virus proliferation inhibitory activity and pharmaceutical compositions containing the same | |
WO2023195529A1 (en) | Uracil derivative having viral growth inhibitory activity and pharmaceutical composition containing same | |
KR20240082359A (en) | Pharmaceutical compositions containing triazine derivatives | |
JP2024512753A (en) | Novel dialkoxynaphtho[2,3-c]furan-1(3H)-one derivatives and pharmaceutical compositions containing the same for the prevention or treatment of respiratory diseases or SARS-CoV-2 infections | |
CN116514734A (en) | Process for producing triazine derivative and orally administered preparation containing triazine derivative | |
BR122023002208A2 (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING TRIAZINE DERIVATIVES HAVING AN EFFECT INHIBITING THE SPREAD OF VIRUS, INHIBITORS AND USES | |
CN117362306A (en) | Amide derivatives having antiviral activity | |
CN109996800A (en) | The crystal of pyrido [3,4-d] pyrimidine derivatives or its solvate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |